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Abstract 
Metal based anti-cancer drugs (metallodrugs) such as cisplatin are a cornerstone of 
cancer chemotherapy. However, development of this class of compound has been hindered by 
our lack of understanding of how they function. This is mainly because existing method to study 
the mechanism of action of metallodrugs are lacking as they were either directly adapted from 
methods to study organic drugs which have very different chemical properties or current limits 
in technology and knowledge were a bottleneck to the development of suitable methods. 
 
Mass spectrometry (MS) has emerged as a powerful tool which can be applied to study 
the mechanism of action of metallodrugs. Many different MS methods exist which can be 
adapted to study different aspects of drug action while accounting for the unique chemical 
nature of metallodrugs. In this dissertation, we develop MS strategies to study how platinum 
and ruthenium metallodrugs work and study a few important aspects of their function. Firstly, 
the in vitro distribution of and ligand state of metallodrugs were studied by imaging mass 
spectrometry. Next, we attempted to find novel protein targets of metallodrugs using a novel 
protein expression profiling approach. Promising metallodrug protein targets obtained from this 
study were then validated via biochemical methods. To facilitate the application of MS based 
protein-metallodrug fragmentation experiments for finding binding sites of metallodrugs on 
proteins, we developed and optimized web-based tools for automatic processing of complex 
spectra from these experiment. We then applied these tools to study the interaction of 
metallodrugs on relevant proteins, which provided insight into the specific binding properties 
of metallodrugs on proteins.  
 
Keywords 
Platinum, ruthenium, metallodrugs, mass spectrometry, anti-cancer, imaging, proteomics, 
fragmentation.   
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Résumé 
Les médicaments anti-cancéreux composés d’un centre métallique (métallodrogues) 
comme le cisplatin sont des médicaments incontournables dans le traitement du cancer par 
chimiothérapie. Cependant, le développement de nouvelles métallodrogues est lent dû à la 
faible compréhension du mode d’action de ces derniers. Ce manque de compréhension est 
essentiellement dû au fait que les méthodes pour étudier les mécanismes des métallodrogues ne 
sont pas adaptées. En effet, ces méthodes sont souvent issues directement de méthodes utilisées 
pour comprendre le fonctionnement de drogues organiques (qui ont des propriétés chimiques 
très différentes). De plus, les limites techniques ont freinés le développement de méthodes 
appropriées pour ces analyses. 
 
La spectrométrie de masse (MS) a émergé comme un outil puissant pour l’étude des 
mécanismes des métallodrogues. De nombreuses méthodologies MS existent, et celles-ci 
peuvent être ajustées, ce qui permettrait d’étudier les différents modes d’actions de la 
métallodrogue, tout en prenant en compte les propriétés uniques de celles-ci. Dans cette thèse, 
nous proposons des stratégies MS pour étudier le fonctionnement de médicaments contenant 
des centres Platine ou Ruthénium. Tout d’abord, la distribution et l’environnement (ligands) 
des métallodrogues a été étudié par imagerie MS in vitro. Ensuite, nous avons utilisé une 
nouvelle méthode de profilage de protéines afin de tenter d’identifier des cibles des 
métallodrogues. Ces cibles potentielles ont ensuite été confirmées par le biais de méthodes 
biochimiques. Afin de faciliter l’identification de sites de fixation de la métallodrogue par le 
biais de méthodes MS basé sur la fragmentation de complexes protéine-métallodrogues, un outil 
web pour le traitement automatique de données a été développé. Ces outils ont ensuite été 
utilisés pour étudier l’interaction des métallodrogues avec des protéines d’intérêt, ce qui a 
apporté des données sur le mode d’action et les modes de fixation des métallodrogues sur les 
protéines. 
 
Mots-clés 
Platine, ruthénium, métallodrogues, La spectrométrie de masse, anti-cancéreux, imagerie, 
profilage de protéines, fragmentation.   
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1.1 Cancer and the history of cancer therapy 
Cancer is a general term used to describe a group of diseases that can affect any organs 
in our body and is characterized by abnormal cells that divide and grow beyond their usual 
boundaries and can potentially invade adjoining parts of the body and spread to other organs.1 
Cancer is a major cause of morbidity and mortality worldwide (ranking second behind heart 
disease) with 14.1 million new cases reported and 8.2 million deaths (13% of deaths) in 20122 
with this number projected to rise to 21.4 million new cases and 13.1 million deaths by the year 
2030. Considering the costs of prevention and treatment of cancer and the economic value of 
lost lives and disability, cancer carries an annual financial burden of 1.16 trillion US dollars 
worldwide.3 The first suspected documentation of cancer was by an ancient Egyptian physician 
Imhotep, who lived around 2625 BC.4 For more than three millennia since its discovery, cancer 
has been regarded as an almost incurable disease. However, in the past 200 years, medical 
sciences have made great strides in the understanding and treatment of cancer.  
 
In the mid-19th century, with major developments in surgery, such as the discovery of 
anesthesia, surgery became a widespread option for cancer treatment.5 The understanding of 
cancer at the time was that it was a localized disease, thus “radical surgeries”, where large parts 
of an organ was removed with its underlying lymph nodes were often performed.6 However, 
upon the discovery of the metastatic character of tumors by Stephen Paget7, such radical 
surgeries fell out of favor and were replaced by precise procedures, where cancerous tissue is 
carefully removed with minimal removal of normal tissue; a practice still the mainstay of cancer 
surgery today.6 
 
The next step forward in cancer treatment came with the discovery of the link between 
hormones and cancer by Thomas Beatson in 18968 which eventually led to the development of 
hormonal therapy based drugs such as aromatase inhibitors and luteinizing hormone-releasing 
hormone analogues and inhibitors. Subsequently, the discovery and subsequent use or radiation 
therapy for cancer by Conrad Roentgen9 led to the development of techniques such as conformal 
radiation therapy, proton beam radiation therapy and intraoperative radiation therapy.  
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During the Second World War, the use of mustard gas led to the discovery of nitrogen 
mustard in 1942 (a DNA alkylating agent), the first chemotherapeutic agent ever used.10  
Subsequently, findings that aminopterin, a folic acid analogue, caused remissions of acute 
leukemia in children led to the development of methotrexate in 195011, a drug still commonly 
used in clinics nearly 60 years later. Modern chemotherapy has evolved tremendously from its 
early days with the development of new drugs and chemotherapeutic combinations, usage of 
more efficient and targeted drug delivery systems12 (e.g. liposomal therapy and monoclonal 
antibodies) and the use of drugs to mitigate side effects (blood cell stimulating agents, 
chemoprotective agents and anti-emetics). With our increased understanding of cancer biology, 
modern therapies have evolved with the introduction of immunotherapies and targeted 
therapies.13 Immunotherapy attempts to either directly utilize our immune system to directly 
alter cancer cell growth14 (e.g. monoclonal antibodies against specific cancer cell types like 
rituximab against lymphomas and trastuzumab against breast cancers), or augment our own 
immune system in fighting cancers15 (e.g. sipuleucel-T therapy, where a patients white blood 
cells extracted are trained to recognize and attack prostate cancer cells before being 
reintroduced into the patient). Targeted therapies on the other hand, seek to utilize specific 
cancer pathways as targets against cancers 16 such as the tyrosine kinase inhibitor imatinib 
(Gleevec) against chronic myelogenous leukemia.17 With these advancements in cancer 
therapy, the prognosis of cancer when has improved significantly, where in developed countries 
such as the United States, two thirds of cancer patients survive for more than 5 years upon 
diagnosis.18 
 
1.2 Cancer chemotherapy, the end of non-targeted therapies? 
Classical cancer chemotherapy which originated in the 1940’s relied mostly on drugs 
which interfered with replicating cancer cells. Examples of these therapeutic agents are 
alkylating agents, topoisomerase inhibitors, antimetabolites and platinum drugs. However, 
these therapies were notorious for being non-specific, where any rapidly dividing cells (hair 
follicles, intestinal cells, blood cells), would also be targeted by these anti-cancer agents leading 
to side effects commonly associated with classical cancer chemotherapy such as hair loss, 
nausea, vomiting and immune suppression.19  
 
With modern developments in cancer biology, we now have a much better fundamental 
understanding of the molecular basis of cancer. For example it has become apparent that 
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cancers, though all characterized by uncontrolled cell proliferation, is not a single disease but a 
group of them with more than 100 different types.1 Furthermore, a myriad of molecular 
pathways are involved in cancer implicating hundreds of possible drug targets.20 With this 
knowledge, modern chemotherapy aims to target these cancer targets specifically to have a 
more controlled anti-cancer effect whilst having less side effects.  
 
However, the paradox of specific targeting against cancer, is that cancers are capable of 
mutation, thus targeted strategies against cancer invariably fail once the cancer target mutates.21 
Thus, in clinical practice, targeted therapies are never given as monotherapies but in 
combination with one or more non-targeted agents.22 Non-targeted agents are also a lot more 
cost effective, as generic versions of many of these agents are available at a fraction of the cost 
of targeted therapies. However, looking to the future, it raises a question, should development 
of non-targeted therapies continue? One could consider an ideal scenario, where targeted 
compounds for every cancer pathway are available and cancer genotyping be used to identify 
susceptible targets for each patient followed by tailored therapies for them. However, in reality 
such a strategy may not be viable for the foreseeable decade due to the high cost and relatively 
scarce availability of genotyping especially in non-developed countries. There also remains a 
large gap in our understanding of cancer targets, and considering the hundreds of potential 
cancer targets the burden of time and cost for drugging these targets would be prohibitive. As 
it stands, the current cost of development of a new drug is 2.6 billion dollars23 and it takes an 
average of 12 years to complete all stages of clinical testing before approval.24 On the other 
hand, non-targeted compound development remains an attractive strategy as these compounds 
are amenable to different cancers, and the ability of cancers to gain resistance to them is 
mitigated by their more general mode of action. In addition, these compounds could be used as 
tools to further increase our knowledge of cancer biology, since they are mostly discovered via 
phenotypic screening based strategies and their exact mechanism of action could involve a 
plethora of pathways, which if elucidated could allow us to discover new cancer pathways. 
Thus, it becomes apparent, that non-targeted therapies still have a role to play in cancer therapy, 
and that the continuous development and study of these compounds is desirable.   
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1.3 Metal based anti-cancer drugs (metallodrugs) 
In 1965, an American chemist named Barnett Rosenberg, chanced upon an observation 
that electrolysis products from a platinum electrode inhibited cell division in Escherichia coli.25 
This anti-proliferative activity was subsequently ascribed to a soluble platinum product called 
cisplatin formed during electrolysis. Further experiments eventually lead to the discovery of the 
anti-cancer activity of cisplatin and, following clinical development, it was approved for use by 
the U.S. Food and Drug Administration in 1978.26 The discovery of cisplatin revolutionized the 
treatment of cancers such as testicular cancer (with cure rates rising from 10% to almost 80%).27 
Now it is still the first line therapy for testicular, ovarian, bladder, cervical and non-small cell 
lung cancers28 and is used in approximately 50-70% of all anti-cancer regimens.29 However, in 
the past 50 years since the discovery of cisplatin, only two other metallodrugs have been FDA 
approved (i.e. carboplatin and oxaliplatin).30 This as opposed to the 88 clinically approved anti-
cancer compounds currently on the market,31 highlights the slow development of metallodrugs. 
The sluggish development could be due to a lack of understanding of how these metallodrugs 
work. For example, though it is generally accepted that cisplatin exerts its action through 
forming adducts with DNA, only 1% of intracellular cisplatin is found attached to DNA.32 
Furthermore, the three platinum compounds used clinically (Figure 1.1), have selectivity 
towards different cancer types and strikingly different side effect profiles which cannot be 
explained by DNA binding alone.  
 
 
Figure 1.1 Structures of the three FDA approved platinum anti-cancer compounds currently in clinical use 
 
  
There has also been an interest in the development of non-platinum based metallodrugs 
for cancer due to problems commonly associated with platinum therapy such as resistance and 
severe side effects.33 Metallodrugs based on iron, ruthenium, osmium, iridium, rhodium, 
rhenium have been explored as potential anti-cancer agents.33  Amongst these new agents, the 
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ruthenium metallodrugs NAMI-A and RAPTA-T (Figure 1.2) have been shown to possess anti-
metastatic and anti-angiogenic properties not seen in platinum compounds. However, there is 
limited data on the biological targets of these upcoming compounds.33 
 
 
 
1.4 Mass Spectrometric Methods for Studying Metal Drugs 
Mass spectrometry (MS) is an analytical technique that measures the distribution of 
mass-to-charge of ionized gaseous atoms/molecules in a sample. The first mass spectrometer 
was created by J.J. Thomson in 1897 to measure the mass-to-charge ratio of electrons.34 Ever 
since, MS technologies have evolved tremendously, and the technique is applied in various 
settings such as environmental research, security checks, sports doping tests, clinical tests, and 
geological research.35 
 
 In the field of drug research, MS has emerged as a powerful tool for studying the 
mechanism of action of drugs. Various aspects of drug action can be studied via MS such as a) 
distribution of drugs in biological systems b) the protein targets of a drug and c) effects of a 
drug on a protein in terms of conformation, binding sites, or thermodynamic properties.  In this 
section we discuss MS methods specifically for the study of metallodrugs and highlight their 
advantages and disadvantages including the recent literature surrounding them.   
 
 
 
 
NAMI-A RAPTA-T 
Figure 1.2 Structures of the ruthenium complexes NAMI-A and RAPTA-T 
  
8 
 
1.4.1 Cellular distribution of metallodrugs 
Imaging mass spectrometry (IMS) for metallodrugs is mainly performed with four 
different techniques, namely matrix assisted laser desorption ionization-mass spectrometry 
imaging (MALDI-IMS), laser ablation-inductively coupled plasma mass spectrometry imaging 
(LA-ICP-IMS) and the secondary ion mass spectrometry (SIMS) techniques nanoscale SIMS 
(NanoSIMS) and time-of-flight SIMS (TOF-SIMS). An overview and comparison of the 
features, advantages and limitations of these mass spectrometry-based imaging techniques is 
shown in Figure 1.3 and Table 1.1, respectively. 
 
 
 
In general, all IMS methods involve the rastering of a primary laser or ion beam onto a 
sample surface generating ions which are detected with a mass spectrometer. Images of single 
m/z ions are then generated where relative abundance is displayed as a false color image (in 
which colors represent signal intensity of each signal). In general, IMS requires no 
modifications of the parent compound for detection. However, isotopic labeling can be applied 
Nano-SIMS TOF-SIMS 
LA-ICPMS MALDI-IMS 
Figure 1.3 Illustration of the ionization sources of the different MS imaging techniques for 
metal drugs (adapted from Dorrestein et. al. Nature  Rev. Microbiol 201136). 
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in certain cases either to increase signal of endogenously ubiquitous elements or for 
quantitation. 
 
 
For metallodrug imaging at the cellular level, an essential requirement is a high lateral 
resolution to resolve cellular structures and organelles. Amongst the IMS techniques used to 
probe the cellular distribution of metallodrugs, NanoSIMS is the most used in current practice, 
as it can achieve spatial resolutions of ca. 50 nm for metals and it can be used in conjunction 
with fluorescence microscopy36 or electron microscopy37, to further resolve cellular structures. 
SIMS methods has been used to characterize the subcellular distribution of several metallodrugs 
based on gold, platinum and ruthenium to elucidate their cellular targets and possible mode of 
action.  
 
Platinum complexes act largely in the nucleus of cells, forming adducts with DNA 
leading to cell apoptosis.38 The first reported use of NanoSIMS was to study cisplatin-induced 
intracellular alterations to the composition of kidney (LLC-PK1) cells treated with 6 µM 
Modality Ion 
source 
Ionization 
strength 
Spatial 
resolution 
Analyte 
type 
Advantages Disadvantages Metal 
drugs 
elements 
imaged 
Nano-SIMS Ion 
gun 
Hard Up to 
50nm   
Atoms High spatial 
resolution  
High sensitivity for 
smaller elements 
Low sensitivity for 
transition metals 
Small sampling 
area 
Sample 
preparation must 
resist high vacuum 
Samples must be 
flat 
Pt, Ru, Au 
LA-ICP-
MS 
UV 
laser 
beam 
Hard Up to  
1-10µm 
Atoms High sensitivity for 
transition metals 
Operates at 
atmospheric 
pressures 
Low spatial 
resolution 
Pt, Ru, 
MALDI-
MS 
UV 
laser 
beam 
Soft Up to 
20µm 
Molecules Analyses a full 
range of m/z 
Can operate at 
atmospheric 
pressures 
Non destructive 
Samples must be 
covered in an 
organic matrix 
Low spatial 
resolution 
Pt 
TOF-SIMS Ion 
gun 
Hard Up to 
100nm  
Molecules Can analyse 
molecules 
Analyses a full 
range of m/z 
Low sensitivity for 
transition metals 
Small sampling 
area 
Sample 
preparation must 
resist high vacuum 
Samples must be 
flat 
Pt 
Table 1.1 Comparison of different imaging MS techniques used in metal-based anti-cancer drug research. 
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cisplatin for 4 hours.39 Although intracellular Pt was detected no subcellular distribution could 
be prescribed due to the low lateral resolution (500 nm) of the experiment. Nevertheless, this 
study showed the potential of NanoSIMS to study the distribution of metallodrugs at a cellular 
level and highlighted the major challenge of low sensitivity for the detection of certain transition 
metals.39 Subsequently, the cellular distribution of the two 15N labelled platinum(II) complexes, 
cisplatin and TriplatinNC, was determined in MCF7 human breast adenocarcinoma cells dosed 
at 20 µM with the compounds. The images showed that the polynuclear Pt compound, 
TriplatinNC, accumulated in the nucleolus and in cytoplasmic vesicle-like structures. 
Interestingly, an increased non-correlation between 15N and Pt signals was observed from 1 to 
2 hours incubations, showing the dissociation of the NH3 ligands from the Pt complex, 
indicating metabolism of TriplatinNC. However, with cisplatin Pt or 15N signals were not 
detected in the cells further exemplifying the sensitivity issues associated with NanoSIMS.40  
 
A more recent study combined fluorescence microscopy with NanoSIMS analysis to 
map the distribution of cisplatin in SW480 colorectal cancer cells.36 Cells were treated with 15N 
labelled cisplatin (at different concentrations ranging from 0-150µM for 24 hours) and Pt was 
found to accumulate in small cytoplasmic sulfur-rich aggregates, acidic organelles and the 
nuclei. From plots of 15N vs. Pt accumulation in different cellular organelles, they observed a 
partial dissociation of the Pt-N bonds in cisplatin, particularly within the nucleolus at high 
cisplatin concentrations (ca. 150 µM). With correlative fluorescence microscopy using 
lysotracker red to label acidic organelles, Pt and florescence images overlapped showing 
accumulation of cisplatin in these organelles.36 
 
The distribution of cisplatin in U87MG human glioblastoma cells has been determined 
using TOF-SIMS in cells dosed with 30 µM of the compound for 48 hours.41 Platinum 
concentrations were found to be up to 1.5 times higher in the nucleus compared to the 
cytoplasm. In addition, up to 40 different phospholipids were identified on the cell membrane, 
highlighting a key strength of TOF-SIMS where besides localization of the metallodrug, 
information on the surrounding cellular environment is also mapped simultaneously. However, 
current limitations in the spatial resolution for Pt detection in TOF-SIMS precluded subcellular 
differentiation other than between the nucleus and cytoplasm .41 
 
Platinum drug loaded nanoparticle formulations help to target the drug to tumors 
potentially reducing side effects.42 Probing the intracellular distribution of such nanomedicines 
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is important to understand release characteristics of the metallodrug from the nanocarrier and, 
in a recent study, the fate of oxaliplatin loaded in polymeric nanoparticles was studied in HeLa 
cells following treatment with 3 µM for 4 and 24 hours. Fluorescence structured illumination 
microscopy and NanoSIMS were combined to image the cellular distribution of the 15N & 
florescent labelled nanoparticle polymer and the oxaliplatin.43 Figure 1.4 shows time dependent 
NanoSIMS maps of nanoparticle treated cells. It can be seen that from 4 to 24 hour incubations, 
there is an increased uptake of the nanoparticles and a dissociation of 15N from Pt signals 
showing the release of free Pt from the nanoparticle which correlates well with the observed 
cyototoxicity of the formulation.  
 
 
 
 
The distribution of two investigational platinum (IV) complexes in tissue and cells 
extracted from an in vivo murine CT-26 colon cancer model was probed using LA-ICP-MS and 
NanoSIMS.44 LA-ICP-MS was used to study the platinum accumulation on tissue level in the 
kidneys and tumor to select areas with highest Pt levels for further cellular distribution 
investigations using NanoSIMS. In the renal cortical cells Pt was found to accumulate in cells 
 
Figure 1.4 (a) Scheme summarizing the time-dependent NanoSIMS experiments carried out in HeLa cells 
treated with Cy-15N-NP. (b and c) HeLa cells incubated with Cy-15N-NP for 4 h (top three panels, b1−3) or 24 h 
(bottom three panels, c1−3) and imaged by NanoSIMS. Removal of layers of organic matter from the cell 
surface followed by imaging shows colocalization (yellow) of the 195Pt (red) and 15N (green) of the NP inside the 
cell. The cell surface is represented by the 12C14N− ion map (blue). Summed observed 195Pt signals (white pixels) 
in HeLa cells incubated for 4 h (d) and 24 h (e). Red circles are the ROIs selected for 15N/14N quantification 
where 195Pt counts are observed. Cell boundaries (yellow line) were delimited from the corresponding 12C14N− 
ion images. The averaged 15N and 195Pt signals per selected ROIs at each of the selected planes are shown for 
panels b and c. The scale bars represent 10 μm. (Adapted from Proetto et. al ACS Nano 2016). 
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of the glomerulus relative to the tubules, with Pt accumulating in sulfur rich organelles in the 
podocytes of the glomerulus. In the tumor cells similar amounts of platinum were detected in 
the nucleus and cytoplasm. However, local Pt levels in the nucleolus were elevated and 
cytoplasmic Pt accumulation was also concentrated in sulfur-rich organelles, namely in 
lysosomes (identified by electron microscopy).  
 
Gold complexes are currently used in clinics as anti-arthritic medications and their 
potential as anticancer agents has also been investigated. 45,46 Gold has a high affinity towards 
organosulfur (S) and selenium (Se) moieties and it has been assumed that a subcellular target 
of certain gold complexes includes the thioredoxin system, a family of proteins responsible for 
redox homeostasis in the cytoplasm, mitochondria and nucleus of cells.47 Gold(I) complexes 
with bidentate phosphine ligands have been shown to be selectively toxic to cancer cells thus 
studying the cellular distribution of these complexes could help to confirm their mechanism of 
action.45 In a combined study using NanoSIMS and energy filtered transmission electron 
microscopy (EFTEM) the subcellular distribution of the Au(I) phosphine complex, 
[Au(d2pype)2]Cl, was investigated in MDA-MB-231 human breast adenocarcinoma cells.
37 
Gold was observed to accumulate in aggregates, mostly in non-DNA containing nuclear areas 
and inside the nuclear membrane. Figure 1.5 shows the elemental images of 31P-, 197Au- and 
34S, with overlaid images mapping Au and S regions. Images (c) and (d) in Figure 1.5 show a 
clear co-localisation of Au and S which is in accordance with the hypothesis that gold 
complexes bind to S rich regions in the thioredoxin system.37 
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The lateral resolution in LA-ICP-IMS is mainly influenced by the laser spot diameter 
and the wash out times of the cell. Depending on the laser parameters used and the nature of 
the experiment the typical lateral resolution for bioimaging studies in tissue samples by LA-
ICP-MS lies in the low µm to the tenths of µm range.48 In recent years, advances in cell design 
as well as strategies in sample preparation (such as antibody or elemental labelling) have 
enabled the detection of elements with LA-ICP-MS at the cellular level.49 Thus far the 
technique has been used to study the distribution of  biomarkers in breast cancer tissue49 and to 
study Ag and Au nanoparticles in cellular substructures of individual cells.50  
  
A recent study adapted a LA-ICP-MS setup to determine the uptake of platinum(IV) 
complexes in multicellular tumor spheroids as possible screening and selection tool for novel 
metallodrugs.51 Three dimensional multicellular tumor models are increasingly used as bridge 
 
Figure 1.5 (a) and (b) NanoSIMS ion maps showing 31P and 197Au and 34S secondary ions in MDA-MB-231 cells 
after 2 h incubation with 1 (100 mM). (c) and (d) are overlays of the 34S and 197Au ion maps shown in (a) and (b), 
respectively, where 34S and 197Au are falsely coloured in green and red, respectively. Yellow pixels indicate 
colocalisation of 34S and 197Au, which can be observed in the cytoplasmic, perinuclear and nuclear regions. Scale 
bars: (a) and (c) = 2 mm, (b) and (d) = 1 mm. (Reproduced from Wedlock et. al Metallomics 2011). 
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between conventional monolayer cell culture systems and animal models in preclinical metal-
based anticancer drug development. Depending on their size they are able to mimic the complex 
tumor microenvironment in terms of oxygen, pH gradients, the development of a necrotic core 
and hypoxic regions.52 The lateral resolution of approximately 10 µm allowed the accumulation 
of platinum in the different compartments of the tumor spheroid to be visualized, showing that 
platinum(IV) complexes are not only taken up by the tumor spheroids, but are also able to 
penetrate into the different layers reaching the necrotic pseudo-tumor core.51 A subsequent 
study was able to correlate the platinum distribution, determined by LA-ICP-IMS, in HCT116 
tumor spheroids with the total platinum uptake determined by ICP-MS and the spatially-
resolved platinum accumulation in tumor tissue.53 
 
1.4.2 Protein target screening 
Mass spectrometric approaches for target screening of small molecules can be broadly 
divided into three types, namely expression profiling based, affinity purification based, and 
proteome stability based approaches. The principles, advantages and disadvantages of each are 
summarized in the following table.  
 
Method Principal Advantages Disadvantages 
Expression 
profiling 
Protein expression between a biological system 
(cell/tissues/animal) treated and untreated with 
small molecule are quantified via MS and 
correlated to its target. 
No modification of parent drug 
required 
Done in intact systems (cells or 
tissue) 
Can obtain information regarding 
pathways affected by the drug 
Does not measure binding 
directly, thus usually 
statistical methods are used 
to correlate small molecule 
target 
Affinity 
purification 
Immobilized small molecule is incubated with 
cell/tissue lysate and washed. The captured 
proteins are then identified via MS and 
correlated to the small molecule target. 
Only method that measures a direct 
binding event 
Requires modification of 
parent compound 
Requires lysis of cells; i.e. 
doesn’t account for 
distribution of small 
molecule into cells 
Proteome 
stability 
Proteome of a biological system (whole cells 
or lysate) is destabilized (by heat or 
enzymatically), and under the assumption that 
small molecule binding stabilizes its target, 
protein quantities measured by MS are 
correlated to the small molecule target.  
Correlates better with actual drug 
target (versus just measuring 
expression) 
Optimized experimental setup would 
also allow expression profiling data 
to be acquired simultaneously  
Assumption of increased 
stability may not always 
hold true generating false 
negatives 
Experimentally more 
complex as destabilization 
method requires 
optimization 
Table 1.2 Comparison of the different mass spectrometry techniques for small molecule target identification. 
  
Ideally a method for screening small molecules protein targets would function on an 
intact cellular/tissue/animal system, involve no or little modification of the small molecule and 
able to measure direct binding of a drug to proteins. As seen in table 1.2, no method 
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encompasses all these characteristics, however for organic molecules, affinity purification 
based proteomics approaches are widely used and have been successful in identifying the 
targets of kinase inhibitors and natural products.54 However, for metal drugs affinity based 
methods are challenging. To immobilize a drug for affinity purification, appropriate chemical 
strategies must be selected such that the resulting molecule is stable with activity similar to that 
of the parent compound. For organic molecules, this is achieved by introducing long linkers 
located far from the drugs binding site. For metal drugs however, this is less straightforward as 
a) most metal drugs are prodrugs, b) ligands surrounding the metal center can be labile and 
might play an important role in the drugs mechanism. Furthermore, metal drugs tend to be 
promiscuous in protein binding, thus strategies that expose these compounds to a mixture of 
proteins (e.g. cell lysate), may yield many unspecific targets.  
 
A study using affinity purification of a ruthenium(II) based RAPTA-type complex was 
described for lysate of ovarian cancer CH1 cells, where RAPTA was chemically bound via the 
arene to biotin.55 Initial pull-down experiments detected 184 protein targets, which were 
narrowed down to 29 via competition experiments with free compound. Amongst these they 
identified several classes of cancer related proteins which were suspected to be the targets or 
RAPTA, ranging from extracellular growth factors, cell cycle regulators, histone related, and 
ribosomal proteins which are listed in Table 1.3.  
 
 
 
 
The mentioned work, while proving the applicability of affinity purification based 
proteomics approaches to metal complexes, also highlights issues with metal drug promiscuity 
where only 15 of the 29 proteins obtained were cancer related. Other studies on RAPTA 
Table 1.3 List of cancer-related proteins identified by chemical proteomics (adapted from Babak et. al Chem Sci 2015). 
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complexes utilized expression profiling for protein target identification which allowed the use 
of unmodified compound and takes into account the distribution of metal drugs into the 
biological system of choice. A profiling study on protein expression in A2780 ovarian cancer 
cells upon treatment with 300 µM of RAPTA-T for 3 hours followed by 2D liquid 
chromatography separation before mass spectrometry analysis was done revealing expression 
changes in 74 different proteins.56 Of these, nearly 40% were histone related, and the remaining 
were mitochondrial related (11%), cytosolic proteins (7%), ribonuclearproteins (4%), plasma 
membrane proteins (4%), and endoplasmic reticulum related proteins (1%). In a related study, 
protein expression profiles of the same A2780 cell line treated with the antimetastatic ruthenium 
metal drugs RAPTA-T and NAMI-A at 50 µM for 24 hours was performed applying a 2D gel 
separation methodology.57 The study discovered a very similar profile of expression changes 
induced by both compounds and was significantly different from that of the platinum compound 
cisplatin. Tables 1.4 and 1.5  summarize the targets found by the study. 
 
 
Table 1.4 Mass spectrometry identified proteins (adapted from Guidi et.al. J Inorg Biochem 2013). 
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For cisplatin, various expression profiling studies have also been performed.58–62 Simple 
expression profiling studies provide a general idea of the possible classes of protein targets 
perturbed by drug exposure, but do not pinpoint the actual proteins targeted by these drugs. 
There are, however, new expression profiling approaches which utilize modified experimental 
conditions combined with biostatistics calculations to deduce drug targets from induced 
changes in protein expression profiles. One such approach deemed functional identification of 
targets by expression profiling (FITExP)63 will be discussed later in chapter 3.   
 
Methods that identify targets based on protein stability could be very useful for finding 
the targets of metal drugs. These methods infer the protein target of a drug by its effect on 
stabilizing its bound target to either enzymatic degradation64 or thermal denaturation.65 Thus, 
protein targets can be identified by comparison with untreated controls. Though not yet applied 
to metallodrugs, these methods have been used successfully to validate known targets and 
identify new targets of drugs such as rapamycin, FK506, dasatinib, staurosporine and 
FSK3182571. Experimentally, these are more complex than simple expression profiling, 
however protein stability methods provide information on both the drug targets, and expression 
profiles of the compound on the biological system of choice.  Furthermore, since no 
modifications to the parent compound are required and such systems can be adapted for use in 
intact cells, they show great potential for the discovery of metal-drug targets.   
 
 
 
 
 
 
 
Table 1.5 Mass spectrometry identified proteins in common between both compounds (adapted from Guidi et.al. J Inorg Biochem 
2013). 
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1.4.3 Specific metallodrug-protein interactions 
Mass spectrometry has emerged as a powerful tool to study interactions of metallodrugs 
with proteins, and properties such as bound amino acid residues, changes in protein 
conformation, and binding constants can be determined. The main MS techniques that can be 
used to study metallodrug-protein interactions are bottom up or top down MS/MS proteomics, 
ion mobility MS, and hydrogen/deuterium exchange, and are detailed in Table 1.6. 
 
Method Principal Instrumentation 
required 
Information 
obtained 
Advantages  Challenges 
Bottom 
up 
MS/MS 
Metallodrug-protein 
incubations are enzymatically 
digested and fragments are 
analysed by MS to correlate 
metallodrug binding sites on 
proteins 
Mass spectrometers 
coupled with LC 
separation would 
work 
Amino acid 
residues in a 
protein 
where 
metallodrugs 
are bound 
Does not 
require high end 
mass 
spectrometers 
Analysis of 
peptide spectra 
simpler 
More sample 
treatment required 
Enzymatic 
digestion/column 
separation may alter 
binding sites 
Top down 
MS/MS 
Metallodrug-protein 
incubations are directly 
analysed by fragmentation 
MS to correlate metallodrug 
binding sites on proteins 
Usually an orbtitrap 
or FT-ICR mass 
spectrometers for 
proteins above 
10kDa, though lower 
resolution machines 
can be used for 
smaller proteins. 
Amino acid 
residues in a 
protein 
where 
metallodrugs 
are bound 
Retains 
modifications 
to proteins more 
readily due to 
minimal sample 
pre-processing 
Efficiency varies 
based on 
fragmentation method 
chosen 
Data interpretation 
difficult 
Requires expensive 
mass spectrometers  
Difficult for proteins > 
30kDa 
Ion 
mobility 
MS 
Metallodrug-protein 
incubations are separated by 
ion mobility based on mass, 
charge, shape and size, 
subsequent MS analysis 
allows identification of 
separated species 
Ion mobility mass 
spectrometer or 
modules allowing ion 
mobility like 
separations to be 
injected into existing 
mass spectrometers  
Number of 
different 
conformers 
of 
metallodrug-
protein 
adducts 
Allows 
separation of 
different 
conformers for 
subsequent 
analysis 
High cost 
Hydrogen 
deuterium 
exchange 
(HDX) 
Metallodrug-protein 
incubations are incubated 
with deuterated solvents and 
the rate of amide 
hydrogen/deuterium 
exchange rates in the presence 
and absence of ligand  are 
correlated to conformational 
changes 
HPLC modified for 
online pepsin 
digestion and column 
separation coupled 
with a mass 
spectrometer for 
peptide analysis  
Protein 
conformation 
and changes, 
when bound 
to metal 
drug,  
binding 
constants. 
Informative Extensive method 
development required 
Need for expensive 
machinery or 
modifications of 
existing equipment for 
use   
Table 1.6 Comparison of the different mass spectrometry techniques for specific metallodrug-protein interaction 
studies. 
 
A bottom up workflow refers to one involving enzymatic digestion of large proteins into 
smaller peptide fragments before MS analysis.66 Data obtained from these small fragments are 
then linked back to their parent proteins hence the term “bottom up”. This workflow was 
extensively developed for proteomic studies due to its amenability to measure complex protein 
mixtures and large proteins as well as being less reliant on high resolution mass spectrometers.     
Top down methodologies on the other hand, involve direct analysis of proteins via MS and 
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application of fragmentation to trapped gas phase ions to obtain structural information.67 A 
comparison of both methods is shown in Figure 1.6. Currently, bottom up approaches provide 
more useful information on metallodrug-protein binding due to not being limited by protein 
size, where in top down analysis of proteins > 30 kDa68 is difficult due to the high MS resolving 
power required for large proteins.  Furthermore, analysis of different digested fragments 
obtained from bottom up experiments provides valuable information on non-terminal 
metallodrug binding sites on proteins. These are typically not seen in top down MS/MS 
experiments because the obtained spectra are complex and challenging to interpret and there is 
a lack of automated tools for such analysis.  On the other hand, data obtained from bottom up 
approaches are thought to be less reliable due to the many processing steps involved prior to 
MS analysis, which could introduce artefacts such as ligand dissociation or shifts.  Thus, with 
continual advancement of MS technology and software for automated analysis, top down 
methods may become the mainstay of metallodrug protein binding studies.  
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Ion mobility spectrometry allows separation of ions in the gas phase based on their size 
and shape.69 When combined with MS detection, it becomes a powerful technique that provides 
structural information on different conformers of ligands bound to macromolecules. This is 
especially useful for metallodrug-protein interactions, which can occur at different sites in a 
protein leading to various protein confirmations. Hydrogen/deuterium exchange coupled to MS 
allow the study of conformational dynamics of proteins following ligand binding. Structural 
M 
M 
M 
M 
M 
M 
M 
M 
 
 M = metal 
Figure 1.6 Comparison of Top Down and Bottom up mass spectrometry (Adapted and modified from Catherman 
et.al. Biochem. Biophys. Res. Commun., 2014). 
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information on binding is obtained by measurement of the rate of hydrogen/deuterium exchange 
rates on the amide in the presence and absence of ligand which can be mathematically linked 
to induced conformational changes.70 
 
For platinum based drugs various MS studies have been carried out. The binding sites 
of cisplatin on the calcium binding protein calmodulin was elucidated via a combinatorial 
bottom up and top down approach. The approach revealed binding of up to 8 atoms of Pt to 
Met, Glu and Asp residues in calmodulin resulting in the displacement of calcium.71 With the 
undecapeptide substance P, cisplatin was bound to Arg and Lys residues and three different 
confirmers of this binding were revealed with ion mobility measurements.72 Utilizing a bottom 
up approach to elucidate cisplatin binding sites to the 80 kDa iron binding glycoprotein 
transferrin,73 Pt was seen at the hydroxyl group of Thr457 which is located in its iron(III) 
binding site. Furthermore, a study of cisplatin with the copper metallochaperone protein74, 
Atox1 revealed the copper binding site Cys12GlyGlyCys15 as the primary binding site of 
cisplatin.  
 
For the analysis of cisplatin-insulin adducts, both bottom up75 and top down76 
approaches have been attempted. Platinum was found bound to the N terminal B chain His5, 
His10, Cys7, Cys19 residues and A chain Cys6, Cys7 Cys20 residues. It was also observed that 
the bottom up approach was more informative with 7 binding sites identified versus only 3 via 
top down. Another study confirmed the His10 binding site on the B chain of insulin72, and also 
found additional binding sites, Glu13 and Glu31 as well as the cross-linking of residues Lys29 
and E21.  
 
A comparison of the fragmentation methods collision induced dissociation (CID), 
higher-energy C-trap dissociation (HCD), and electron transfer dissociation (ETD) for 
determining binding sites of oxaliplatin on ubiquitin was performed via top down MS. The 
study found Met1, Glu64 and His68 as the binding sites of the drug and showed that ETD was 
more useful than CID or HCD fragmentation for adduct site determination. Subsequently, 
binding of ubiquitin with three platinum drugs; cisplatin, transplatin and oxaliplatin was studied 
via top down MS with CID and infrared multiphoton dissociation (IRMPD).77 It revealed 
binding of oxaliplatin and cisplatin to Met1 and transplatin to a short oligopeptide section of 
19Pro-Ser-Asp-Thr-Ile-Glu24.  
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A comparative study of RAPTA-C, cisplatin and transplatin incubated with ubiquitin, 
cytochrome c and superoxide dismutase was performed using high resolution MS.78 Through 
competitive experiments incubations of all 3 proteins in excess of metallodrug, it was found 
that platinum compounds were less selective than RAPTA-C, which was more reactive towards 
ubiquitin and cytochrome c than superoxide dismutase. Furthermore, both cisplatin and 
RAPTA-C have affinities towards similar amino acid residues upon binding. Bimetallic 
RAPTA complexes were incubated with a model peptide (amino acid sequence 
DAEFRHDSGYEVHHQK) and binding properties were studied via top down MS and IM-
MS.79 ETD fragmentation revealed binding and cross linking of the complex at His residues, 
and additional IM-MS studies revealed two isomeric adduct species leading the authors to 
propose crosslinking between His6-His13 and His6-His14.  
 
1.5 Research objective and thesis layout 
The study of how metallodrugs function is important for two reasons. Most metallodrug 
design approaches involve synthesizing libraries of these compounds and performing 
phenotypic screens against cancer models which has had limited success in generating new 
clinically approved drugs. Thus, an increased understanding of metallodrug action could allow 
tailoring of its ligands to achieve desired drug properties such as specific targeting and release 
or in choosing different metallodrugs for different cancer types, which could increase the 
success rate of metallodrug development. Also, metallodrugs which posess unique properties 
such as anti-metastic or anti-angiogenic action can be useful as tools to understand the 
molecular mechanisms of cancer. This knowledge could then be used to develop more effective 
cancer therapies.  
 
As seen before, MS based approaches for studying the mechanism of action of 
metallodrugs has shed much light on the distribution, protein targets and specific interactions 
of these compounds. However, there are also various drawbacks associated with current MS 
methods, and some potentially useful MS based methodologies have been left unexplored. In 
this work, we develop and utilize MS approaches to study the mechanism of action of 
metallodrugs with a focus on cisplatin and RAPTA-type complexes. Specifically, the IMS 
method Nano-SIMS was developed and used to answer relevant biological problems related to 
cisplatin and RAPTA-T distribution in cells (chapter 2). Functional Identification of Target by 
Expression Proteomics (FITExP), was utilized to screen for potential protein targets of cisplatin, 
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RAPTA-T and RAPTA-EA (chapter 3), and we validated promising protein targets of RAPTA-
T via enzymatic and binding assays (chapter 4). Finally, an automated tool for matching of 
complex mass spectra from high resolution top down and bottom up tandem MS was  developed 
using ubiquitin-cisplatin/RAPTA-T as a model system (chapter 5) and then applied to study the 
binding of RAPTA-C and RAPTA-EA on the zinc finger region of the breast cancer 
susceptibility protein type 1 (chapter 6).  
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2 Chapter 2 
NanoSIMS analysis of an isotopically labelled 
metallodrugs to probe their distribution and 
ligand state in cells.  
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2.1 Introduction 
Mapping the distribution of drugs in cells is essential as it gives valuable insight into its 
site preference and mechanism of action and is therefore a useful tool for tuning the desired 
distribution properties of a drug. For metallodrugs, various strategies for mapping cellular 
distribution have been attempted such as florescence microscopy, radiation induced X-ray 
florescence (SR-XRF), energy-filtered transmission electron microscopy (EFTEM), and 
imaging mass spectrometry (IMS) which have been summarized well in the following review.80 
A unique property of metallodrugs is that they are usually prodrugs which undergo activation, 
either via ligand exchange or changes in oxidation state, before interacting with their desired 
target. This makes it difficult to apply methods that require external labels as used in florescence 
microscopy, as judicious selection of a non-labile site for attachment would be necessary in 
addition to selecting a suitable label which does not affect the physicochemical properties of 
the parent metallodrug.  
 
An ideal technique for studying metallodrug distribution in cells, would involve 
minimal to no modification to the original compound, whilst possessing the ability to visualize 
the metal centre and all ligands simultaneously, with a good sensitivity and spatial resolution. 
In this respect the IMS technique nano-scale secondary ion mass spectrometry (NanoSIMS) 
provides a good balance of desirable properties such as a spatial resolution of up to 50 nm, often 
no requirement of labelling, and the ability to visualize both the metal centre and the ligands if 
isotope labels are applied or the ligands have elements rarely found in biological systems. 
 
 
 
 
 
Figure 2.1 Structures of isotopically labelled metal complexes. 
  
28 
 
NanoSIMS mapping of metallodrugs has been carried out for both gold and platinum 
compounds in cells.37,81 However, for ruthenium, an important metal where certain ruthenium 
metallodrugs are in clinical trials,82 no NanoSIMS methods have been applied to probe the 
cellular distribution of these compounds. Here we developed a NanoSIMS method to study the 
distribution of ruthenium and platinum based metallodrugs in cells. We then apply this 
methodology to explore important biological problems related to the distribution of ruthenium 
and platinum based metallodrugs utilizing isotopically labelled RAPTA-T and cisplatin (Figure 
2.1).   
 
2.2 Results and discussion 
2.2.1 Cell fixation  
 Samples prepared for NanoSIMS must meet several requirements for analysis. They 
must be topographically flat, conducting and able to resist high vacuum.83 Thus cell sample 
preparation for NanoSIMS usually involves dehydration of the sample followed by resin 
embedding and sectioning for NanoSIMS and other complementary analysis. Fixing can be 
achieved via either chemical or cryo fixation methods, and with, cryo fixation achieved via high 
pressure freezing (HPF) and freeze substitution (FS) considered as the best method for 
preserving sample integrity.84  
 
In this study, both chemically fixed and HPF-FS methodologies were used for 
NanoSIMS sample preparation. Figure 2.2 shows counts per layer of 
102
Ru
-
 as
194
Pt
-
 for all 
NanoSIMS runs carried out. Although not directly comparable, as different cell lines and dosing 
regiments and fixation methods were used, the data gives a general idea of the sensitivity of 
NanoSIMS for these metals. On average, the sensitivity of NanoSIMS for ruthenium is lower 
than for platinum regardless of the sample preparation method. A 5-fold loss in sensitivity was 
observed when HPF-FS fixation was used instead of chemical fixation.  This estimate takes into 
account that cisplatin was dosed for twice as long in chemically fixed cells and that previous 
reports show negligible difference in cisplatin concentration in A2780CR cells dosed for 3 or 
24 hours at 10 µM.85 For ruthenium a loss of sensitivity of about 2.5 fold was observed in HPF-
FS fixed cells.   
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Figure 2.2 Graphs of mean counts 
102
Ru
-
 and
194
Pt
-
 per layer. A: 
194
Pt
-
 counts of chemically fixed A2780CR cells 
treated with cisplatin (30 µM, 24 hours). B: 
194
Pt
-
 counts of high pressure freeze fixed A2780CR cells treated with 
cisplatin (30 µM, 12 hours). C:
 102
Ru
-
 counts of chemically fixed A2780CR cells treated with RAPTA-T (500 µM, 
24 hours). D:
 102
Ru
-
 counts of chemically fixed MDA-MB-231 cells treated with RAPTA-T (500 µM, 24 hours). 
 
 The overall loss in sensitivity between conditions can be mostly attributed to the matrix 
difference due to sample preparation. Samples treated by HPF-FS have to be mixed with 
cryoprotectants (fetal bovine serum in our case). This could have reduced the sensitivity of 
NanoSIMS for ruthenium or platinum, thus judicious selection of cryoprotectants for HPF-FS 
should be taken to avoid such losses in sensitivity. 
 
2.2.2 Sample cutting and considerations for TEM imaging  
A challenging aspect of metallodrug analysis in NanoSIMS is the inherent low 
sensitivity for certain transition metal elements such at Pt and Ru due to: 1) Low quantity in the 
sample due to low uptake/dose or sample loss during sample preparation, 2) Low secondary ion 
yields of these elements, 3) matrix effects leading to lowered sensitivity.  
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For platinum and ruthenium based metallodrugs, the low sensitivity necessitates the use 
of long scan times of ~20 hours per image to obtain sufficient signals. Since NanoSIMS is a 
destructive technique, firing an ion beam for such long periods necessitates a sample surface 
thickness of 200-1000nm to avoid puncturing the sample during analysis and minimize signal 
drift during long analysis times. However, due to the limits of electron transmission, thick 
samples are difficult to analyze via transmission electron microscopy (TEM), a useful method 
providing ultrastructural details of cellular organelles which cannot be seen using NanoSIMS 
alone.  
 
In our work, we attempted to circumvent this issue by consecutive sectioning of thin 
sections (~50 nm) for TEM followed by semi-thin sections (~500 nm) for NanoSIMS.  As a 
result of the overlay of the TEM and NanoSIMS images, though not perfectly correlating, was 
considered sufficiently accurate, considering that the size of most cellular organelles are above 
1 µm in diameter and that ion beam rastoring during analysis would only remove < 100 nm of 
the sample surface.    
 
2.2.3 NanoSIMS imaging of isotopically labelled RAPTA-T in A2780CR cells. 
To develop a NanoSIMS method for ruthenium imaging, we dosed a cisplatin resistant 
ovarian cancer cell line (A2780CR) with 500µM of isotopically labelled RAPTA-T (enriched 
with six 13C atoms on 6-toluene, and three 15N atoms on PTA) for 24 hours. Subsequently the 
cells were chemically fixed, dehydrated, resin embedded and cut into semi thin sections for 
NanoSIMS imaging. 
 
     NanoSIMS was used to image the distribution of 13C, 15N, and Ru and in order to 
visualize where in cells the RAPTA-T molecules located, and if they remain intact, using the 
NanoSIMS we sputtered semi-thin sections with a primary Cs+-beam current of 4 pA and a 
probe size of ~150 µm (see experimental section for details) for a scanning .time of ca. 22 hours, 
corresponding to 120 consecutive images with 256*256 pixels over an area of 30x30 µm2. 
102Ru- counts steadily increased with time, plateauing at around 8 hours (~40 planes) into the 
analysis (Figure 2.2, C), demonstrating that a large dose of Cs+ implantation is required before 
efficient ionization of 102Ru- is achieved. Such long analysis times represent a severe challenge 
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with respect to machine stability. For example, even small thermal perturbations can cause the 
instrument, and hence the images, to drift. By minimizing any thermal perturbation to the 
instrument for over one week (including not entering the lab-space around the instrument), we 
obtained an image drift totaling only 6 pixels during the 22 hour acquisition period, 
corresponding to 0.7 microns. Such stable instrument conditions make it possible to add all 
images together with minimal drift correction, and thus obtain clear total images of even very 
weak signals. 
 
 
 
Figure 2.3 shows the elemental distribution maps obtained from a resin-embedded 
section of A2780CR cells after 24 hours exposure to 500 µM of isotopically labelled RAPTA-
T. Highly resolved images of 14N12C-, 32S-, and 31P- allow clear visualization of the cellular 
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Figure 2.3 Secondary ion maps of 
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-, 
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S-/
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C
2
-, 
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-, 
15
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C-/
 14
N
12
C-
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 12
C
2
- and
 13
C
12
C-/
12
C
2
- (Figure 
labels have been simplified) in A2780CR cells treated with 
15
N and 
13
C-labelled RAPTA-T (500 µM, 24 hours). White line 
(AB) represents the line profile shown in Figure 2.6.  
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compartments of the cell (labelled in Figure 2.5, B). The 13C/12C map (Figure 2.3) shows faint 
variations in the 13C/12C between cell interiors and the adjacent epoxy resin (also observed in 
untreated controls, Figure 2.4), but no clear enrichments that can be ascribed to the presence of 
isotopically labeled RAPTA-T molecules, or its subcomponents. This absence of discernable 
13
C enrichment in regions clearly enriched in 
15
N and Ru (Figure 2.3 and 2.6) could indicate 
that sample preparation (which includes epoxy embedding) dilutes the 13C-isotopic enrichment 
from the 13C-enriched 6-toluene ligands to below the detection limit of the NanoSIMS.86 
However, given the strength of the 15N enrichment observed, the presence of the corresponding 
13C-enriched 6-toluene ligands should be visible in these NanoSIMS 13C/12C images, which 
would reveal 13C-enrichment anomalies down to about 30‰. Thus, it is not unreasonable to 
hypothesize that the 13C-enriched 6-toluene ligands have partially detached from the complex 
and have been diluted over the sample. Indeed, dissociation of the arene has been previously 
observed in binding studies to isolated oligonucleotides.87 In humans, this detached toluene 
would undergo detoxifaction in the liver to hippuric acid which would then be excreted in the 
kidneys.88  
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Figure 2.4 Secondary ion maps of 
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- in 
untreated A2780CR cells. (Figure labels have been simplified). 
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On the other hand, overlaid images of 15N/14N, Ru/C (Figure 2.5, D) and line profiles 
(Figure 2.6, B) reveal co-accumulation of 15N and Ru indicating that the PTA ligand remains 
coordinated to the metal center after 24 hours. Enrichment via 15N (hereby used as a marker for 
RAPTA-T enrichment) is mainly seen on the cell membrane or interphase between cells (Figure 
2.5 A, B & C). The observed localization of RAPTA-T indicates that interactions with 
membrane receptors or extracellular proteins are likely to be critical to its mode of action. In 
this respect, it has been previously shown that RAPTA-T interacts with cell adhesion proteins 
such as fibronectin and collagen IV, preventing detachment and re-adhesion of highly 
metastatic breast cancer cells.89,90  
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Figure 2.5 Composite RBG images of semi thin sections of A2780CR cells treated with 
15
N and 
13
C labelled RAPTA-
T (500 µM, 24 hours).  
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34 
 
 
 
Only small pockets of Ru were observed inside the cells, (Figure 2.3, arrows). From the 
cellular compartments identified (Figure 2.5, B), these pockets seem to lie generally within the 
nuclear region of the cells which is likely as RAPTA complexes have been shown to bind to 
histones.91,92 However, the exact subcellular localization cannot be determined accurately 
without correlated electron microscope imaging. The lack of correlation between these 102Ru- 
hotspots and 32S- shows that RAPTA-T distributes differently to cisplatin, which was found to 
accumulate in the nucleolus and S-rich regions of the cells.81 This difference is not unexpected 
considering the contrasting in vitro and in vivo anti-tumor effects of cisplatin and RAPTA-T, 
respectively. The observed distribution pattern is in reasonable agreement with cell uptake 
studies of RAPTA-T in A2780 CR cells,93 where ruthenium was found in the membrane as well 
as the particulate, cytoskeletal and nuclear fractions under similar treatment conditions.  
 
From our data, the observed co-accumulation of 15N and Ru shows that the PTA ligand 
remains coordinated to the ruthenium ion. This result highlights one of the key strengths of 
NanoSIMS for the detection of metal-based drugs, i.e. that the stability/lability of the ligands 
coordinated to the metal center can be probed via isotopic labelling. The ability to differentiate 
between the accumulation of a compound on the membrane versus intracellular accumulation 
in specific organelles illustrates the utility of the NanoSIMS relative to other techniques used 
to probe metallodrug distribution, other such techniques include inductively coupled plasma 
mass spectrometry and atomic absorption spectroscopy,93,85,94,95 where such a spatial distinction 
cannot be made without cell fractionation, a process likely to introduce other distribution 
artifacts.       
 
In the case of RAPTA-T, the liability of the 6-toluene ligand presumably acts, in 
addition to aquation, as an activation mechanism of the compound, although the extent of 
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detachment is difficult to assess from the data. Moreover, the observed accumulation of Ru on 
the membrane or at the interface between cells is in agreement with a number of in vitro and in 
vivo properties of RAPTA-T93,96 and provides further insight into the drugs mechanism of 
action.  
2.2.4 NanoSIMS imaging of isotopically labelled cisplatin in ovarian cancer 
cells. 
The method used to image RAPTA-T was adapted for imaging platinum via NanoSIMS. 
As a proof of principle, A2780CR cells were exposed to 30 µM of isotopically labelled cisplatin 
(enriched with two atoms of 15N) for 24 hours. Subsequently the cells were chemically fixed 
and prepared for NanoSIMS imaging as semi-thin sections.  
 
From secondary ion maps of Pt (Figure 2.7) there is no enrichment observed in the 
nucleus of A2780CR cells. This is not surprising considering cisplatin acts by forming adducts 
with DNA and thus its site of action is the nucleolus.38 Therefore the resistance of this cell line 
could be due to reduced net Pt accumulation in the nucleus caused by mechanisms such as 
reduced uptake, increased efflux or increased detoxification of the drug.38 Pt enrichment is 
generally well correlated with sulfur rich hotspots which could be associated with sulfur 
containing molecules such as glutathione, metallothioneines and thioredoxins which detoxify 
metals in cells. This was similarly observed in other reports of NanoSIMS for studying Pt 
distribution in cells.81 
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There was a co-enrichment of 15N and Pt observed at various Pt hotspots (red boxes in 
the 15N/14N maps in Figure 2.7). This shows that there is at least some detachment of the NH3 
ligand from cisplatin correlating to what was previously reported.81 Surprisingly, we also 
observed an enrichment of 15N in the nucleolus of the cells. Though we cannot explain this 
observation with our current experimental data, presumably over the course of the 24 hour 
incubation, cisplatin entered the nucleolus and subsequently the Pt moiety could be detoxified 
or effluxed leaving only the NH3.  
 
Having developed a Pt imaging method via NanoSIMS, we proceeded to apply this to 
study cellular resistance to cisplatin. Though cisplatin is used as first line treatment for a wide 
range of malignancies including testicular, ovarian and lung cancers, a major challenge with its 
use is the development of resistance to the drug which results in the recurrence of cancers 
insensitive to platinum therapy.97 This resistance is thought to be mediated by a plethora of 
factors including under expression of membrane transporters, overexpression of drug efflux 
pumps, expression of proteins related to stress response such as heat shock and ribosomal 
Nu 
N 
NM 
C 
CM 
Figure 2.7 Secondary ion maps of 
31
P-/
 12
C
2
-, 
32
S-/
 12
C
2
-, 
15
N
12
C-/
 14
N
12
C-
  
and 
194
Pt-/
 12
C
2
- of  two A2780CR cells 
treated with cisplatin (30 µM, 24 hours). Yellow boxes are platinum enriched hotspots. Subcellular 
compartments N (nucleus), Nu (nucleolus), C (cytoplasm), NM (nuclear membrane) and CM (cell membrane) 
have been labelled in the 
31
P-/
 12
C
2 map. 
  
37 
 
proteins, epigenetic changes in DNA methylation, chromatin and histones, changes in 
transcription factors and signalling pathways and involvement of microRNAs.97  
 
Due to the complexity of cisplatin resistance, developing strategies for overcoming 
resistance to these drugs is challenging due to the many facets of resistance development. Thus 
it is important to understand which factors contribute most to resistance in order to find 
solutions to this issue.  Imaging of the distribution of cisplatin in cells could shed light on 
resistance to cisplatin, as certain aspects of resistance can be localized to particular cellular 
organelles or seen as shifts in distribution or concentrations of the drug in cellular systems. 
Here, we studied the distribution of A2780 cisplatin sensitive and resistant cells exposed to 30 
µM of isotopically labelled cisplatin for 12 hours. We applied HPF-FS as a fixation method as 
it is reported to be superior to chemical fixation in terms of retaining cellular morphology and 
distribution of diffusible ions.98 The selection of a shorter incubation period of 12 hours and 
different fixation method was mainly due to our previous unexplained observation where 15N 
was enriched in the nucleus in the absence of Pt. This could potentially be caused by 
distributional effects which occur over long incubation times or distributional defects caused 
by organic solvent dehydration during cell preparation for NanoSIMS thus we modified these 
parameters accordingly to resolve this.  
 
 
 
Cisplatin 
sensitive  
Cisplatin 
resistant 
Figure 2.8 Secondary ion maps of 
194
Pt-/
 12
C
2
- of A2780 sensitive and cisplatin resistant cells treated with cisplatin (30 
µM, 12 hours). 
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NanoSIMS elemental maps of 
31
P-/
 12
C
2
-, provide clear visualization of the major cellular 
compartments, including the nucleus, nucleolus, cytoplasm and nuclear/cellular membranes 
(Figure 2.9). The TEM images provided extra structural details of smaller organelles such as 
autophagosomes, mitochondria, and lysosomes. From the 194Pt- maps of A2780 and A2780CR 
cells (Figure 2.8), we observed much lower amounts of platinum in the cisplatin resistant cell. 
This difference in accumulation is in accordance with various studies comparing cisplatin 
resistant and sensitive cell lines85,99,100, and agrees well with resistance being mediated by 
mechanisms of increased efflux or impaired uptake.97 
 
 
 
We next scrutinized the distribution of platinum in the two cell lines to compare if 
resistance may be brought about by distributional differences between the cells. Significantly, 
combining NanoSIMS images with ~100 nm spatial resolution with excellent low nm spatial 
resolution of TEM images, allowed unparalleled comparison for determination of distribution 
of Pt in the cells. In A2780 cells (Figure 2.9), platinum was seen to distribute diffusely 
throughout the cell with some areas having larger agglomerations of Pt signal. These Pt hotspots 
Figure 2.9 Secondary ion maps of 
31
P-/
 12
C
2
-, 
32
S-/
 12
C
2
-, 
194
Pt-/
 12
C
2
- and TEM of A2780 cells treated with 
cisplatin (30 µM, 12 hours). Boxes represent platinum enriched hotspots which were overlaid in other elemental 
maps and the TEM images. Mitochondria and autophagosome are labelled in red and blue boxes respectively in 
the TEM image. Subcellular compartments N (nucleus), Nu (nucleolus), C (cytoplasm), NM (nuclear membrane) 
and CM (cell membrane) have been labelled in the 
31
P-/
 12
C
2 map. 
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seem to co-accumulate at nucleolus of the cell as seen in both 
31
P-/
 12
C
2
- and TEM images. This 
is in agreement with cisplatins mechanism of action of entering the nucleolus and forming 
crosslinked adducts with DNA.101 The distribution pattern however, also shows that only a 
small fraction of Pt is in the nucleolus and the remaining is thus largely available to interact 
with other cellular organelles and proteins as confirmed by various proteomic studies.  
 
 
From TEM images, we found platinum hotspots accumulating in both an 
autophagosome and in the mitochondria of A2780 (Figure 2.9). The formation of 
autophagosomes is important for removing damaged organelles and molecules, which are then 
degraded by lysosomes.102 A previous study has shown that the formation of autophagosomes 
is involved in the detoxification of cisplatin,103 which correlates well with our findings. 
Cisplatin has been also shown to act in the mitochondria either by binding mitochondrial 
DNA104,105 or inducing a mitochondrial-reactive oxygen species response,106 which contributes 
to its cytotoxicity. In A2780CR cells however (Figure 2.10), little nuclear accumulation was 
observed and the small pockets of Pt seen were mostly co-accumulated with sulfur in the cell, 
which correspond to areas associated with sulfur containing molecules involved in metal 
detoxification as seen previously in section 2.2.3.  
 
 The switch in fixation method and dosing duration however resulted in no enrichment 
of 15N in the samples (Figure 2.11). Considering that only very weak 15N enrichment in cells 
dosed with isotopically labelled platinum complexes has been observed before,40,81 and the 
weak 15N enrichment observed previously in chemically fixed samples dosed with cisplatin 
(Figure 2.7), presumably the change in fixation methods resulted in a lowered ionization yield 
of 15N resulted in no observable enrichment.   
Figure 2.10 Secondary ion maps of 
31
P-/
 12
C
2
-, 
32
S-/
 12
C
2
-, 
194
Pt-/
 12
C
2
- of A2780CR cells treated with cisplatin (30 
µM, 12 hours). Boxes represent Pt enriched spots in cells. 
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Overall, we used NanoSIMS combined with TEM for studying the distribution of 
cisplatin in ovarian cancer cells sensitive and resistant to the drug. NanoSIMS elemental maps 
allowed us to semi-quantitatively determine cellular accumulation and distribution of Pt in cells. 
We observed a reduced accumulation of Pt in cisplatin resistant cells as compared to its cisplatin 
sensitive counterpart. We also visualized for the first time Pt accumulation in mitochondria and 
autophagosomes, which was previously shown indirectly with methods such as cell 
fractionation followed by ICP-MS32 or inferred from phenotypic studies.103 Our findings 
demonstrate the potential of using NanoSIMS to shed light on complex biological problems 
related to the clinical use of Pt metallodrugs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 
2.2.5 NanoSIMS imaging to study the distribution of RAPTA-T in non-
invasive and invasive breast cancer cells. 
 The ruthenium(II) metallodrug RAPTA-T has been shown to possess in vitro anti-
metastatic properties, where the drug prevented migration, detachment and reattachment of 
invasive MDA-MB-231 breast cancer cells significantly more effectively than non-invasive 
MCF-7 breast cancer cells.96 In addition, studies in an in vivo mammary carcinoma murine 
model showed RAPTA-T treatment was effective in preventing the lung metastasis of these 
tumors.96 Thus, having shown the applicability of NanoSIMS for imaging RAPTA-T in 
A2780CR cells, we extended this work to study its distribution in MDA-MB-231 and MCF-7 
cells to probe whether there is a difference in distribution in cells possessing different metastatic 
phenotypes. Both MCF-7 and MDA-MB-231 breast cancer adenocarcinomas isolated from 
pleural effusions.107 Genetically, MDA-MB-231 are a triple negative cell line lacking estrogen 
and progesterone receptors in addition to having no HER2/Neu amplification leading to it being 
resistant to most chemotherapeutic agents versus MCF-7 cells which are positive for both 
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 14
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cisplatin (30 µM, 12 hours). 
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estrogen and progesterone receptors and thus sensitive to hormonal based therapies.108   For this 
work, cells were dosed with 500 µM of isotopically labelled RAPTA-T for 24 hours and applied 
HPF-FS for cell fixation in lieu of chemical fixation used in the previous study with RAPTA-
T in 2.2.3.  
 
 As seen in A2780CR cells treated with RAPTA-T, 13C enrichment was not observed in 
RAPTA-T treated MDA-MB-231 and MCF-7 cells showing that there is at least partial 
detachment of the 6-toluene in RAPTA-T during the 24 hour incubation period. In MDA-MB-
231 cells, all Ru hotspots found were co-enriched with 15N (Figure 2.12, green boxes) showing 
that part of the phosphine ligand in RAPTA-T stays intact. However, there were several 15N 
enriched hotspots which did contain Ru.  This could be attributed to either detachment of PTA 
from Ru or the loss of sensitivity for Ru detection due to matrix changes induced by HPF-FS 
fixation (Figure 2.2). Having, previously shown a strong correlation between 15N and Ru signal 
(section 2.2.3) we used 15N maps as a marker for the presence of RAPTA-T.  
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RAPTA-T was seen to distribute into the nucleolus of MDA-MB-231 cells (Figure 
2.12). This is highly likely considering RAPTA-T has been shown to interact with the histone 
proteins which package and order DNA into nucleosomes.91 We also observed accumulation of 
RAPTA-T on the cell membrane of MDA-MB-231 cells where it could interact with 
extracellular cell adhesion proteins implicated in its anti-metastatic activity.96 When Ru/15N 
maps are overlaid with TEM images, we observed RAPTA-T accumulation in autophagic 
vacuoles as well as mitochondria. Since autophagy is involved in detoxification of harmful 
substances in cells,102 presumably RAPTA-T is also removed by this mechanism. The 
distribution and action of RAPTA-T in mitochondria has been shown previously, where 
treatment with the drug resulted in an appreciable accumulation in mitochondrial fractions of 
cells85 and results in perturbation of the expression of several mitochondrial proteins.93 We 
observed a general co-accumulation of sulfur in RAPTA-T enriched hotspots which is 
unsurprising considering most organelles in which RAPTA-T is distributed to contain sulfur 
rich molecules such as iron sulfur clusters in mitochondria and the nucleus109 as well as sulfur 
containing molecules such as glutathione, metallothioneines and thioredoxins which detoxify 
metals in cells. 
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TEM of MCF-7 cells treated with 
15
N and 
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C-labelled RAPTA-T (500µM, 24 hours). Blue boxes show Ru enriched hotspots, 
yellow boxes show 15N enriched hotspots and green boxes show hotspots co-enrichment with 15N and Ru. 
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In MCF-7 cells, we found accumulation of RAPTA-T in the nucleolus and a general co-
accumulation of the drug at sulfur rich hotspots, which was similarly observed in MDA-MB-
231 cells (Figure 2.13). We did not see any accumulation of RAPTA-T in the nucleus or cell 
membrane. However, from overlaid TEM images RAPTA-T was seen to accumulate in 
mitochondria and lysosomal structures. The lack of distribution in the nucleus and membrane 
of MCF-7 cells could partially explain the weaker activity of RAPTA-T in preventing 
migration, detachment and reattachment of these cells compared to MDA-MB-231 cells. 
Similar to MDA-MB-231 cells, mitochondrial accumulation was expected and lysosomal 
accumulation could be attributed to cellular processes related to detoxification of heavy metals.  
 
 When compared to our earlier study on A2780CR cells, we see a marked decreased in 
accumulation of RAPTA-T in the membrane of both MDA-MB-231 and MCF-7 cells. These 
could be caused by various factors. Firstly, the cells were derived from two different cell lines 
where A2780CR is an ovarian cancer cell, and MDA-MB-231 and MCF-7 are breast cancer 
cells. Thus the difference in RAPTA-T distribution is partially caused by the heterogeneity both 
in terms of cell type and phenotype. It has been shown previously that A2780CR cells unlike 
their cisplatin sensitive counterparts undergo metastasis and shorten survival rates of mice 
xenografted with these cells.110 Considering the fact that both A2780CR and MDA-MB-231 
are both highly invasive, this strengthens the tenet that membrane association of RAPTA-T 
could be correlated with its anti-metastatic properties. This is further exemplified by the lack 
of membrane accumulation of RAPTA-T in noninvasive MCF-7 cells.  
 
 Overall, we successfully applied NanoSIMS to differentiate between the distribution of 
RAPTA-T in invasive and non-invasive breast cancer cell lines. The distributional differences 
observed provide some insight into how RAPTA-T distribution correlates with the phenotypic 
changes induced by its activity on cancer cells.   
 
2.3 Conclusion 
 We have successfully developed methods for visualizing Pt and Ru metallodrugs in cells 
using NanoSIMS. We applied this method to study distribution of the metallodrugs cisplatin 
and RAPTA-T in biologically relevant cell lines to investigate the differences and whether they 
correlate well with the mechanisms of action and resistance to these drugs. For cisplatin, ovarian 
cancer cells resistant to cisplatin exhibit markedly reduced accumulation of the drug and in the 
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sensitive variant we observed accumulation of cisplatin in the mitochondria and 
authophagosome. For RAPTA-T, we observed partial loss of the arene and possibly the 
phosphine ligand which could be important for drug activation. RAPTA-T’s distribution pattern 
was markedly different between ovarian and breast cancer cells, and we observed a larger extent 
of membrane association of the drug in invasive cancer cell lines, which could partly explain 
how RAPTA-T exerts its anti-metastatic activity. These findings showcase the applicability of 
NanoSIMS to study complex biological problems involving cellular metallodrug distribution. 
With further developments in speed, sensitivity, and spatial resolution of NanoSIMS 
instrumentation, it could potentially be applied for metallodrug development, where tuning of 
ligands to achieve specific subcellular distribution of metallodrugs could be facilitated by this 
technique.   
 
2.4 Experimental 
Cell preparation for NanoSIMS (fixation, resin embedding and cutting) and TEM imaging 
was performed by the biological electron microscopy centre in the EPFL. Sample gold 
coating and NanoSIMS data acquisition was performed in the Laboratory for Geological 
Biochemistry, EPFL.  
 
2.4.1 Synthesis of 15N labelled cisplatin and 13C, 15N labelled RAPTA-T.  
15N labelled cisplatin was synthesized according to literature method111 by replacing 14NH4OH 
with 15NH4OH. 
15N enriched 1,3,5,7-tetraazatricyclo[3.3.1.1 (3,7)] decane was synthesized 
using a literature method112 by replacing 14NH4OH with 
15NH4OH and used to prepare 
15N 
labelled 1,2,5-triaza-7-phosphatricyclo[3.3.1.1.] decane (PTA).113 13C labelled metyl-
cyclohexadiene was synthesized from a birch reduction of Toluene-(phenyl-13C6) and used to 
prepare RAPTA-T.114 
15N, 13C Enriched RAPTA-T 
1H NMR (400 MHz, Methanol-d4) = δ 5.95 – 5.22 (m, 5H), 4.60 (s, 6H), 4.35 (s, 6H), 2.17 (s, 
3H). 
13C NMR (101 MHz, Methanol-d4) only enriched 
13C = δ 108.33, 88.64 – 85.31 (m), 77.87 – 
75.73 (m). 
31P NMR (162 MHz, Methanol-d4) = δ -33.43. 
HRMS (ESI+) m/z calculated for C7
13C6H20Cl
15N3PRu [M-Cl+H]
+: 395.0239; found: 395.0242 
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2.4.2 Cell culture 
A2780 cisplatin sensitive and resistant (human ovarian carcinoma) [A2780 and A2780CR] cells 
(ATCC) were cultured in RPMI 1640 Glutamax medium supplemented with 10% fetal calf 
serum, penicillin 100 units/mL streptomycin 100 µg/mL (Invitrogen). MDA-MB-231 and 
MCF-7 (human breast adenocarcinoma) were cultured in DMEM medium supplemented with 
10% fetal calf serum, penicillin 100 units/mL streptomycin 100 µg/mL (Invitrogen). Cells were 
incubated at 37⁰C in a moist environment containing 5% CO2. 
 
2.4.3 Cell preparation  
Cells were seeded 50000 cells/well in 24-well or 500000cells/well in 6-well clear bottom plates 
fitted with 13mm thermanox slips or sapphire disks. After 24 hours, cell media was aspirated 
and fresh media containing 15N cisplatin 30 µM or 15N, 13C, RAPTA-T 500 µM was added.  
Chemical fixation 
Upon incubation, media was aspirated, and cells were washed twice with PBS. Subsequently 
cells were fixed with buffered aldehydes (2% PAF, 2.5% Gluteraldehyde in PBO 1M, pH 7.4) 
for one hour and then washed in cacodylate buffer (0.1M, pH 7.4). Then cells were postfixed 
for 40 minutes in a solution of 1% osmium tetraoxide and 1.5% potassium ferrocyanide in 
cacodylate buffer. This was followed by a further staining of 1% osmium tetraoxide in 
cacodylate buffer, for 40 minutes, and then 1% aqueous solution of uranyl acetate for 40 
minutes. The samples were then dehydrated in an ascending alcohol series (1 X 50%, 1 X 70%, 
2 X 96%, 2 X 100%, 3 minutes each) and resin embedded with Durcupan resin which was then 
hardened overnight at 65 ⁰C. The resin embedded cells were semi-thin sectioned onto glass 
coverslips ready for analysis in the nanoSIMS. 
HPF-FS fixation 
Upon incubation, sapphire disks were removed from media and then high pressure frozen (Leica 
HPM100, Leica Microsystems), with excess 20% BSA solution in 0.01M PBS (phosphate 
buffer solution) to avoid any air bubbles becoming trapped and the formation of ice crystals. 
The frozen cells were then embedded in resin at low temperature.115 Sapphire discs were placed 
on a frozen solution of 1% osmium, 0.5% uranyl acetate, 5% water in pure acetone. The samples 
where then warmed to room temperature in an ice bucket containing solid carbon dioxide blocks 
that was allowed to sublime over a period of 2 hours until room temperature was reached. At 
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this point the solution was removed and replaced with dry acetone. After washing a further 2 
times with acetone the samples were embedded in increasing concentrations of epon resin in 
acetone. At 100% concentration of resin the samples were then left overnight to fully infiltrate 
and then polymerised in a 60C oven for at least 12 hours. Samples where then glued to empty 
resin blocks, trimmed, and sections of alternating thickness of 500nm and 50 nm cut 
sequentially from the face. The thicker sections were collected onto a glass coverslip stained 
with 1% touldine blue and imaged with light microscopy, and nanoSIMS, and the 50 nm thick 
sections collected on to an electron microscopy slot grid ready for imaging with transmission 
electron microscopy at a final magnification of around 1400 times (Tecnai Spirit, FEI 
Company, Netherlands). 
 
2.4.4 Nano-SIMS analysis  
NanoSIMS measurements were performed at the Laboratory of Biological Geochemistry, EPFL 
and the Universtiy of Lausanne. Prior to NanoSIMS imaging, the samples were gold-coated in 
order to avoid charging effects. Before acquiring an image, Cs ions were implanted into the 
surface of the sample in order to enhance the ionization of the element of interests. In our study, 
the electron multiplier detectors were set up to measure 12C2
−, 13C12C−, 12C14N−, 12C15N−, 31P−, 
32S−, 102Ru− and 194Pt− secondary ions, generated by bombarding the sample with a ~4 pA Cs+ 
primary beam focused to a spot size of approximately 160 nm. In order to resolve the possible 
isobaric interferences, the instrument was operated at a mass-resolving power (MRP) of about 
10.000. For102Ru- and 194Pt− due to the very low signal obtained on cells, peak-shape and mass 
resolving power was checked using a Ru and Ptmetal standard. Data acquisition was performed 
by scanning the Cs+ primary beam over areas of 34x34µm with a 256x256 pixel image 
resolution. The per pixel dwell time of the primary ion beam was 10 ms. The final images are 
the accumulation of 120 layers obtained by sequential scanning and correspond to a cumulated 
acquisition time per pixel of 1.2 seconds. Between every layer, the focusing of the secondary 
ion beam was optimized and automatic peak centering was performed for 12C2
−, 13C12C−, 
12C14N−, 12C15N−. The Ru and Pt peak could not be centered due to the low count rates. 
However, post-analysis check revealed that there was no significant change in the peaks 
position during the entire acquisition time. The total acquisition time including the centering 
procedure was 22 h per image. 
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2.4.5 Data extraction and image processing 
All Nano-SIMS image processing was performed using MatLab with the look@NanoSIMS 
program (http://nanosims.geo.uu.nl/nanosims-wiki/doku.php/nanosims:lans) and with L'image 
(L. Nittler, Carnegie Institution of Washington). Over the 22 hours of image acquisition, the 
image drift of a 34x34 µm image was less than 7 pixels (i.e. less than 1µm). The data reduction 
software can easily correct for such a drift by aligning the position of identified structures. 
Regions of interest (ROI’s) were defined manually based on identifiable cell features on 12C14N-
, 31P- and 32S- elemental maps. Images were accumulated from planes where accumulated counts 
per ROI were stable with 12C14N- used as the alignment mass. Natural abundance ratios of 
13C/12C and 15N/14N were obtained from elemental maps of untreated cells. Ratios for 
isotopically enriched elements were calculated using the delta-notation:     
 
δ = [(
𝐫𝐚𝐭𝐢𝐨 𝐦𝐞𝐚𝐬𝐮𝐫𝐞𝐝
𝐬𝐭𝐚𝐧𝐝𝐚𝐫𝐝 𝐫𝐚𝐭𝐢𝐨 𝐦𝐞𝐚𝐬𝐮𝐫𝐞𝐝
) − 𝟏] ∗ 𝟏𝟎𝟎𝟎 
 
All other elements were normalized against 12C2, the images of which are essentially flat, to 
normalize out small ionization variations across the sample surface. 
For comparative red, green, blue (RGB) images, 15N12C-/14N12C- is colored green and 102Ru-
/12C2
-, 14N12C-/12C2
-, 31P-/12C2
-, and 32S-/12C2
- are colored red.  
Data for line profiles and mean counts/region of interest graphs were extracted using L'image 
and replotted using GraphPad Prism version 6.00 for Windows.   
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3 Chapter 3 
Functional identification of targets by expression 
proteomics (FITExP) for identification of 
cisplatin, RAPTA-T and RAPTA-EA protein 
targets. 
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3.1 Introduction 
Simple RAPTA complexes (with benzene, toluene or p-cymene arenes) are not known 
to be as toxic to primary tumors as classical metallodrugs such as cisplatin.116 However, these 
complexes possess interesting anti-metastatic96 and antiangiogenic117 properties, and various 
functionalities can be introduced via the arene or PTA moiety to augment their anti-cancer 
activity. Due to their very different activity from cisplatin, the biological target of RAPTA 
complexes are thought to be proteins and not DNA.33 Furthermore cellular fractionation of 
cancer cells exposed to RAPTA complexes have also revealed that an appreciable amount 
distributes to cytosolic and mitochondrial fractions containing proteins.32   
 
 
 
 
 
 
 
Identifying the protein targets of metallodrugs presents unique challenge as these drugs 
exhibit promiscuity in protein binding, where any exposed labile amino acid residues such as 
cysteine, methionine, glutamic acid and histidine can potentially coordinate to these 
compounds.118 Thus, affinity purification based methods for protein target screening, which are 
extremely useful for organic molecules, are less useful for metallodrugs due to the amount of 
unspecific interactions which can occur.55 To be useful for metallodrug target identification 
methodologies must also take into account the pharmacokinetics of absorption and distribution 
of compounds into their cellular compartments. Thus, methods such as proteome expression 
profiling which rely on probing targets in whole cells,119 are more informative for metallodrugs. 
Standard proteome expression profiling experiments provide a general profile of regulated 
proteins in the presence and absence of drug treatment and this information is then linked to the 
mechanism of the drug. Two such approaches were performed on RAPTA-type complexes.57,119 
However, these studies do not directly reveal the primary protein target of the drugs as changes 
in protein regulation can be brought about by a plethora of mechanisms besides ligand binding 
to proteins.  
            RAPTA-EA                                                                RAPTA-T             
Figure 3.1 RAPTA complexes used in the FITExP study 
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Recently, a protein expression profiling method for direct identification of the protein 
target of small molecules called Functional Identification of Target by Expression Proteomics 
(FITExP) was reported.63 FITExP operates based on the observation that for the protein target 
of small molecules, the abundance change in late apoptosis is exceptionally large compared to 
other proteins that are normally co-regulated with the drug-target.63 Experimentally, two to 
three different cancer cell lines are treated with apoptosis inducing concentrations of the 
compound of interest and several control anti-cancer drugs which proteins targets are known. 
For every cell line, protein and drug treatment three characteristics namely regulation, 
specificity and exceptionality are calculated. Regulation denotes the change in protein 
expression from untreated controls. Specificity was defined as regulation for a given treatment 
normalized by the average regulation in other treatments and controls. Exceptionality is a 
quantitative assessment of unexpected character of a proteins regulation in a given treatment. 
These three characteristics were then subjected to rank product analysis that calculated final 
ranks and p-values for protein candidates. For drug target identification, using exceptionality 
and regulation provided a short list of statistically significant candidates (hereby called the 
“main target list”), while for mechanism of action using regulation and specificity provided a 
longer list of implicated proteins (hereby called the “associated protein list”) to be mapped on 
protein-protein networks (Figure 3.2). This approach overcomes the limitations associated with 
standard proteome expression profiling methods in identification of protein targets of anti-
cancer compounds.   
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Figure 3.2 General workflow of the FITExP method for drug target identification. (a) a panel of cell lines 
is treated by a panel of drugs; (b) LC-MS/MS based proteomics identifies and quantifies ≥3,500 proteins, 
proteomic profiles are shown in a schematic heatmap with color-coded normalized abundances; the 
dendrogram shows hierarchical clustering of proteomic profiles with correlation-based distances; (c) for 
each protein, cell line and treatment, regulation (Reg), specificity (Spec) and exceptionality Exc are 
calculated; (d) for each treatment, final protein ranks based on Reg and Exc are established and the p-values 
are calculated using the Bonferroni correction; the protein list is sorted in ascending order of p-values; (e) 
proteins with p ≤ 0.05 (threshold p-value) represent the most likely drug targets; (f) top n proteins with 
p ≤ 0.05 according to Reg and Spec rankings are mapped on protein networks to identify the drug target 
mechanism. (Figure adapted from Chernobrovkin et. al. Sci. Rep. 2015). 
 
In this work, we used FITExP to study the protein targets of RAPTA-T, a GSH 
inhibiting RAPTA complex RAPTA-EA120 and cisplatin. We performed analysis in two breast 
cancer cell lines, highly invasive MDA-MB-231 cells and non-invasive MCF-7. Paclitaxel 
served as controls of known biological targets.  
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3.2 Results and discussion 
3.2.1 Experimental validation  
To validate the reliability of the experimental data generated, FITExP analysis was 
carried out to find protein targets of paclitaxel. Paclitaxel is a cytoskeletal drug that is known 
to bind to tubulin promoting polymerization of microtubules leading to mitotic arrest in cells.121 
From the main drug target list generated based on protein regulation and exceptionality 
characteristic, tubulin beta-6 chain as the only statistically significant target. This is in 
agreement with the actual biological target of paclitaxel.121 We then mapped associated protein 
lists generated based on regulation and specificity (Appendix A, Table A.1) onto a STRING 
network.   
 
 
 
Figure 3.3 STRING protein-protein interaction network associated protein list of Paclitaxel generated using 
protein lists from specificity and regulation criteria. 
STRING is an open web-based biological database of known and predicted protein-
protein interactions (http://www.string-db.org/).122 The database aggregates most of the 
available information on protein-protein interactions, scores and weighs it and augments with 
predicted interactions and results of automatic literature-mining searches. In our case, mapping 
the FITExP obtained targets on a STRING network allowed observe the interactions between 
the protein targets obtained to better understand the mechanism of our compounds. In STRING, 
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individual proteins are represented in different coloured bubbles and lines linking these bubbles 
represent the interactions between these proteins with increasing line thickness representing the 
increased confidence of these interactions based on available data. From the STRING network 
generated (Figure 3.3), we observed a network of closely linked proteins implicated in the 
mechanism of action of Paclitaxel. From the protein network, we identified 4 different tubulins 
and various proteins involved in microtubule regulation and function such as cyclin-dependent 
kinase, Rac GTPase activation protein 1 and microtubule associated protein, RP/EB family. 
Overall, our results agree with the proposed protein target and mechanism of action of 
Paclitaxel and with this validation we proceeded to analyse targets obtained from metallodrugs.  
  
3.2.2 Targets of Cisplatin 
The main mechanism of cisplatin is thought to be binding to nucleophilic N-7 sites of 
purine based in DNA forming DNA-DNA interstrand and intrastrand adducts which inhibit 
DNA replication and cause cell death.101 However, cisplatin is also known to bind to proteins.38 
From our main target list, two significant cisplatin targets were identified, receptor tyrosine-
protein kinase erbB-2 (ERBB2) and DNA damage-binding protein2 (DDB2). ERBB2 or 
HER2/Neu is the protein product of an oncogene and plays an important role in the development 
of aggressive forms of breast cancer.123 Breast cancer chemotherapy regiments which combine 
the anti-HER2/neu antibody trastuzumab with cisplatin has been shown to be clinically 
efficacious.124 Thus cisplatins effect on this protein could explain its synergistic activity when 
combined with trastuzumab. DDB2 is a required protein in the nucleotide excision repair (NER) 
pathway to initiate DNA repair.125 DNA repair pathways have been implicated in the efficacy 
of cisplatin treatment where reduced levels of DNA repair proteins in testicular cancers account 
for the effectiveness of cisplatin treatment for this malignancy.126,127 On the other hand, 
alternations in DNA repair processes are important in mediating resistance of cancers to 
cisplatin therapy.128 Considering that NER is the main DNA repair pathway involved in 
detoxifying cisplatin-DNA adducts129 binding to DDB2 could be implicated in its mechanism 
of action.  
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Figure 3.4 STRING protein-protein interaction network associated protein list of Cisplatin generated using protein 
lists from specificity and regulation criteria. 
 
From a STRING network generated from the associated protein lists of cisplatin (Figure 
3.4 and Table S 3.2), we found a few networks of associated proteins. In general, there was a 
significant downregulation of various ribosomal proteins upon cisplatin treatment (Appendix 
A, Table A.2). Ribosomal proteins are implicated in the function of ribosomes for protein 
translation130 and cisplatin induced reduction of  ribosomal protein expression has been 
observed in breast cancer cells.131 Cisplatin was also seen to perturb the regulation of another 
network of proteins consisting of oncogenes and tumor suppressor genes such as ERBB2, cyclin 
dependent kinase inhibitor 1B, HEAT repeat containing 6 along with proteins involved in tumor 
metastasis and proliferation such as matrix metallopeptidase 1 and integrin alpha 6 and GATA 
binding protein 3. Considering that ERBB2 was one of the two cisplatin targets identified in 
the main target list its effect on regulation of associated proteins is thus not surprising. Finally, 
we observed an overexpression of tubulin subunits 2A and B3 from cisplatin treatment, which 
  
57 
 
is possible considering cisplatin is known to bind to tubulin causing aberrant microtubule 
protein polymerization.132 However, we could not draw any conclusions on a main mechanistic 
pathway of cisplatin from the STRING network as multiple different protein associations were 
observed. This could also be indicative of the fact that the main target of cisplatin is DNA and 
its secondary effects on proteins are not very specific.   
 
3.2.3 Targets of RAPTA-EA 
Glutathione transferases (GST) are involved in the removal of exogenous substances 
such as cancer chemotherapeutic agents.133 GST is often overexpressed in solid tumors upon 
exposure to anti-cancer drugs,134 thus inspiring the development of RAPTA-EA, a RAPTA-
type compound tethered to the GST inhibitor ethacrynic acid (EA) to enhance its anti-tumor 
activity (Figure 1). RAPTA-EA shows in vitro GST inhibition levels superior to that of EA 
alone120 and has a much higher cytotoxicity than simple RAPTA-type complexes. However, an 
unbiased analysis of its protein target in cells was never performed leading us to apply the 
FITExP methodology to find its most important protein targets.  
 
Protein Acronym P-value Regulation 
Heat shock 70 kDa protein 1A/1B HSPA 1A/1B 2.46E-05 Up 
Heme oxygenase 1 HMOX1 7.44E-05 Up 
TRAF-type zinc finger domain-containing protein 1 TRAFD1 5.94E-04 Up 
Sulfiredoxin-1 SRXN1 2.17E-03 Up 
Thioredoxin reductase 1, cytoplasmic TXNRD1 2.21E-02 Up 
DnaJ homolog subfamily B member 4 DNAJB4 3.52E-02 Up 
Flavin/bilverdin reductase (NADPH) BLVRB 4.47E-02 Up 
Glucose-6-phosphate 1-dehydrogenase G6PD 4.48E-02 Up 
Table 3.1 Main target list for RAPTA-EA obtained from FITExP analysis  
 
 
 
 Table 3.1 lists the main target list obtained from FITExP analysis of RAPTA-EA. We 
obtained a total of 8 RAPTA-EA protein targets. The top hit, heat shock 70 kDa protein 1A/1B 
(HSPA 1A/1B), comes from the class of heat shock proteins (HSPs), a class of proteins 
produced by cells in response to environmental or metabolic stress such as heat, anoxia, 
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ischemia or heavy metals.135 Most HSPs also function as chaperones which  stabilise pre-
existing proteins against aggregation and facilitates proper folding of newly translated and 
misfolded proteins.136 Another HSP protein in the main target list DnaJ homolog subfamily B 
member 4, functions as both a chaperone and tumor repressor protein mainly involved in the 
targeting and degradation of the cell adhesion protein E-cadherin.137 A previous proteome 
profiling revealed HSPs are possibly implicated in the mechanism of RAPTA-type 
compounds.119 Furthermore HSPA 1A/1B, overexpression has been similarly demonstrated in 
MCF-7 cells treated with RAPTA-EA for 48 hours.138 
 
Heme oxygenase 1 (HMOX 1) is an enzyme which cleaves heme at the alpha methane 
bridge forming bilverdin and is involved in hematopoesis (Figure 3.5). It is also a marker of 
oxidative stress, and deficiency in this protein results in impaired stress hematopoiesis resulting 
in marked erythrocyte fragmentation, coagulation abnormalities, and iron deposition in renal 
and hepatic tissues.139 Exposure to EA has been previously shown to result in elevated 
expression of this protein140, leading us to believe that the observed hit is due to the EA moiety 
in RAPTA-EA. Flavin/bilverdin reductase is an oxidoreductase that catalyzes the NADPH-
dependent reduction of bilverdin to bilirubin (Figure 3.5),136 the next step in heme catabolism 
thus it was not surprising to find co-regulation of this related protein in RAPTA-EA 
 
 
 
Figure 3.5 Enzymatic reaction of heme catabolism to bilirubin. 
 
Sulfiredoxin-1 (SRXN1) contributes to oxidative stress resistance by reducing cysteine-
sulfinic acid formed by exposure to oxidants into peroxiredoxins. As both HMOX1 and SRXN1 
play a role in oxidative stress and have been shown to be co-regulated in cells exposed to anti-
cancer compounds141, we predict that the regulation of both were due to EA. Glucose-6-
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phosphate 1-dehydrogenase, is a cytosolic protein whose main role is the production of NADPH 
an electron donor in the defense against oxidising agents and in reductive biosynthetic 
reactions.137 Deficiency in this protein in humans can cause neonatal jaundice and haemolysis 
upon exposure to oxidative stress. Thioredoxin reductase 1 reduces thioredoxins and other 
substrates and plays a role in selenium metabolism and protection against oxidative stress137. 
Since depletion of GST is correlated to increased levels of oxidative stress response142, 
regulation of this protein upon exposure to RAPTA-EA is unsurprising.  
 
TRAF-type zinc finger domain-containing protein 1 is a negative feedback regulator 
that controls excessive immune response in vertebrates.143 Though not expected to be a target 
of RAPTA-EA, it was shown in previous studies that RAPTA-type complexes can bind to 
proteins containing zinc-finger domains possibly perturbing the regulation of this protein.55  
 
We subsequently mapped the associated target list obtained from RAPTA-EA into a 
STRING network (Figure 3.6 and Appendix A, Table A.3). From the STRING map, we saw a 
very strong network of oxidative stress related proteins perturbed by RAPTA-EA treatment. A 
large family of heat shock proteins and proteins involved in cellular respiration along with all 
the protein candidates from the main target list of RAPTA-EA were implicated in the 
association network, strongly suggesting that the mechanism of action of the drug was related 
oxidative stress response.  
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Figure 3.6 STRING protein-protein interaction network associated protein list of RAPTA-EA generated using 
protein lists from specificity and regulation criteria. 
 
Overall, the RAPTA-EA protein targets found via FITExP were mostly related to 
oxidative stress response, which is possibly to the GST inhibition activity of this compound. 
Surprisingly the suspected main target of the protein, GST was not found as one of the 
significant hits of the screen. Possibly tethering of EA to a RAPTA-type compound, though 
potentiating GST inhibition, could switch its dominant action to the binding to other oxidative 
stress response proteins. We attributed most of the targets of RAPTA-EA to the EA moiety and 
not the RAPTA fragment. 
 
3.2.4 Targets of RAPTA-T 
The organometallic ruthenium(II) complex, RAPTA-T has been previously shown to 
possess both in vitro and in vivo anti-metastatic properties. Specifically in RAPTA-T treated 
breast cancer cells, highly metastatic MDA-MB-231 showed a greater reduction to the extent 
of detachment, readhesion, migration and invasion compared with less metastatic MCF-7 
cells96. This motivated our choice of MDA-MB-231 cells and MCF-7 cells for our FITExP 
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analysis.   
 
Protein Acronym P-value Regulation 
Phospholipase D3 PLD3 9.11E-04 Up 
S-adenosylmethionine synthase isoform type-2 MAT2A 1.11E-03 Up 
Metallothionein-2 MT2A 2.33E-03 Up 
Zinc finger HIT domain-containing protein 2 ZNHIT2 1.39E-02 Up 
RNA-binding protein 47 RBM47 1.86E-02 Up 
Pyruvate dehydrogenase phosphatase catalytic subunit 1, 
mitochondrial 
PDP1 3.56E-02 Up 
Chromatin target of PRMT1 protein CHTOP 4.01E-02 Up 
Chromosome transmission fidelity protein 8 homolog isoform 2 CHTF8 4.37E-02 Up 
Table 3.2 Main target list for RAPTA-T obtained from FITExP analysis. 
 
Table 3.2 shows the main target list obtained from FITExP analysis of RAPTA-T, a total 
of eight protein targets. The top ranked protein target obtained PLD3, is from the phospholipase 
D (PLD) family of enzymes which catalyse the hydrolysis of membrane phospholipids.137 
PLD3 is the least well studied phospholipase D subtype and current data does not implicate it 
in cancer progression. However, its transcript variants phospholipases D1 and D2 have been 
shown to be involved in the progression of metastatic breast cancers,144 and isoform-selective 
inhibitors of  PLD were shown to modulate invasiveness in metastatic breast cancer models.145 
Thus, we selected this target for further validation (See Chapter 4).  
 
The second ranked protein hit MAT2A, is a protein that catalyses the production of S-
adenosylmethionine from methionine and ATP. S-adenosylmethionine is a key methyl donor 
in cellular processes. MAT2A has been shown to be overexpressed in gastric cancers.146 
Furthermore, inhibition of expression of MAT2A has been shown to significantly supress 
growth of hepatocellular carcinomas.147 In addition, specific inhibitors of MAT2A have also 
been shown to be effective agents against colorectal cancers.148 Since this was a well-
established protein implicated in cancer progression, we selected MAT2A as a target for further 
validation (See Chapter 4).  
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Metallotheinins (MTs) are a class of proteins with high content of cysteine residues that 
are responsible for detoxifying heavy metals, and high levels of MT expression has been 
associated with poor clinical outcomes of cancer patients undergoing therapy with platinum 
based metallodrugs.149 MT2 has been previously shown to bind to a RAPTA-C, an analogue of 
RAPTA-T with p-cymene instead of toluene as the arene, and shows very similar phenotype in 
terms of anti-cancer activity.150 RAPTA binding to MT2 caused a displacement of zinc 
suggesting binding occurred in Cys residues in MT2.    
 
 Zing finger HIT (zf-HIT) are sequence motifs found in various proteins which contain   
conserved cysteine and histidine residues that can coordinate zinc atoms.151 These motifs are 
suggested to play important roles in gene regulation and chromatin remodelling. It was shown 
previously that RAPTA complexes bind proteins with zinc finger domains55 and these 
complexes can also displace zinc.150 Furthermore top down MS/MS results also show binding 
of these complexes to zinc finger domains in the breast cancer type 1 susceptibility protein 
(BRCA1) (Chapter 6).  
 
 RNA binding proteins (RBMs), are proteins that bind to single or double stranded RNA 
and play a role in post-transcriptional control of RNAs such as splicing, mRNA stabilization, 
mRNA localization and translation.152 RBM47 has been shown to play an important role in 
metastatic breast cancers, where low expression of this protein is associated with highly 
metastatic phenotype.153 Furthermore RMB47 knockout mice xenografted with lung 
adenocarcinomas were found to show enhanced tumor formation and metastasis.154 It is 
possible that treatment with RAPTA-T activates compensatory pathways causing increased 
expression of RMB47 which could link to its anti-metastatic activity.  
 
 The pyruvate dehydrogenase complex converts pyruvate into acetyl-CoA a substrate 
used in the citric acid cycle for cellular respiration. Pyruvate dehydrogenase phosphatases 
(PDPs) in the mitochondria catalyze the dephosphorylation and reactivation of the alpha subunit 
of the E1 component of the pyruvate dehydrogenase complex136. PDP1 has been implicated in 
promoting the Warburg effect and growth in tumors and has been suggested to be a promising 
anti-cancer target.155 In vitro studies of the cellular effects of RAPTA-T has shown that the 
compound accumulates appreciably in the mitochondria and perturbs the expression of a large 
number of mitochondrial proteins including  causing an overexpression of ATP synthetase119 
an enzyme heavily involved in cellular respiration.  
  
63 
 
 
 Protein arginine methyltransferases (PRMTs) catalyze the process of arginine 
methylation a widespread post translational modification in eukaryotic cells. PRMTs use S-
adenosyl-L-methionine as the methyl donor a product of another RAPTA-T obtained target 
MAT2A. The chromatin target of PRMT1 protein (CHTOP) is a chromatin associated protein 
which has been shown to be critical for estrogen-dependent gene activation156 and is also 
implicated in the tumorgenicity of glioblastoma cells157. Considering that RAPTA complexes 
are known to bind to histones (Figure 3.7)92 a component of chromatin, and could be a binding 
partner to MAT2A, it is possible that its activity also perturbs expression of CHTOP.  
 
Figure 3.7 Chemical structures and nucleosomal adducts of RAPTA-C. X-ray structures of adducted 
nucleosome core particles are shown looking down the DNA superhelical axis, with the nucleosome pseudo-
twofold axis running vertically (arrow). Histone proteins are shown in blue (H3), green (H4), yellow (H2A) and 
red (H2B), and the two 145-nucleotide DNA strands are cyan and orange. RAPTA-C adducts appear with space-
filling representation (sites 1–3, histone associated). (Adapted from Adhireksan et. al Nat Commun. 2014). 
 
 The chromosome transmission fidelity factor 8 (CTF8) is a chromosome cohesion 
protein involved in sister chromatid cohesion and fidelity of chromosome transmission.2.9 It has 
been implicated in the DNA replication and repair pathway and has been shown to have reduced 
expression in renal and prostate tumours.137 Since it is a nuclear protein associated with 
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chromatin, RAPTA-T could possibly bind to this target too.  
 
 
 
Figure 3.8 STRING protein-protein interaction network associated protein list of RAPTA-T generated using 
protein lists from specificity and regulation criteria. 
 
Figure 3.8 shows a STRING network of proteins from the associated protein list of 
RAPTA-T (Appendix A, Table A.4). As seen, there is generally little association between the 
different proteins in the network. Thus, the effects of RAPTA-T may be brought about by 
binding to distinct proteins. Indeed, the different phenotype changes of primary toxicity, anti-
angiogenesis and anti-metastasis which can be induced by RAPTA-T are not thought to 
originate from binding to a single class of proteins.  
 
 Overall, of the eight potential RAPTA-T protein targets obtained from this study, two 
of them were previously validated.  The remaining six targets were physiologically viable based 
on what is known on the phenotypic effects or RAPTA-T and affinity proteomics/expression 
profiling based studies. We selected two targets PLD3 and MAT2A for further evaluation.  
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3.3 Conclusion 
A proteomics profiling approach, FITExP was used to probe potential protein targets of 
cisplatin, RAPTA-T and RAPTA-EA. Validation experiments with paclitaxel showed the 
reliability of the method, and main protein target lists for all three compounds gave 
physiologically viable anti-cancer protein targets. The main targets obtained for cisplatin were 
DNA repair related, which were in line with the main mechanism of cisplatin on nuclear DNA. 
RAPTA-EA’s mechanism of action is mainly on regulation of oxidative stress response and is 
thought to be conferred by the ethacrynic acid moiety in the drug. This is in great contrast to 
the simple RAPTA-type complex RAPTA-T, which seemed to have a broad mechanism of 
action targeting proteins involved in both metastasis and tumorigenicity. From a therapeutic 
standpoint, RAPTA-EA could be explored in cancers where EA alone has shown potency such 
as chronic lymphocytic leukemias158 or where EA combined with another agent shows synergy, 
such as the combination of EA with afatinib, an irreversible epidermal growth factor receptor 
tyrosine kinase inhibitors for breast cancers159. On the other hand, due to its broad mechanism 
of action, RAPTA-T could potentially be more useful if used concomitantly with drugs that 
target specific cancer pathways and could also play a role in therapies for later stage cancers 
due to its anti-metastatic properties. From this study, we selected two targets of RAPTA-T for 
binding confirmation.  
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3.4 Experimental 
All cell culture experiments and interpretation of protein lists obtained were performed in the 
EPFL. Preparation of samples for LC-/MS/MS, data acquisition, and biostatistical analysis was 
performed at the lab of Professor Roman Zubarev, Karolinska Institute, Sweeden. 
 
3.4.1 Cell maintenance, treatment and preparation for expression profiling 
MDA-MB-231 (human mammary gland adenocarcinoma) and MCF-7 (human mammary gland 
adenocarcinoma cells),  were cultured in DMEM Glutamax medium supplemented with 10% 
fetal calf serum, penicillin 100 units/mL Streptomycin 100 µg/mL (Invitrogen). Cells were 
incubated at 37⁰C in a moist environment containing 5% CO2. For proteomic expression 
experiments, cells were seeded at a density of 5x105 cells in a 6-well plate for 24 hours. Media 
was aspirated and cells were rinsed with 1 X PBS before addition of fresh media containing 
solutions of compound (Paclitaxel, Cisplatin, RAPTA-EA and RAPTA-T, dosed at a 
concentration to achieve a cell kill of approximately 50% after 48 hours). After 48 hours, cells 
were detached with enzyme free cell dissociation solution and centrifuged at 200G for 5 
minutes. Cell pellets were snap frozen in liquid N2 and stored at -80 ⁰C before sample 
preparation for mass spectrometry.  
 
3.4.2 Protein digestion 
Breast cancer cell pellets were thawed on ice and depending on the number of cells/pellet 
reconstituted in 100-200µl 8M Urea with 100 mM NaCl. Cells were disrupted by probe 
sonication (Vibra-Cell™ CV18, Sonics & Materials, Newtown, USA) two times for 5/5 
seconds cycles over 20 seconds followed by centrifugation at 12,000 rpm for 10 minutes at 4°C. 
Solubilized proteins were transferred into fresh vials and the protein concentrations were 
determined using microBCA from Pierce (Thermo Fisher Scientific Inc). From each sample 10 
µg extracted protein were dissolved in a final concentration of 0.1% ProteaseMax (Thermo 
Fisher Scientific Inc), 50 mM ammonium bicarbonate and 10% acetonitrile in a total volume 
of 80 µl. The resulting protein solutions were incubated for 45 minutes at 37 °C while shaking 
followed by an additional bath soncication of 10 minutes at room temperature. Samples were 
centrifuged and directly subjected to a tryptic digestion protocol carried out by a liquid handling 
robot (MultiProbe II, Perkin Elmer). This included protein reduction in 5 mM DTT at 56 °C 
and alkylation in 15 mM iodacetamide for 30 minutes at room temperature in the dark. Trypsin 
was added in an enzyme to protein ratio of 1:30 and digestion was carried out over night at 
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37°C. Samples were acidified by adding 6 µl concentrated formic acid, incubated for 30 minutes 
at room temperature and centrifuged for 20 minutes at 3000 rpm in order to remove undigested 
material. 
 
3.4.3 LC-MS/MS experiment 
Tryptic peptides were cleaned with C18 StageTips (Thermo Fisher Scientific Inc) and the 
resulting peptide mixture was injected into a nano-Ultimate system (Thermo Scientific, 
Bremen, Germany) in-line coupled to a QExactive mass spectrometer (Thermo Scientific, 
Bremen, Germany). The chromatographic separation of the peptides was achieved using an 28 
cm long in-house packed column (C18-AQ ReproSil-Pur®, Dr. Maisch GmbH, Germany) with 
the following gradient: 4−26% acetonitrile in 120 minutes, 26−95% ACN for 5 minutes and 
95% ACN for 5 minutes all at a flow rate of 300 nl/ minutes.  
The MS acquisition method was comprised of one survey full scan ranging from m/z 300 to 
m/z 1650 acquired with a resolution of R= 140,000 at m/z 200 and a target value of 5e6, 
followed by data-dependent higher-energy collisional dissociation fragmentation scans from 
maximum sixteen most intense precursor ions with a charge state ≥ 2. Sequencing was done 
with a target value of 2e5 ions determined with predictive automatic gain control, for which the 
isolation of precursors was performed with a window of 4 m/z. Scans were acquired with a 
resolution of R=17,500 and normalized collision energy was set to 26. 
 
3.4.4 Data processing 
Fragmentation spectra were extracted using Raw2MGF (in-house developed software), and the 
resulting mascot generic files were searched against a SwissProt protein database (reversed 
protein sequences had been added to database for decoy search) using the Mascot 2.3.0 (Matrix 
Science Ltd.). Mascot was set up to search a concatenated SwissProt protein database (selected 
for Homo sapiens) with enzyme specificity set as C-terminal to arginine and lysine, allowing 
cleavage before proline and a maximum of  and two missed cleavage sites. The allowed peptide 
mass deviation was set to 10 ppm and 0.02 Da for the fragment ions. Carbamidomethylation of 
cysteine was specified as a fixed modification, whereas oxidation of methionine, N-termianl 
protein acetylation and deamidation of asparagine and glutamine were defined as variable 
modifications.  
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Quantitative information was extracted using in-house developed label-free software Quanti 
v.2.5.3.122. Only reliably identified (FDR<0.01), unmodified peptides with unique sequences 
were considered and only proteins discovered with at least two such peptides were quantified. 
For each protein, one database identifier (ID) was selected, covering all the peptide sequences 
identified for this specific protein. If two proteins belonging to different protein groups had a 
partial sequence overlap, then all the peptides belonging to this overlap were ignored. The 
results were reported as a set of relative protein abundances A scaled such that the geometric 
mean of the abundance of each protein over all samples was 1.0. 
 
3.4.5 Scoring system  
For combining the data from replicate analysis, “medians of ratios” are used instead of 
“ratios of medians”, as has previously been suggested.160 If relative protein abundance of i-
th quantified protein in c-th cell line under j-th treatment is denoted as , then 
regulation Reg is calculated as: 
 
and specificity Spec is defined as: 
 
where j = 0 corresponds to untreated cells for Reg calculation, and j≠k for Spec calculations. 
 
3.4.6 Exeptional behavior measure 
For each I-th protein and each J-th drug treatment, two vectors were calculated: 
 
 
 
where  are the Pearson’s correlation coefficients of expression profiles over all 
treatments of i-th and I-th proteins, while  are correlation coefficients of the expression 
profiles of i-th and I-th proteins excluding treatment J. Then, the linear 
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model  was created and the coefficient of determination of the model was used 
to calculate the measure of exceptional behavior ExcI,J of I-th protein under J-th treatment: 
 
 
3.4.7 p-value calculation 
In estimation of the p-value of a protein with a certain rank, we used the rank 
product method, which has previously been found to be robust and tolerant to missing values 
in detection differentially regulated genes in replicated experiments.161 The method has also 
been successfully applied to proteomics datasets for detection of significantly regulated 
proteins.162 In adaptation of the method by Schwämmle et al., we treated Reg, Spec and Exc 
ranks as independent variables, and their values for different cell lines as well as at different 
incubation times were considered as independent replicate measurements. The rank product 
was considered to have a gamma distribution under null hypothesis, from which we calculated 
the p-values for the set of ranks of every protein. Adjusted p-values were calculated using 
standard Bonferroni correction, using the total number of proteins as a multiplication factor. 
 
3.4.8 Network mapping 
STRING v9.116163 was used to map drug-specific, significantly regulated proteins 
onto protein-protein interaction networks. Gene names corresponding to up- and down-
regulated proteins were submitted into STRING web-site (http://string-db.org). Medium 
confidence threshold (0.4) was used to define protein-protein interactions. Gene set enrichment 
analysis built in STRING with the whole genome background was used to identify enriched 
gene ontology terms and KEGG pathways. A 0.05% threshold was applied to the p-values after 
Benjamini-Hochberg correction. 
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4 Chapter 4 
Validation of potential RAPTA-T protein targets 
Phospholipase D3, and S-adenosylmethionine 
synthase isoform type-2 obtained from FITExP 
analysis  
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4.1 Introduction 
In general, targets obtained via protein target screening methodologies have to be 
externally validated as false positives can occur when such strategies are applied. Furthermore, 
since the approach FITExP deduces the most likely protein target of a small compounds via the 
exceptional regulation of its protein target during late apoptosis and not through a physical 
binding event, evidence of binding or inhibition was necessary. Validation of ligand-protein 
binding can be carried out via binding assays or in the case of enzymes, inhibitory constants 
can be obtained if activity assays can be developed. Ligand-binding assays can be broadly 
classed into labelled, label-free, structural and thermodynamic assays. Table 4.1 lists the 
different binding assays used and their operating principle. 
 
Group of assays Assay Principle 
Labeled ligand-
binding assays 
Fluorescent 
ligand binding 
assays 
Fluorescent labeled ligand is used to detect its binding to 
a target. 
Radioligand 
binding assays 
Radioactively labeled ligand is used to detect its binding 
to a target. 
Label-free 
ligand binding 
assays 
Surface plasmon 
resonance  
Light-excited surface plasmon polaritons are applied to 
track the binding of ligands to proteins bound to a gold 
surface. 
Plasmon-
waveguide 
resonance  
Polarized continuous wave lasers are applied to excite 
electromagnetic waves in a resonator made of a thin silver 
film with a layer of SiO2 and a glass prism. Ligand binding 
changes amplitude, position and width of reflected lights. 
SPR imaging for 
affinity-based 
biosensors 
Binding kinetics are measured and related to intensity 
modulation and the reflectivity of monochromatic 
incident p-polarized light detected at a fixed angle. 
Whispering 
gallery 
microresonator  
Binding of molecules to the surface of the cavity induces 
changes of the resonant wavelength changes. The resonant 
changes of light permit multiple analyses of molecules. 
Resonant 
waveguide 
grating  
A nanograting is used to couple light into the waveguide 
via diffraction. The light illuminates the biosensors in 
microplate at a nominally normal incident angle. The drug 
binding of the immobilized receptors results in a shift in 
the resonant wavelength. 
Biolayer 
Interferometry 
Biosensor  
A spectrometer is used to detect interference patterns 
formed by light reflected from an optical layer and a 
biolayer containing proteins of interest. 
Structure-based 
ligand binding 
assays 
Nuclear 
magnetic 
resonance  
Magnetic characteristics of certain atomic nuclei, which 
absorb electromagnetic radiation in the magnetic field are 
related to ligand binding characteristics 
X-ray 
crystallography 
The diffracted X-ray beams of ligand bound protein 
crystals are resolved to produce a three-dimentional image 
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of electron density. 3D structure obtained gives 
knowledge of binding sites of ligand on protein.   
Thermodynamic 
binding assays 
Thermal 
denaturation 
assays  
Thermal denaturation of proteins is measured by 
differential scanning fluorimetry, which applies a probe 
fluorophore to monitor thermal denaturation process of 
proteins in the presence of ligands. 
Isothermal 
titration 
calorimetry  
Measures the enthalpy variation of ligand-protein binding 
which is mathematically related to its binding properties.  
Table 4.1 Ligand-protein binding assays and their principles (Adapted from Konstantin Y. Mater Methods 2011). 
 
In our study, the two targets we obtained, phospholipase D3 (PLD3) and methionine 
adenosyltransferase II, alpha (MAT2A) are both enzymes, thus our initial validation strategy 
involved expressing both proteins and developing activity assays to assay the inhibition of 
RAPTA-T towards these enzymes. 
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4.2 Results and discussion 
4.2.1 Expression and purification of proteins 
 PLD3 is a 55 kDa transmembrane glycoprotein thought to be localized in the 
endoplasmic reticulum membrane.164 Phospholipase D enzymes catalyse the hydrolysis of the 
phosphodiester bond in phospholipids into phosphatidic acid165 and choline as seen in Figure 
4.1. 
 
 
 
Figure 4.1 Enzymatic reaction catalysed by phospholipase D. 
 
Being a glycosylated membrane protein we opted for a mammalian expression system 
for PLD3. Its gene sequence was synthesized commercially with an N-terminal IgG kappa 
secretory sequence and a C-terminal His-tag for purification. The gene of interest was cloned 
into the mammalian pXLG-eGFP plasmid vector for expression. Tests cultures were first 
carried out in both human embryonic kidney 293 (HEK293) cells, and chinese hamster ovary 
(CHO) cells with and without inducers DMSO and valproic acid (VPA), respectively.   
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Figure 4.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of test cultures of PLD3 
expression. 
 
Negligible difference was observed in the expression yields between all expression 
conditions tested (Figure 4.2). Thus, we selected HEK293 for cost savings, as transfection in 
these cells requires half the DNA load of an equivalent batch of CHO cells. Though PLD3 has 
a molecular weight of 55 kDa its appearance as a relatively thick band near 70 kDa is probably 
caused by the effects of glycosylation on SDS-PAGE, where the heterogeneity of glycosylation 
can dramatically increase the mass of the protein, and interactions of SDS with sugars and 
amino acids are different leading to the observed band shift and thickening.  
 
MAT2A is a 44 kDa cytosolic enzyme which catalyses the formation of S-
adenosylmethionine (SAMe or AdoMet), from the reaction of methionine and adenosine 
triphosphate (ATP) as seen in Figure 4.3. SAMe is the principle methyl donor in cells and plays 
a central role in cellular biochemistry as a precursor to methlation, aminopropylation and 
transulfuration pathways.166 Expression of MAT2A was relatively simple as the protein has no 
post translational modifications and its plasmid vector for bacterial expression was available in 
the AddGene167 database. Both MAT2A and PLD3 were expressed with good yields of 25mg/L 
and 4.5mg/L and purities of ~90% which were deemed suitable for enzyme assays. (Figure 4.4) 
 
 
A    A’    B      B’    C    C’     D    D’ 
Legend 
A = CHO (+DMSO) 
B = CHO (-DMSO) 
C = HEK (+ VPA) 
D = HEK (-VPA) 
X = Dilute 
X’ = Concentrated 
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Figure 4.3 Enzymatic reaction catalysed by MAT2A. 
 
 
Figure 4.4 SDS-PAGE of MAT2A and PLD3 proteins after immobilized ion affinity chromatography. 
 
4.2.2 MAT2A assay development and RAPTA-T IC50 measurements 
A MAT2A assay was developed based on a similar assay reported previously148 with 
modifications. Briefly, the activity of the MAT2A enzyme is quantified as the concentration of 
free phosphate liberated from ATP during conversion to SAMe (Figure 4.3), which occurs at a 
1:1 stoichiometric ratio to the product formed. Free phosphate is measured by the malachite 
green phosphate colorimetric assay, based on formation of a complex between malachite green, 
ammonium molybdate and free orthophosphate under acidic conditions, which is then measured 
at a λmax 640nm (Figure 4.5).  In our assays, buffer conditions were selected carefully to avoid 
the inclusion of chelating agents (e.g. EDTA) of reducing agents (e.g. DTT) which could 
coordinate with RAPTA-T. Since the substrate L-methionine contained a sulphur group which 
could potentially coordinate to ruthenium(II) complexes168 we tried to minimize the 
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concentration of substrate added. In enzymatic reactions, reaction rates can be described using 
the Michaelis-Menten model: 
v =
Vmax[S]
Km
 
Where [S] is substrate concentration, v is reaction rate, Vmax is the maximum rate achieved by 
the system, and KM is the substrate concentration at which reaction rate is half of Vmax. From a 
Michaelis-Menten saturation curve of absorbance vs. L-methionine concentration (figure 4.6), 
we found the KM of MAT2A to be 35 µM and selected a non-saturating L-methionine 
concentration of 50 µM, which provided a good signal-to-noise ratio in the calorimetric 
phosphate assay used as activity readout.  
 
 
Figure 4.5 Principle of malachite green phosphate assay. 
Figure 4.6 Michaelis-menten curve of MAT2A activity vs. L-methionine concentration. 
 
  
 
 
Km = 35 µM 
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Since RAPTA-T is a prodrug which undergoes aquation of its chloride ligands before 
binding169, we attempted to study the effect of RAPTA-T and MAT2A pre-incubation time on 
the IC50 of RAPTA-T to determine if this greatly influenced its inhibition. There was a reduction 
of the IC50 of RAPTA-T from 121 µM to 75 µM upon increasing the pre-incubation time from 
30-90 minutes which did not change further upon longer pre-incubations, indicating an 
equilibrium state of binding is achieved after 90 minutes (Figure 4.7).  
 
 
Figure 4.7 IC50 value of RAPTA-T on MAT2A as a function of different ligand-protein pre-incubation times. 
 
Since the inhibition type of RAPTA-T on MAT2A was unknown, we made initial 
attempts to determine if its inhibitory activity was competitive, non-competitive or 
uncompetitive.  Differentiation of these inhibition-types can be done via observing the shifts in 
KM and Vmax from Michaelis-Menten curves plotted with different concentrations of 
inhibitor.170 Competitive inhibition is characterized by reversible binding of inhibitor to free 
enzyme and is characterized by an increase in KM with no change in Vmax. Non-competitive 
inhibitors bind equally well to the free enzyme and enzyme-substrate complex resulting in a 
lowered Vmax but with an unchanged KM values. Uncompetitive inhibition occurs when the 
inhibitor binds exclusively to the enzyme-substrate complex, inactivating it and is characterized 
by a drop in both KM and Vmax. Michaelis menten curves of MAT2A in the presence of 100µM 
and 300µM of RAPTA-T showed a clear reduction of both KM and Vmax of MAT2A, showing 
RAPTA-T has properties of uncompetitive inhibition (Figure 4.8). 
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Figure 4.8 Michaelis-menten curve of MAT2A with different concentrations of of RAPTA-T. 
 
 Overall, RAPTA-T appears to be an uncompetitive inhibitor of MAT2A with an IC50 of 
~75 µM. This indicates a rather weak inhibition as compared to specific inhibitors of MAT2A 
such as the fluorinated N,-N-dialkylaminostilbene agents (FIDAS) agent FIDAS-3 which has 
an MAT2A inhibition IC50 of 5µM (Figure 4.9).
148 Considering MAT2A is one of several 
potential RAPTA-T binding targets, perhaps inhibition of this enzyme though weak, still 
contributes partially to the overall anti-cancer activity of the compound. These results should 
also be interpreted with caution, as inhibition measurements done on purified proteins are 
markedly different than conditions in cells or tissues. Thus, these results should be followed up 
by measurement of MAT2A inhibition by RAPTA-T directly in cells and performing other 
binding assays. 
 
 
Figure 4.9 FIDAS-3 a specific inhibitor of MAT2A. 
 
 
 
 
Km = 33 µM 
Km = 56 µM 
Km = 147 µM 
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4.2.3 PLD3 activity assay  
PLD3 activity was assayed with the commercial Amplex Red Phospholipase D (PLD) assay 
kit. Briefly, PLD activity was measured from a series of three stoichiometric reactions, firstly 
the conversion of phosphotidylcholine to choline by PLD (Figure 4.1), followed by oxidation 
of choline to betaine liberating H2O2 which then reduces the Amplex red reagent into a 
florescent substrate resorufin (Figure 4.10). Floresence intensity of resorufin is then measured 
at absorption and emission of 540 and 590 nm respectively and correlated with PLD activity. 
PLD from Streptomyces chromofuscus was used as a positive control for PLD activity, H2O2 
was used as a positive control for assay function and PLD3 buffer functioned as a negative 
control.  
 
 
Figure 4.10 Principle of AmplexRed phospholipase D assay kit. 
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Figure 4.11 PLD activity measurement for recombinant human PLD3 and PLD from Streptomyces 
chromofuscus. 
 
We observed no activity from the expressed recombinant human PLD3 (Figure 4.11). 
This was similarly observed by the group who first identified the protein.164 We expressed only 
the lumenal portion of the topological domain of PLD3 thought to be in charge of catalytic 
activity.136 However, it is possible that its association with the membrane structure is critical 
for enzymatic activity, or expression in our organism of choice led to misfolding or an incorrect 
glycosylation pattern on PLD3 leading to loss of function. Thus, an alternative option would be 
to assay PLD3 activity in intact cell assays, which should be explored subsequently.  
 
4.3 Conclusions 
We successfully expressed recombinant human MAT2A and PLD3. We show that 
RAPTA-T is potentially an uncompetitive inhibitor of MAT2A with an IC50 of ~75 µM. From 
this, RAPTA-T could be useful for cancers where MAT2A is upregulated such as liver and 
colorectal cancer.148 Recombinant PLD3 shows no enzymatic activity as previously reported, 
thus other validation strategies have to be considered.  
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4.4 Experimental 
All protein expression was performed by Dr. David Hacker at the protein expression core 
facility Ecole Polytechnique Fédérale de Lausanne. 
 
4.4.1 Materials 
Amplex red phospholipase D assay kit was purchased from ThermoFisher Scientific and used 
based on manufacturer’s instructions. Phosphate colorimetric kit was purchased from Sigma 
Aldrich and used based on manufacturer’s instructions. Phospholipase D (PLD) from 
Streptomyces chromofuscus was purchased from Sigma Aldrich. All other reagents were 
commercially purchased and used without further purification.  
 
4.4.2 Recombinant protein expression  
MAT2A/2B 
hMAT2A and hMAT2B plasmid was obtained from Addgene (www.addgene.org, plasmid 
#53648 & *34795 respectively) as a bacterial stab. Plasmid DNA was amplified in antibiotic 
media and extracted with a plasmid miniprep kit (Qiagen) according to manufacturer’s 
instructions and sequenced by GATC biotech for validation. The plasmid was transformed 
into competent E. coli strain BL21 (DE3) Rosetta and selected with ampicillin.  One colony 
was picked from the LB agar plate and used to inoculate a 10-mL culture of LB with 
ampicillin.  The culture was grown overnight at 37°C with agitation at 150 rpm in an 
incubator shaker.  The next day, 10-mL culture was used to inoculate a 1-L culture of LB and 
ampicillin.  The culture was incubated at 37°C with agitation as before until an OD600 of 0.6 
was reached.  The temperature of the incubator shaker was then reduced to 16°C, and IPTG 
was added to the culture to a final concentration of 1 mM.  The culture was allowed to 
incubate overnight at 16°C.  In the morning, the culture was centrifuged at 3,500 rpm for 20 
minutes, and the cell pellets were maintained frozen at -80°C.  The frozen cell pellet was 
allowed to thaw and was resuspened in 60 mL of binding buffer (150 mM NaCl and 25 mM 
sodium phosphate (pH 7.3)) containing the Roche protease cocktail.  The resuspended cells 
were sonicated 8 x 20 seconds.  The solution was then centrifuged at 11’000 rpm for 30 
minutes.  The supernatant was retained and imidazole was added to 10 mM.  Then 2 ml of 
FastFlow IMAC beads (GE Healthcare) were added.  The solution was mixed by rotation for 
1 hour at 4°C.  The resin was transferred to a column and the washed with 10 column 
volumes (CV) of binding buffer with 10 mM imidazole.  Then washed sequentially with 10 
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CVs of binding buffer with 25 mM imidazole, 5 CVs of binding buffer with 50 mM 
imidazole, and 5 CVs of  binding buffer with 100 mM imidazole.  The protein was then eluted 
with 4 x 2Cvs of binding buffer with 250 mM imidazole.  The washes and elutions were 
analyzed by reducing SDS-PAGE.  The fractions with the recombinant protein were pooled 
and dialyzed twice against 2 L of PBS.  After dialysis the concentration of the protein was 
determined by absorbance at 280 nm. 
 
PLD3 
PLD3 plasmid with N-terminal IgG kappa secretory sequence and a C-terminal His-tag was 
obtained commercially from GeneArt gene synthesis (ThermoFisher Scientific). Gene of 
interest was extracted and cloned into the mammalian pXLG-eGFP plasmid vector for 
expression using Gibson assembly.171 Plasmid was amplified in E.coli and extracted with a 
plasmid miniprep kit for mammalian expression. Final plasmid obtained was sequenced 
before use. Suspension-adapted HEK-293E cells were routinely maintained in serum-free 
ExCell 293 medium (SAFC Biosciences, St. Louis, MO) with 4 mM glutamine with 
inoculation at 0.3 x 106 cells/mL as described.172 On the day before transfection, cells were 
inoculated into fresh medium at a density of 1 x 106 cells/ml. The next day, 2 x 108 cells were 
harvested by centrifugation at 1,200 rpm for 5 min and resuspended at a density of 20 x 106 
cells in 10 ml of RPMI 1640 medium with 0.1% pluronic F68 (SAFC Biosciences) in a 
TubeSpin® bioreactor 50 tube (TPP, Trasadingen, Switzerland).173Plasmid DNA (0.3 mg) 
and linear 25 kDa polyethylenimine (0.6 mg; 1 mg/ml in H2O; Polysciences, Eppenheim, 
Germany) were sequentially added and mixed.  The culture was agitated by orbital shaking at 
180 rpm in an ISF-4-W incubator (Kühner AG, Birsfelden, Switzerland) at 37°C in the 
presence of 5% CO2.  After 60 min, the transfected culture was transferred to a 500-mL glass 
bottle containing 190 ml of Excell293e medium (Invitrogen) with 4 mM glutamine and 3.75 
mM valproic acid (500 mM in H2O) (SAFC Biosciences).
174 The culture was transferred to an 
incubator shaker at 37°C with 5% CO2 with agitation at 110 rpm.  At 7 d post-transfection, 
the cell culture medium was recovered by centrifugation at 2,500 rpm for 20 min and filtered 
through a 0.22 µm membrane. Imidazole was added to the medium to 10 mM, then 2 ml of 
FastFlow IMAC beads (GE Healthcare) were added.  The solution was mixed by rotation for 
1 hour at 4°C.  The resin was transferred to a column and the washed with 10 column 
volumes (CV) of binding buffer with 10 mM imidazole.  Then washed sequentially with 10 
CVs of binding buffer with 25 mM imidazole, 5 CVs of binding buffer with 50 mM 
imidazole, and 5 CVs of binding buffer with 100 mM imidazole.  The protein was then eluted 
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with 4 x 2Cvs of binding buffer with 250 mM imidazole.  The washes and elutions were 
analyzed by reducing SDS-PAGE.  The fractions with the recombinant protein were pooled 
and dialyzed twice against 2 L of PBS.  After dialysis the concentration of the protein was 
determined by absorbance at 280 nm. 
 
4.4.3 MAT2A Enzymatic assays 
Recombinant human MAT2A stored in 50% glycerol was dialysed into MAT2A buffer 
containing 50mM MOPS at pH 7.4, 50mM potassium acetate, 20mM magnesium acetate. All 
substrates and compounds used were dissolved in MAT2A buffer. Final reaction volumes were 
fixed at 150 µL. 
Michaelis menten curves 
MAT2A was pre-incubated in the presence/absence of RAPTA-T for 30 minutes at 37°C. L-
methionine in different concentrations (1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.8 and 0 µM) 
and subsequently 1mM ATP was added to start the reaction. After 30 minutes, reactions were 
quenched with 5uL acetic and cooled on an ice pellet. 25uL of sample is used for a phosphate 
colorimetric assay and Km values are calculated in Graphpad Prism.  
IC50 value determination 
MAT2A was pre-incubated with different concentrations of RAPTA-T (1000, 500, 250, 125, 
62.5, 31.3, 15.6, 7.8 and 0 µM) at various time-points at 37°C.  50 µM L-methionine and 1 mM 
ATP was added to start the reaction. After 30 minutes, reactions were quenched with 5 µL 
acetic and cooled on an ice pellet. 25 µL of sample is used for a phosphate colorimetric assay 
and IC50 values are calculated in Graphpad Prism. 
 
4.4.4 PLD3 Enzymatic assays 
Recombinant human PLD3 stored in 50% glycerol was buffer exchanged were performed with 
amicon 10 kDa cutoff centrifugal filters according to manufactueres instructions, into PLD3 
reaction buffer containing 250 mM TrisHCl, 25 mM CaCl2, pH 8.0. All substrates and 
compounds used were dissolved in PLD3 buffer except commercially available reagents from 
the assay.  
Determination of recombinant PLD3 activity 
A sample of 5 µg in 100 µL of PLD3 and 100 units in 100µL of PLD from Streptomyces 
chromofuscus was used for the Amplex Red Phospholipase D assay according to 
manufacturer’s instructions.  
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5 Chapter 5 
Development of an automated approach to 
determine metallodrug-protein binding sites 
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5.1 Introduction 
An important aspect of the clinical development of new metallodrugs is studying the 
interaction of these compounds with proteins, as these interactions could account for the 
pharmacokinetic and pharmacodynamics properties of these compounds including their 
mechanism and side effects. In this respect, the development of high resolution mass 
spectrometers and fragmentation methods such as collision induced dissociation (CID), higher 
energy collisional dissociation (HCD) and electron capture dissociation (ETD) has made 
fragmentation mass spectrometry a valuable tool for studying metallodrug-protein binding. 
Such methods have in recent years, been applied to the study of metallodrug binding to proteins 
such as insulin, metallothionein-2, carbonic anhydrase, calmodulins and ubiquitin.1–6  However, 
data processing for such applications still remains a significant challenge owing to the 
complexity of the mass spectra obtained from such experiments, in terms of a) quantity of peaks 
to assign b) isotopic complexity of the drug-protein adducts associated with metals c) the 
numerous ligand bound states which could adduct with proteins.  
 
Here we developed the mass spectra analysis of protein modifications (MSAPM) tool, 
which calculates theoretical MS and MS/MS spectra based on a given protein/peptide sequence, 
and user defined modifications to this sequence, and automatically matches these to 
experimental MS spectra. The tool was developed based on chemcalc,180 a web based 
architecture developed in the EPFL to create tools to solve chemistry related problems. In 
chemcalc, a series of web accessible applications known as web services are combined in a 
modular fashion to create web based tools. Using chemcalc, tools for isotopic distribution 
simulation, protein mass fragmentation and generation of molecular formulas for a given mass 
were previously developed, and this architecture was then adapted for creating MSAPM tool. 
The MSAPM tool was originally developed for the study of binding of a homo-bimetallic 
ruthenium complex on a polypeptide chain.79 We subsequently realized the potential of this 
approach to study other protein-metallodrug related problems, and decided on further 
developing the MSAPM tool. For this purpose, we studied the binding of metallodrugs based 
on platinum (cisplatin) and ruthenium (RAPTA-T) with the 8.5 kDa protein ubiquitin. Ubiquitin 
was considered a suitable test protein as it is a relatively small full protein with no disulfide 
bridges or complex post translational modifications, thus posing less of a challenge 
instrumentally for resolving. Moreover, the binding of cisplatin to ubiquitin has been well 
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described in literature,77,175,177,181,182 providing us a wealth of data for comparison and validation 
of the tool.  
 
The initial version of the MSAPM tool allowed matching of MS/MS spectra of modified 
proteins by specifying separately the protein sequence, protein modification (metallodrug 
adduct in this case), and the type of expected fragments (a, b, c, x, y, z type fragments) based 
on the fragmentation type. The tool then generates theoretical spectra based on the specified 
parameters and automatically matches these to imported experimental spectra producing a list 
of possible fragments (Figure 5.1 and 5.20). The tool generates theoretical isotopic patterns for 
each possible protein-adduct fragment with peak areas defined as trapezoids with fixed bottom 
and top widths. However, an initial problem we encountered was the variation of peak widths 
across the m/z range in MS spectra. Since for any MS spectra recorded a fixed resolving power, 
the relationship between mass, peak widths and resolving power is given by; 
Mass resolving power = 
𝑚𝑎𝑠𝑠
𝑝𝑒𝑎𝑘 𝑤𝑖𝑑𝑡ℎ
 
thus, the peak widths of individual isotopic peaks increasingly broaden from low to high m/z. 
This posed a problem because with fixed peak widths, similarity scores were inaccurate for m/z 
of fragment adducts far from the isotope width specified. We thus implemented the option of 
specifying a variable peak width based on mathematical functions to resolve this feature. 
Subsequently, we implemented the option of handling digested fragments from 6 different 
enzymes (trypsin, chymotrypsin, LysylC, GlucylC, thermolysin and cyanogen bromide) for 
bottom up experiments.  
 
Recent literature on metallodrug-protein top down experiments do not take into account 
internal fragmentation. Taking into account the analytical burden of calculating the myriad of 
possible internal fragments, and the fact that currently no automated means of matching internal 
fragment spectra of proteins with modifications exists, it was not surprising that this had not 
been explored. For metallodrug-protein interactions, analysis of internal fragments is important, 
as they provide important information regarding the binding of metallodrugs to residues far 
from the termini. Thus, we implemented this function into the MSAPM tool to calculate a-y 
and b-y type fragments of CID and HCD based MS/MS spectra. Currently implementation of 
c-y, c-z fragments from ETD fragmentation is also underway. Subsequently, we also 
implemented neutral loss calculations which was especially important for higher energy 
MS/MS fragmentation such as HCD. Specifically the tool considers loss of H2O on Ser, Thr, 
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Glu, Asp residues, NH3 on Arg, Lys, Gln, Asn, H3PO4 on phosphorylated Ser, Thr, and Tyr 
residues and SOCH4 for oxidized Met residues.  
 
 
 
One problem encountered in tandem mass spectrometry experiments is the loss of peak 
signal-to-noise ratio during subsequent rounds of fragmentation and the generation of very 
complex spectra with a large number of overlapping peaks. In the initial matching algorithm, 
the tool considered a user defined zone before and after the monoisotopic mass of the adduct 
peak of interest for calculation of matching similarities. However, this posed a problem when 
in spectra where there were many overlapping peaks and signal-to-noise ratio of the peak of 
interest was low. We thus modified the tool to consider each individual isotope peak within an 
isotopic pattern as a separate entity, eliminating the influence of surrounding peaks on the 
matching similarity score (Figure 5.1, inset). With these developments, the tool became a 
powerful tool that for matching complex MS/MS spectra of proteins and its modifications.  
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Figure 5.1 Example of matching performed by MSAPM tool. Top down MS/MS spectra from HCD fragmentation 
of [RuC
7
H
8
+ Ub]
9+
, where the tool detected various terminal fragments (in blue) and internal fragments (in red) from 
the experimental spectra. Inset shows second zone matching of experimental peaks (blue) to theoretical peaks (red). 
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5.2 Results and discussion 
5.2.1 Analysis of full scans of metallodrug-ubiquitin incubations 
To validate the applicability of the tool to detect different metal-adduct species and to find 
suitable adducts for fragmentation, we performed full scans of 5:1 (metallodrug: ubiquitin) 
incubations from 0.5 to 18 hours. In cisplatin samples, as the incubation time was increased, 
we observed a general shift towards species which were either hydrolysed or had lost chloride 
ligands and also an increasing number of platinated adducts (up to 5) on the protein over the 
18 hour incubation period (Figure 5.2). Surprisingly, we observed a ubiquitin adduct with 
Pt(NH3)2Cl2 corresponding to full cisplatin across all incubation times tested. This is probably 
due to non-covalent type interactions such as Van der Waals forces, hydrogen and halogen 
bonding.  
 
 Upon an 18 hour incubation, RAPTA-T also showed multiple adduct species with 
ubiquitin, but a lesser extent of ruthenation of up to 2 adducts (Figure 5.3). Multiple charge 
states of each adduct species were also detected via the tool. Similar to the case with cisplatin, 
we saw ubiquitin adduct of full RAPTA-T, which could be explained by similar non-covalent 
inreactions. Overall, this showed the ability of the tool for assigning different types and amounts 
metal-protein adduct species with multiple charge states.  
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Figure 5.2 Changes of adduct types (A,B and C) and number of platinated adducts (D, E and F) of  1:5 
(ubituitin:cisplatin) incubated for 0.5 hours (A & D) , 4 hours (C & E) and 18 hours (C & F) at 37 °C. There is a 
general shift towards increased adduct species with hydrated or displaced ligands as well as increase in platination of 
the protein as the incubation time increases. 
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5.2.2 Analysis of top down MS/MS of metallodrug-ubiquitin incubation 
To investigate the suitability of the tool for interpretation of high resolution 
fragmentation mass spectrometry data, we performed CID, HCD and ETD fragmentation 
experiments on the metal-drug ubiquitin incubated samples, selecting two high charge states (> 
+8) for each adduct species examined. The tool provided an extensive coverage of both terminal 
and internal adduct fragments from MS/MS experiments, discriminating well the different 
adduct types (terminal a, b, c, x, y, z, and internal a-y and b-y ions) with high similarities.  
 
As proof of principle to show the tool could find binding sites of a well-known 
metallodrug-protein system,77,175,177,181 we attempted to validate the tool by identify binding 
sites of cisplatin on ubiquitin. Upon 1:1 incubations of cisplatin:ubiquitin for 18 hours in water, 
fragmented two metallated cisplatin adducts [7H+ Ubiquitin + PtN2H6]
9+
 and [8H+ Ubiquitin 
+ PtN2H8O]
10+ were subjected to HCD, CID and ETD fragmentation. Importantly, none of the 
prepared solutions were diluted in organic solvents or acid before electrospray ionization, but 
were directly sprayed in water. When compared against spraying in a 1:1 water:ACN mixture 
with 0.1% formic acid, directly spraying from water showed much better retention of metallated 
fragments. For interpretation of Pt binding sites we considered all metallated fragments with 
similarity scores of over 65% (Figure 5.4).  
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Figure 5.3 Adduct types (left panel) and number of platinated adducts (right panel) of 1:5 (ubituitin:RAPTA-T) incubated 
for 18 hours at 37 °C. Different adduct species of RAPTA-T were matched by the tool and up to 2 ruthenation sites was 
observed. 
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Figure 5.4 Top down MS/MS from CID fragmentation of [7H+ Ubiquitin + PtN2H6]
9+
 and [8H+ Ubiquitin + 
PtN2H8O]
10+ 
A: Full length ubiquitin sequence with most accessible metal binding sites in red and inaccessible 
binding sites in blue B: full length ubiquitin sequence with detected metallated fragments highlighted in red. 
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In CID and HCD fragmentation considering internal fragments, we obtained a large 
coverage of metallated fragments covering nearly the whole ubiquitin sequence. From 
literature reports of cisplatin binding to ubiquitin, cisplatin has been shown to bind to Met1, 
His68, Thr12, Thr14, and Asp32 residues.175,181 In general, our data validated these findings. 
From the N-terminal [a11+Pt] 2+ fragment of CID fragmentation of [7H+ Ubiquitin + 
PtN2H6]
9+
 we validated the Met1 binding site. From the C-terminal [y17+PtNH3]+ & 
[y17+PtN2H6]2+ fragments from ETD fragmentation of adducts [7H+ Ubiquitin + PtN2H6]
9+
 & 
[8H+ Ubiquitin + PtN2H8O]
10+ respectively, His68 was the most likely binding residue. For 
the reported binding sites of Thr12, Thr14 and Asp32, multiple platinated internal fragments 
obtained covered sequences containing these residues (Figure 5.4). This highlights an 
important strength of the MSAPM tool which calculated internal fragmentation, where these 
internal binding sites were previously identified through a bottom up approach,175 whereas 
here we managed to reproduce these for the first time via top down MS.  
  
 However, from the extensive coverage of metallated fragments we obtained due to 
automated tool matching, it became apparent that cisplatin binding to ubiquitin is more complex 
than that reported so far. From combined information of the crystal structure of ubiquitin, and 
coordination chemistry of transition metal complexes along with our incubation and spray 
conditions, we predicted the most likely metal binding sites on ubiquitin. Since incubations and 
electrospray ionization was done in water (~pH 6), the most likely metal binding sites are acidic 
Asp and Glu residues, sulphur containing Met and nucleophilic His residues. All basic residue 
side chains were expected to be charged at this pH and thus unable to coordinate to the metal 
centre. Further scrutiny of the crystal showed some of these sites were sterically inaccessible 
leading us to a total of 12 possible metal binding sites in the metal (Figure 5.5.). In general, all 
internal and terminal fragments obtained contained at least one of these possible metal binding 
residues. This suggested that cisplatin likely coordinates to all these binding sites probably 
through multiple coordination modes.  
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Figure 5.5 Most likely binding sites of metals on bovine ubiquitin. Crystal structure of bovine ubiquitin is above 
its full amino acid sequence bottom. Predicted accessible binding residues are labeled red, and inaccessible 
binding residues are labelled blue. 
 
We were then interested in knowing whether there was a preference in binding of Pt to 
specific sites in the ubiquitin sequence. For this, we tried to analyze the abundance of all 
metallated fragments ions obtained from CID/HCD of cisplatin-ubiquitin metallated adducts. 
For all fragments obtained with a good similarity, we sub-categorized them into N-terminal 
fragments from residue 1-39 abbreviated L, C-terminal fragments from residue 1-37 
abbreviated R, and all other fragments abbreviated M (Figure 5.6).  
 
 
Figure 5.6 Classification of L, R, M fragments. Full sequence of ubiquitin given above with examples of 
different fragments and their classifications given below. N-terminal fragments from residue 1-39 abbreviated L, 
C-terminal fragments from residue 1-37 abbreviated R, and all other fragments abbreviated M. 
 
Initially, we analyzed the distribution of M, L and R fragments obtained from MS/MS 
fragmentation of plain ubiquitin via CID (Figure 5.7) and HCD (Figure 5.8) to observe the 
distribution of daughter ions produced from the different fragmentation methods and the 
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reliability of the data for subsequent analysis of metallated adducts. In this case, we required a 
fragmentation method should produce an equal distribution of R to L fragments which would 
allow us to see if metalation modified this distribution. Both HCD and CID fragmentation of 
different charge states of ubiquitin gave very reproducible results. In CID, there was a very even 
distribution between L and R fragments (Figure 5.7), however for HCD, there was a bias 
towards L fragments with a L:R ratio of around 6:4 (Figure 5.8). Thus, we selected CID 
fragmentation for analysis of metallated adducts.  
 
 
Figure 5.7 Percentage abundance of L, R and M metallated daughter ions from CID fragmentation of ubiquitin. 
Parents ions [5H+ Ubiquitin]
5+
, [6H+ Ubiquitin]
6+ 
and [7H+ Ubiquitin]
7+
 were chosen for fragmentation. Criteria 
for L, R, M fragments are in Figure 5.6.   
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From CID fragmentation of cisplatin-ubiquitin adducts with charge states of +9, +10, 
and +11, we saw a higher abundance of L  type adducts where there was a 2:1 ratio of L:R 
metallated adducts observed (Figure 5.9). This showed that there was a preference of binding 
of Pt to residues corresponding to L residues in ubiquitin. Considering this, we compared the 
polarity of both halves of the protein and found that L sequence had an isoelectric point (PI) of 
4.62 and the R sequence had a PI of 9.34. Since cisplatin is aquated with loss of Cl ligands 
forming a cationic species in water, it was thus likely that the binding preference for L portion 
of ubiquitin was due to the relative negative polarity of this portion.  
 
Figure 5.8 Percentage abundance of L, R and M metallated daughter ions from HCD fragmentation of 
ubiquitin. Parents ions [5H+ Ubiquitin]
5+
 and [6H+ Ubiquitin]
6+ 
were chosen for fragmentation. Criteria for L, 
R, M fragments are in Figure 5.6.   
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We also observed an increase in the percentage of M fragments from an average of 70% 
in platin ubiquitin to 85% in platinated ubiquitin (Figures 5.7 & 5.8). When analyzed as a 
distribution of the number of amino acid residues per fragment, we saw that the number of 
amino acid residues from platinated M fragments was higher than that of M fragments from 
ubiquitin (Figure 5.10). This observation could be explained by the binding of Pt stabilizing the 
protein against fragmentation. Alternatively, the collision energy from CID could be absorbed 
by the Pt center or spent on fragmentation of cisplatin bound ligands thus reducing its 
availability for breaking peptide bonds resulting formation of larger fragments.  
 
 
Figure 5.9 Percentage abundance of L, R and M metallated daughter ions from CID fragmentation of ubiquitin 
incubated with cisplatin. Parents ions [7H+ Ubiquitin + PtN2H6]
9+
, [8H+ Ubiquitin + PtN2H8O]
10+ 
and [9H+ Ubiquitin 
+ PtN2H6]
11+
 were chosen for fragmentation. Criteria for L, R and M fragments are in Figure 5.6.   
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Figure 5.10 Percentage abundance of M metallated daughter ions classified into different amino acid lengths 
from CID fragmentation of ubiquitin incubated with cisplatin. Parents ions [7H+ Ubiquitin + PtN2H6]
9+
, [8H+ 
Ubiquitin + PtN2H8O]
10+ 
and [9H+ Ubiquitin + PtN2H6]
11+
 were chosen for fragmentation. Criteria for L, R, M 
fragments are in Figure 5.6.   
 
Next, we proceeded to study the binding of RAPTA-T to ubiquitin. For incubations of 
1:5 (protein:drug) ratio of ubiquitin with RAPTA-T, the metallated adducts [8H+ Ubiquitin + 
RuC7H8]
10 
and [9H+ Ubiquitin + RuC7H8]
11+
 were subjected to MS/MS fragmentation via CID, 
HCD, ETD (Figure 5.11). We observed very similar metallated fragments covering nearly the 
full protein sequence showing the complexity of Ru binding to ubiquitin where the metal can 
potentially bind to multiple binding sites (up to 11 residues) on ubiquitin. The only possible 
binding residue where we did not see a metallated fragment was Glu16. We observed a similar 
trend with cisplatin, where ruthenated ubiquitin fragments obtained upon CID fragmentation 
consisted of mostly L type fragments with a L:R ratio of approximately 2:1 (Figure 5.12). This 
could be explained by a similar activation mechanism of RAPTA-T forming a cationic species 
thus preferring the more negatively charged L region in ubiquitin. There was a decrease in the 
number of M fragments from CID found in ruthenated ubiquitin, from an average of 70% in 
plain ubiquitin (Figure 5.7) to 50% in ruthenated ubiquitin (Figure 5.12). However, the 
distribution of the number of amino acid residues per fragment still showed a shift towards 
larger M fragments from CID on ruthenated ubiquitin (Figure 5.13). 
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Figure 5.11 Top down MS/MS results from CID, HCD and ETD fragmentation of [8H+ Ubiquitin + RuC7H8]
10+
 
and [9H+ Ubiquitin + RuC7H8]
11+
. In each row, the full ubiquitin sequence is shown and metallated fragments 
found are highlighted in red. 
 
  
103 
 
 
 
Figure 5.12 Percentage abundance of L, R and M metallated daughter ions from CID fragmentation of ubiquitin 
incubated with RAPTA-T. Parents ions [8H+ Ubiquitin + RuC7H8]
10+
 and [9H+ Ubiquitin + RuC7H8]
11+ 
were 
chosen for fragmentation. Criteria for L, R, M fragments are in Figure 5.6. 
 
 
Figure 5.13 Percentage abundance of M metallated daughter ions classified into different amino acid lengths from CID 
fragmentation of ubiquitin incubated with RAPTA-T. Parents ions [8H+ Ubiquitin + RuC7H8]
10+
and [9H+ Ubiquitin + 
RuC7H8]
11+ 
were chosen for fragmentation. Criteria for L, R, M fragments are in Figure 5.6.   
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5.2.3 Analysis of bottom up MS/MS of metallodrug-ubiquitin incubations 
To validate the bottom up analysis option in the MSAPM tool we digested both cisplatin 
and RAPTA-T incubated ubiquitin samples with LysylC and GluC which cleaves peptide bonds 
at the C-terminal to Lys and Glu residues respectively.  In full scans of ubiquitin digested with 
LysylC and GluC, we obtained digested fragments covering the full protein sequence of the 
protein with no miscleavage sites (data not shown). For analysis of metal-protein digests, the 
tool enabled matching of multiple metal-protein adduct species with high similarities enabling 
us to easily map metallated digested fragments along the protein sequence. The tool also 
simplified selection of parent ions for MS/MS fragmentation and subsequent interpretation of 
these results for narrowing down metal binding residues. In cisplatin-ubiquitin incubations 
digested with LysylC, we detected a large number of metallated digest fragments spanning the 
full protein sequence (Figure 5.14). Similarly LysylC digested samples of ubiquitin incubated 
with RAPTA-T revealed metallated digested fragments covering the full protein sequence 
(Figure 5.15) but for GluC digests metallated fragments covered 85% of the protein sequence 
(Figure 5.16). These results validated the proteolytic enzyme function implemented in the tool 
and also confirmed our top down findings of multiple possible metal binding sites on ubiquitin.  
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Figure 5.14 MS full scans of bottom up digestion of Cisplatin:Ubiquitin incubations with LysylC. A: Full length 
ubiquitin sequence with predicted binding sites in red and inaccessible binding sites in blue. B: List of metallated 
digested fragments detected by the tool (similarly labelled as A) C: List of metallated digested adducts (different 
digest fragments highlighted in different colors). 
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Figure 5.15 MS full scans of bottom up digestion of RAPTA-T: Ubiquitin incubations with LysylC. A: Full 
length ubiquitin sequence with predicted binding sites in red and inaccessible binding sites in blue. B: List of 
metallated digested fragments detected by the tool (similarly labelled as A) C: List of metallated digested 
adducts (different digest fragments highlighted in different colors). 
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Figure 5.16 MS full scans of bottom up digestion of RAPTA-T: Ubiquitin incubations with GluC. A: Full length 
ubiquitin sequence with predicted binding sites in red and inaccessible binding sites in blue. B: List of metallated 
digested fragments detected by the tool (similarly labelled as A) C: List of metallated digested adducts (different 
digest fragments highlighted in different colors). 
 
We then proceeded to perform MS/MS experiments on selected digested metal 
fragments to show the applicability of the tool to facilitate narrowing down of metal binding 
sites on digested proteins. For cisplatin-ubiquitin incubated samples digested with LysylC, we 
selected the parent ions [PtNH3 + Met1-Lys6]2+, [PtN2H6 + Thr-Lys27]2+, [PtN2H6 + Ile30-
Lys48]3+, and [PtN2H6 + Glu49-Lys63]3+ for MS/MS fragmentation via CID, HCD or ETD 
(Figure 5.17). We analyzed the smallest terminal N and C metallated adducts and internal 
fragments to narrow down metal binding sites. CID fragmentation of [PtNH3 + Met1-Lys6]2+ 
revealed a single metallated a5 fragment. Since this ion did not contain any other potential metal 
binding sites, we assigned the metal binding site to the terminal Met residue. For the ion 
[PtN2H6 + Thr12-Lys27]2+ CID fragmentation revealed a single y15 fragment, which did not 
allow precise assignment of a specific residue considering this ion contained 4 possible metal 
binding residues. Fragmentation of [PtN2H6 + Ile30-Lys48]3+ via HCD revealed a y15 terminal 
and b13y18 internal metallated fragment. CID fragmentation of the same ion revealed an N-
terminal a10, C-terminal y11 and internal a18y18 metallated fragment. Combined results 
allowed us to unequivocally assign the cisplatin binding site on this ion to Asp39. The [PtN2H6 
+ Glu49-Lys63]3+ ion was fragmented by CID, HCD, and ETD fragmentation. We found a 
b11y10 metallated internal fragment from CID, a13 N-terminal and b11y12 internal metallated 
fragments from HCD together with a c10 N-terminal and z9 C-terminal metallated fragments 
from ETD. Combined results allowed us to assign the binding site on this ion to Asp58.  
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Figure 5.17 MS/MS of metallated fragments of Cisplatin: Ubiquitin incubations digested with LysylC. Full 
length ubiquitin sequence with probable binding sites in red and inaccessible binding sites in blue is shown 
above. Each metallated digest parent ion chosen for MS/MS is displayed with fragmentation type, mass and 
charge state. Relevant metallated MS/MS daughter ions obtained are displayed as N-terminal ions top, C-
terminal ions bottom and internal ions highlighted green on the parent ion sequence.   
 
For RAPTA-T:Ubiquitin incubations digested with LysylC, we fragmented the ions 
[C13H20N3PRu + Met1-Lys6]2+, [C13H20N3PRu + Ala28-Lys63]4+, [C7H8Ru + Glu34-Lys48]3+, 
[C13H20N3PRu + Gln49-Gly76]3+ (Figure 5.18). With CID fragmentation of [C13H20N3PRu + 
Met1-Lys6]2+ we found a single metallated a5 fragment allowing us to assign Met1 as a binding 
site of RAPTA-T. CID & HCD fragmentation of [C13H20N3PRu + Ala28-Lys63]4+ revealed two 
metallated internal fragments b16y35 and b35y19 showing there were at least two metal binding 
sites in this 35 amino acid peptide digest. This combined with HCD fragmentation of [C7H8Ru 
+ Glu34-Lys48]3+ which had a11 N-terminal, y11 c-terminal and a b11y9 internal metallated 
fragment allowed us to assign Asp39 as a RAPTA-T binding site. Though CID fragmentation 
of the [C13H20N3PRu + Gln49-Gly76]3+ we obtained a26, y23 and b24y16 metallated fragments. 
HCD fragmentation of the same ion revealed an additional b23y17 internal metallated fragment 
allowing us to narrow down binding of RAPTA-T to either Glu64 or His68.  
 
  
109 
 
 
Figure 5.18 MS/MS of metallated fragments of RAPTA-T: Ubiquitin incubations digested with LysylC. Full 
length ubiquitin sequence with probable binding sites in red and inaccessible binding sites in blue is shown 
above. Each metallated digest parent ion chosen for MS/MS is displayed with fragmentation type, mass and 
charge state. Relevant metallated MS/MS daughter ions obtained are displayed as N-terminal ions top, C-
terminal ions bottom and internal ions highlighted green on the parent ion sequence.   
 
For GluC digests, we chose two terminal metallated digested ions [C13H20ClN3PRu + 
Met1-Glu16]3+ and [C13H20N3PRu + Ser65-Gly76]3+ (Figure 5.19). CID and HCD 
fragmentation of revealed terminal a7 and y8 metallated fragments confirming Met1 as a 
binding site and allowing us to assign Glu16 as an additional binding residue of RAPTA-T. 
Though fragmenting the [C13H20N3PRu + Ser65-Gly76]3+ ion via HCD and CID we observed 
a10, y9 and y10 metallated fragments allowing us to assign His68 as a RAPTA-T binding site.  
 
 
Figure 5.19 MS/MS of metallated fragments of RAPTA-T: Ubiquitin incubations digested with GluC. Full length 
ubiquitin sequence with probable binding sites in red and inaccessible binding sites in blue is shown above. Each 
metallated digest parent ion chosen for MS/MS is displayed with fragmentation type, mass and charge state. 
Relevant metallated MS/MS daughter ions obtained are displayed as N-terminal ions top, C-terminal ions bottom 
and internal ions highlighted green on the parent ion sequence.   
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5.3 Conclusions 
 Here we developed and optimized a web-based tool for automated analysis of complex 
mass spectra of proteins with modifications. The tool enables a comprehensive match of all 
possible combinations of user defined protein modifications and is especially useful for top 
down and bottom up MS experiments on metal-protein adducts. Using ubiquitin as a model 
protein, we studied its interaction with the metallodrugs cisplatin and RAPTA-T. Our results 
revealed the complexity of the interactions of these metallodrugs with ubiquitin, where the 
metal can potentially bind more than 10 different sites on ubiquitin. Through analysis of 
abundance of different metallated fragments obtained, we show a preference of metal binding 
at more negatively charged regions on the proteins, and reason that this is due to the cationic 
nature of the metallodrug upon activation. Taken together our results suggest that design of 
metallodrugs that target a specific protein site can be a challenging due to the promiscuity of 
metal binding to proteins. Careful tuning of ligands in terms of sterics and kinetics would be 
essential to achieve such selectivity.  
 
5.4 Experimental 
Tool development was performed by Dr. Luc Patiny. MS data acquisition was performed with 
aid from Dr’s. Laure Menin and Daniel Ortiz from the EPFL mass spectrometry centre.  
 
5.4.1 Materials 
Ubiquitin from bovine erythrocytes was purchased from Sigma Aldrich, cisplatin was 
purchased from Tokyo Chemical Industries, RAPTA-T was synthesized according literature 
methods.116 . MS grade LysylC and GluC endoproteinase was purchased from Thermo Fisher 
Scientific, USA.  
 
5.4.2 Sample preparation 
100 µM ubiquitin was incubated with metal complexes (RAPTA-T or cisplatin) at a 1:1 and 1:5 
protein: drug ratio at 37° C for 0.5 to 18 hours. All incubations were performed in sterile MiliQ 
water.  Excess drug was removed with three rounds of centrifugation using 3kDa-cutoff Amicon 
Ultra centrifugal filters according to manufacturers instructions. Incubated proteins were snap 
frozen in liquid N2 and stored at -20 ° C prior to top down analysis. For bottom up sample 
preparation, metallodrug-protin inccubations were digested with MS grade LysylC or GluC 
according to manufacturer’s instructions.  
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5.4.3 Mass spectrometry analysis  
CID, HCD and ETD fragmentation studies were performed on an ETDenabled hybrid linear 
ion trap (LTQ) Orbitrap Elite mass spectrometer (Thermo Scientific, Bremen, Germany) 
coupled to a Triversa Nanomate (Advion) chip-based electrospray system. The samples were 
diluted at a final concentration of 10 µM in a solution of CH3CN/H2O/HCOOH (50:49.9:0.1) 
or directly infused in water using a spray voltage of 1.6 kV. The automatic gain control (AGC) 
target was set to 1 x 106 for full scans in the Orbitrap mass analyzer. ETD experiments used 
fluoranthene as the reagent anion and the target for fluoranthene anions was set to 5 x 105. 
Precursor ions for MS/MS were detected in the Orbitrap mass analyzer at a resolving power of 
30,000 (at 400 m/z) with an isolation width of 8, and product ions were transferred to the FTMS 
operated with an AGC of 5 x 104 over a m/z range of 200-3000. The reaction time with the 
fluoranthene radical anions into the LTQ was set from 50 to 100 ms. For CID and HCD 
fragmentation normalized collision energies of 20-35% were used. A total of 100 scans were 
averaged for each fragmentation spectra. The Orbitrap FTMS was calibrated for the high mass 
range, keeping a mass accuracy in the 1-3 ppm level.  
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5.4.4 Tool development and layout 
The MSAPM tool was developed based on http://www.chemcalc.org.180 General layout of the 
tool is described in Figure 5.15, and the parameter input window is described in Figure 5.21.  
 
 
Figure 5.20 Cheminfo tool graphical user interface. Various modules are labelled A to J corresponding to A) 
experimental description, B) parameter input (detailed description in figure 5.21) C) fragment list with 
modifying groups (part 1-5), fragment sequence, fragment type, theoretical mass, experimental/observed mass, 
percentage similarity and charge  D) enlarged window for fragment sequence E) experimental MS spectra (blue), 
with theoretical match of selected fragment (red) selection carried out by left clicking fragment of interest in 
module C F) fragment details  G) matching of theoretical to experimental spectra window (with comparison zone 
specified in module B) H) drag and drop spectra (accepts.txt files) I) process and cancel commands. 
D 
E 
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G 
H 
A 
B 
C 
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Figure 5.21 Cheminfo script parameter input module, labelled I to IV. I) List of modifiable groups applied onto 
the protein sequence specified in the sequence box II) Enzymatic digest parameters for bottom up experiments 
III) MS/MS experiment parameters including fragment types, internal fragments and length of internal fragments 
IV) Other option including protonation of basic amino acids, neutral losses, bottom and top widths for of 
trapezoid for matching theoretical to experimental spectra (inputting a formula overwrites the fixed value 
specified), zone which specifies the mass range in Da/charge where theoretical spectra is overlapped with 
experimental spectra to calculate similarities (low and high specifies mass range in Da/charge before and after 
the monoisotopic mass of the peak of interest respectively), common zone (which specifies how similarity 
matching between theoretical and experimental spectra is performed), best result range which keeps only the best 
defined number of results within the scanned zone, max results number and minimal similarity score displayed. 
5.4.5 Input parameters and data interpretation 
General  
Pre-processing of all MS/MS spectra obtained was done in ThermoFisher Excalibur, and files 
were exported as .txt files before input into the Cheminfo tool. Hydrogens, modifiable charge 
and metal adduct types were introduced in the various boxes (Figure 2, I). In the options section 
(Figure 2, IV), protonation of basic amino acids was left unchecked. Neutral loss was scanned 
for MS/MS spectra of selected shorter peptides in bottom up experiments. Trapezoid widths 
were calculated via polynomial fitting of widths (FWHM) across the m/z range of each spectra 
(calculated in ThermoFisher Excalibur), and inputted as a general formula: 
 
I 
II 
III 
IV 
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𝑣𝑎𝑟 𝑤𝑖𝑑𝑡ℎ𝑏𝑜𝑡𝑡𝑜𝑚 = [a(mass)(mass) + b (mass) + c]. 2; var widthtop =
Width Bottom
4
  
Zone widths were selected based on complexity of the expected isotopic pattern (typically 
applied values, -3 to 7.5 for ruthenium and -2 to 6.5 for platinum) and the common zone 
parameter “second” was used for all processing. Best result range was set at 3, max results at 
500 and minimal similarity at 30%.  
 
Enzymatic digests 
Enzyme used was selected from the dropdown menu (in our case LysC, and GluC), maximal 
missed cleavage sites were set at 3, and min/max residue numbers were set at 1 and 999 
respectively.  
 
MS/MS spectra 
Selection of fragment ions were based on fragmentation type. a, b and y ions including y-b and 
y-a internal fragments were chosen for CID and HCD fragmentation and c, y and z ions were 
chosen for ETD spectra.  
 
Data interpretation 
Though the tool provides percentage similarity scores, a general cutoff of 65% was used. In 
cases of ambiguity, spectral peaks were compared manually in the spectral window (Figure 
5.20, G & E), before selection.  
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6 Chapter 6 
Application of the MSAPM tool to aid 
determination of protein-metallodrug binding 
sites on the breast cancer susceptibility protein 
type-1 (BRCA1) zinc binding domain.  
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6.1 Introduction 
Zinc finger (ZF) proteins participate in protein/nucleic acid and protein/protein interactions 
in many groups of proteins. They play a diverse role in many cellular processes, including 
transcription, DNA repair, cellular signaling and apoptosis. They are classified into several 
groups based on the structural properties in the region of the zinc-binding site.183 The Really 
Interesting New Gene (RING) finger protein is a one of them. The structure of RING finger 
domain is characterized by two zinc ions coordinated to eight amino acids, typically cysteine 
and histidine (Cys3His1Cys4) residues. The coordinated zinc maintains the functional tertiary 
structure184 and its substitution by another metal ion causes a loss of tertiary structure leading 
to loss of protein function.185–187 Currently, ZF proteins have been investigated as therapeutic 
targets for treatment of diverse conditions including cancer, HIV, and bacterial infection. Most 
ZF protein inhibitors act by coordinating to the active-site metal ion or interacting with residues 
around the active site, leading to distortion of tertiary structure, displacement of zinc ions and 
loss of protein conformation and function.185,188–193 
 
Breast cancer is also the most common cause of cancer death among women (522,000 
deaths in 2012) and the most frequently diagnosed cancer among women in 140 countries 
worldwide, accounting for one in four of all cancers in women.194 The breast cancer 
susceptibility gene 1 (BRCA1) is responsible for a hereditary predisposition to breast cancer. 
BRCA1 is essential for maintaining genomic stability and is associated with a number of 
cellular processes, including DNA repair, cell cycle checkpoint, transcriptional regulation and 
protein ubiquitination.194,195BRCA1 contains three major domains, including the Zn2+ finger 
RING domain (BRCA1 RING domain) at the N-terminus, the nuclear localization signal 
domain (NLS), and the BRCA1 C-terminal domain (BRCT domain).196 The RING domain is 
characterized by a conserved pattern of one histidine and seven cysteine residues arranged in 
an interleaved fashion forming two distinct Zn2+-binding sites in which two pairs of cysteines 
(Cys24, Cys27 and Cys44, Cys47) form site I and a cysteine and histidine pair together with 
another pair of cysteines (Cys39, His41 and Cys61, Cys64) form site II.196 The BRCA1 RING 
domain preferentially forms a heterodimer with another RING domain (BRCA1-associated 
RING domain 1, BARD1).196,197 The structure of the BRCA1/BARD1 RING dimer comprises 
a four helix bundle forming the binding interface. Heterodimerization stabilizes the proper 
conformation of the BRCA1 RING domain to allow E3 ubiquitin ligase activity.198,199 This 
activity is subsequently lost on chelation of Zn2+ in the BRCA1 RING domain, suggesting the 
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activity is regulated by the Zn2+ ion concentration.199 Many cancer-predisposing substitution 
mutations, such as C24R, T37R, C39Y, C61G,and C64Y, which potentially impair Zn2+ 
coordination and BRCA1 RING structural integrity have been identified.196,200 In addition, these 
mutations have been shown to affect ubiquitin ligase function and, in turn, many cellular 
processes, including cell-cycle progression, cell differentiation, apoptosis, response to DNA 
damage, DNA repair and transcription.201 Other mutations, for example L52F and L63F, are 
located in proximity to site II and may exert an indirect effect on Zn2+ coordination and, in turn, 
ubiquitination.201 The D67Y BRCA1 mutation has been identified in eight European patients. 
At the same site D67E has been observed.202 This amino acid resitdue is located in the vicinity 
of Zn2+-binding site II (defined by residues 58-68), and forms a recognition interface with a 
ubiquitin-conjugating enzyme.201 The consequences of the mutations have yet to be elucidated. 
 
Several preclinical and clinical studies have identified the possibility of using BRCA1 
inactivation as a target for breast and ovarian cancer treatment.203–207 There is evidence to 
suggest that mutations in the BRCA1 RING domain result in a loss of the E3 ubiquitin ligase 
activity and conferred hypersensitivity of cancer cells to DNA-damaging chemotherapy and γ-
irradiation.200,208–210 In addition, cisplatin  has recently been reported to affect the conformation 
of the apo-form of the BRCA1 RING finger domain forming intra- and intermolecular Pt-
BRCA1 adducts.211 A preferential Pt(II)-binding site was found at His-117,211 that led to 
inactivation of the BRCA1-mediated ubiquitin ligase activity of both wild-type and variant 
BRCA1 proteins.26,30 These studies suggest that the ZF motif of the BRCA1 protein could be a 
target for metal-based drugs.   
 
RAPTA complexes, Ru(η6-arene)(PTA)Cl2 (PTA = 1,3,5-triaza-7-phosphaadamantane), 
have been shown to exhibit promising antitumor properties.212 The mechanism of action of 
these complexes has been partially elucidated and is profoundly different to the biochemical 
mode of action of classical platinum anticancer drugs.213–217 For example, whereas cisplatin 
targets DNA, the RAPTA complexes form strong interactions with proteins.55,213 Studies 
indicate that the RAPTA complexes have high affinities for cysteine residues, possibly targeting 
cysteine-rich proteins such as those involved in DNA regulation and thereby mediating their 
therapeutic effect via epigenetic pathways.55  
 
To the best of our knowledge, the interactions of RAPTA compounds with the BRCA1 
protein have not been reported and, hence, we describe an investigation of the interactions of 
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ZF domain RING of BRCA1 proteins, both wild-type and variants D67Y and D67E, with 
RAPTA-C and RAPTA-EA in comparison with cisplatin.  
 
6.2 Results and discussion 
Adducts formed following incubation of the complexes with BRCA1 were initially 
investigated by gel shift assays (Figure 6.1), showing that the RAPTA complexes induce 
intermolecular crosslinks, resulting in dimers or larger aggregates. The binding affinity of each 
complex to the proteins was further investigated using ICP-MS. RAPTA-EA was found to 
exhibit a similar binding affinity to the BRCA1 RING domain (both wild-type and variants), 
which was ca. 5-fold higher than RAPTA-C and RAPTA-T. However, the binding affinity of 
each complex was not significantly different for the mutations compared to the wild-type 
(Figure 6.2).  
 
 
 
 
Figure 6.1 Intermolecular cross-linking of the metal-BRCA1 adducts. Ten µM of BRCA1 protein was pre-
incubated with 30 µM of ZnCl2 at  4 C for 8 h. Holo-BRCA1 were incubated with cisplatin or RAPTA complexes 
at various molar ratios (protein: drug) of 1:0, 1:1, 1:2, 1:4, and 1:6, at 4 C for 24 h, and electrophoresed on 8 % 
SDS/PAGE. The bands of protein were detected by silver staining. Lane M corresponds to the electrophoretic 
mobility of standard protein markers indicated in kDa.     
  
120 
 
 
 
 
Figure 6.2 The binding affinity of cisplatin and the RAPTA complexes to the BRCA1 proteins evaluated by 
ICP-MS analysis. RAPTA-EA1 and cisplatin have a ca. 5-fold high binding affinity compared to RAPTA-C and 
RAPTA-T. Statistically significance differences from the untreated control are indicated by *p<0.01. The 
binding affinity is not significantly affected by the amino acid substitutions. 
Cancer therapies include inducing DNA damage and disrupting DNA repair pathways. 
Among the different types of DNA damage, DNA double-strand breaks (DSB) are one of the 
most deleterious and harmful. Cells mount a coordinated response to these lesions, the failure 
of which can lead to genomic instability and cell death.78,218–223 Hence, blocking this response 
during chemo- or radiotherapy could potentiate the therapy. As the BRCA1 protein is involved 
in the DSB repair process and, as RAPTA complexes have been shown to be inhibitors of this 
protein, they may prove to be useful in combination therapies. Many studies of BRCA1 
functions have shown that it is involved in genomic stability maintenance. The malfunction of 
this protein reportedly results from mutations at the N-terminus of Zn2+ finger RING domain 
gene. In particular, cancer-predisposing site II substitutions at positions 39, 61, and 64 
potentially impair Zn2+ ion coordination and have been shown to disrupt the RING integrity 
and protein function.196,201 As shown in Figure 6.1, RAPTA compounds form intermolecular 
metal-BRCA1 crosslinks.  
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Figure 6.3 The CD spectra of the complexes induced secondary structure change of holo-form of the BRCA1 
RING domain (residues 1-304), both wild-type and variant (D67Y and D67E) at a number of concentration. Ten 
µM of BRCA1 protein was pre-incubated with 30 µM of ZnCl2 for 8 h. Samples were incubated with complexes 
in the dark at 4 °C for 24 h before CD measurement at 25 ºC with the scanning rate of 50 nm/min. The mean 
residues ellipticity and wavelength ranging from 200 to 260 nm were plotted.  A) wild-type protein. B) D67E 
protein. C) D67Y protein. 
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Circular dichroism (CD) was used to verify whether the RAPTA complexes alter the 
conformation of the N-terminal BRCA1 RING domain proteins (Figure 6.3). CD spectra of 
both wild-type and variant BRCA1 RING domain proteins change upon RAPTA binding in a 
concentration dependent manner, characterized by a large increase in negative elipticity at 208 
and 220 nm. Using the CONTIN program, the content of the secondary structure of both wild-
type and variant BRCA1 RING proteins were predicted (Figure 6.4A-C). The complexes 
disrupt the secondary structure of the BRCA1 RING proteins leading to an increase in α-helical 
content and a decrease in β-sheets forms. The binding constant (K) and free energy (∆G) of the 
RAPTA-BRCA1 complexes (1:5; protein to metal) were predicted224 (Table 6.1). RAPTA-EA1 
has a higher binding constant and gave rise to a lower free energy than other complexes. In 
addition, the RAPTA complexes and cisplatin have higher binding constants and lower free 
energies in the D67Y protein than in the D67E or wild-type proteins. This suggests that 
RAPTA-EA1 interacts with the Zn2+ binding sites and other residues rather than the Zn2+ 
binding sites of the protein alone, and affects the overall conformation of BRCA1. The 
differences in the binding constants and free energies may be attributed to the differences in the 
structure of the metal complexes (preferential binding sites of the complexes were determined 
by mass spectrometry – see below). Moreover, it is notable that the structure of the D67Y 
protein is more susceptible towards binding the RAPTA complexes than the D67E or wild-type 
proteins, consistent with previous studies which showed that cisplatin perturbs the secondary 
structure of BRCA1 RING domain protein.211,213 
 
Table 6.1 Binding constant and free energy predicted by the CONTIN program on the binding of RAPTA 
complexes to the BRCA1 proteins. ±SD of three independent experiments. 
 
 
 
Complexes Wild-type D67E  D67Y  
 
Binding constant 
(K) M-1 
Free energy 
(∆G) cal mol-1 
Binding constant 
(K) M-1 
Free energy 
(∆G) cal mol-1 
Binding constant 
(K) M-1 
Free energy 
(∆G) cal mol-1 
cisplatin 4.85 ± 0.23 x 104 1792.64 6.11 ± 0.44 x 105 291.46 6.46 ± 0.46 x 105 285.97 
RAPTA-EA1 2.72 ± 0.65 x 106 -594.32 8.85 ± 0.68 x 105 72.44 2.99 ± 0.02 x 106 -650.81 
RAPTA-C 2.03 ± 0.02 x 105 945.44 2.99 ± 0.04 x 105 714.81 3.69 ± 0.02 x 105 589.68 
RAPTA-T 2.13 ± 0.07 x 105 916.47 2.89 ± 0.03 x 105 735.57 3.73 ± 0.07 x 105 582.65 
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Figure 6.4 Secondary structure and thermal alteration of the treated BRCA1 RING domain proteins, both wild-
type and variants (D67Y and D67E). The effect of the complexes on the secondary structure of proteins were 
predicted using the CONTIN program. (A-C) The relative secondary structure of treated BRCA1 proteins with 
20, 50, and 50 µM of the complexes. (D-F) Thermal denaturation curves of the metalated BRCA1 adducts. The 
denaturation curves of the metal-BRCA1 adducts are plotted in terms of ∆[Ө]208 nm /∆T. 
 
The thermal stability of the BRCA1 RING proteins induced by the complexes was also 
determined by CD. The thermal denaturation curves were plotted and analyzed (Figure 6.4, D-
F and Table 6.2). The RAPTA complexes stabilize the wild-type protein structure with an 
associated increase in melting temperatures (Tm). In contrast, the Tm in both the D67Y and 
D67E proteins decreased as a result RAPTA binding. The results are consistent with previous 
studies which show that the ZF domain forms the thermostable structure.225 The Tm of the 
BRCA1 RING domains are high (in the range 74-79C), however, the interactions between 
surface residues and solvent appear to be altered as the variant proteins were slightly less 
thermostable compared to the wild-type protein.226 This difference may also reflect an altered 
microenvironment around the mutation site.  
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Control 
Tm (°C) 
cisplatin 
Tm (°C) 
RAPTA-EA1 
Tm (°C) 
RAPTA-C 
Tm (°C) 
RAPTA-T 
Tm (°C) 
WT 78.9 ± 0.2 >95 >95 83.1 ± 0.4 85.2 ± 0.2 
D67E 75.2 ± 0.3 63.8 ± 0.5 60.1 ± 0.2 64.2 ± 0.2 66.8 ± 0.4 
D67Y 74.9 ± 0.4 65.0 ± 0.2 64.2 ± 0.3 65.3 ± 0.2 65.1 ± 0.1 
Table 6.2 Thermal stability of the wild-type and variant (D67E and D67Y) BRCA1 RING protein treated with 
the complexes and characterized by CD. The melting temperatures (Tm) were analyzed by Δ[]/∆T. ±SD of three 
independent experiments. 
 
The zinc ejection assay was used ascertain whether the complexes disrupt the conformation 
of the BRCA1 RING domain protein sufficiently to dislodge the zinc ion from its binding sites 
(Figures 6.5 and 6.6). The results show that the binding of RAPTA complexes and cisplatin to 
all three BRCA1 proteins releases the Zn2+ ion in a dose dependent manner (Figure 6.6). In 
addition, the rate of zinc ion ejection by RAPTA-EA1 is markedly higher than that induced by 
the other compounds (Figure 6.5). Targeting the ZF motif of the BCA2 protein by metalation 
was shown to result in the release of the zinc ion and led to a reduction in E3 ligase activity.189 
Similarly, platinum complexes have been reported to interact with the C-terminus of the HIV 
nucleocapsid NCp7 zinc ﬁnger domain and leading to the ejection of Zn2+ ions.185 
 
 
Figure 6.5 Time-dependent zinc ejection assay on BRCA1 RING domain, both wild-type and variant (D67E and 
D67Y) proteins were treated with the complexes. Reactions were performed in zinc ejection buffer (10% 
glycerol, 50 mM Tris-HCl buffer, pH 7.6). The ejection of zinc ions from the protein was monitored by the 
change in fluorescence of the zinc-selective fluorophore TSQ (6-Methoxy-8-p-Toluenesulfonamido-Quinoline) 
using a spectrofluorometer (excitation filter, 360 nm; emission filter, 490 nm). 
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Figure 6.6 Concentration-dependent zinc ejection assay on the BRCA1 RING domain. Both wild-type and variant 
proteins were treated with the complexes. (A) wild-type protein, (B) D67E protein and (C) D67Y protein. 
 
The effect of the RAPTA complexes on BRCA1 E3 ubiquitin ligase activity was 
investigated (Figure 6.7). The BRCA1/BARD1 RING complex in the presence of ATP exhibits 
an E3 ubiquitin ligase activity that promotes the formation of high molecular weight 
polyubiquitin species, which are not observed in the absence of ATP. The N-terminal BRCA1 
RING domain proteins, both wild-type and variants (D67E and D67Y) were incubated with 
various concentrations of the complexes at 4 oC for 24 hours, and then assaying for E3 ligase 
activity; E3 ligase activity decreases in a dose-dependent manner in all cases (Figure 6.8). The 
IC50 value for inactivation of E3 ubiquitin ligase activity by RAPTA-EA1 is markedly greater 
  
126 
 
than the corresponding values for RAPTA-C, RAPTA-T and cisplatin (Table 6.3). The 
inactivation of BRCA1 E3 ligase activity induced by RAPTA-EA1 is similar to that induced by 
other complexes.227 Surprisingly, the D67E and D67Y variant proteins showed hypersensitivity 
to the RAPTA complexes, especially the D67Y variant (Figure 6.8), consistent with previous 
study showing that platination of the wild-type BRCA1 protein hardly affects the native 
structure and function of the protein whereas platination of the D67E BRCA1 results in distinct 
changes on structure and function.208 
 
WT (µM) D67E (µM) D67Y (µM) 
RAPTA-EA1 55.4 ± 0.3 5.6 ± 0.8 2.8 ± 0.5 
RAPTA-C 167.8 ± 0.5 148.3 ± 0.4 126.5 ± 0.6 
RAPTA-T 95.3 ± 0.2 78.9 ± 0.3 74.6 ± 0.1 
Cisplatin* 60* 60* 32* 
Table 6.3 Half inhibition of BRCA1/BARD1 E3 ligase activity inactivated by the complexes. ±SD of three 
independent experiments. 
* A. Atipairin, A. Ratanaphan, Breast Cancer: Basic and Clinical Research, 2011, 5, 201-208. 
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Figure 6.7 In vitro E3 ubiquitin ligase activity metallated-BRCA1 RING domain.  The E3 ligase reaction in the 
presence or absence of E3 ligase component was evaluated. Complete reaction mixtures, containing 20 µM Ub, 
300 nM E1, 5 µM UbcH5c, 3 µg BRCA1 (residues1-304), and 3 µg BARD1 (residues 26-327), were incubated 
at 37°C for 3 h. Lack of ATP components in the reactions were carried out under the same conditions. Samples 
were then resolved on 8% SDS-PAGE and then performed by western blotting with anti-6-His –HRP conjugated 
antibody. An apparent ubiquitinated product was indicated by filled diamond. 
 
 
 
Figure 6.8 The effect of the RAPTA-treated BRCA1 RING domain proteins on E3 ubiquitin ligase activity. The 
apparent ubiquitinated products (indicated by filled diamonds) in the gels shown in Figure S3 were quantified 
with a Bio-Rad GS-700 Imaging Densitometer. The relative E3 ligase activity of the BRCA1 adducts (%) is 
plotted as a function of the concentration of the RAPTA complexes. 
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The effect of the complexes on cell viability was determined on MCF-7, HCC1937 and 
MDA-MB-231 breast cancer cell lines (Table 6.4). The HCC1937 cell line was selected as it 
contains a BRCA1 mutation, 5382insC.228 RAPTA-C and RAPTA-T are inactive (IC50 > 1000 
µM), whereas RAPTA-EA1 is considerable more cytotoxic than cisplatin in this cell line. Real-
time monitoring of the proliferation of these breast cancer cells was probed in situ using a 
xCEELigence system, showing that RAPTA-EA1 and cisplatin inhibit the proliferation of all 
three cancer cell lines within a few hours, indicative of a direct cytotoxic response. A continuous 
reduction in the cell index (CI) was observed at a high concentration of the complexes (Figure 
6.9). 
 
Figure 6.9 Real-time monitoring of the affect of the complexes on human breast cancer cells using the 
xCEELigence system. Cells were seeded onto an E-plate and allowed to grow prior to the introduction of the 
complexes at various concentrations. After addition of the complexes the cells were allowed to grow for a further 
24 h. The cell index (CI) was recorded every 15 min. Each concentration was performed in triplicates. 
 
 MCF-7 MDA-MB-231 HCC1937 
Cisplatin 19±1 >150 23±1 
RAPTA-EA1          54±1 15.5±0.5 11.2±0.3 
RAPTA-C                  >1000 >1000 >1000 
RAPTA-T                   >1000 >1000 >1000 
Table 6.4 IC50 values (µM) for the complexes on MCF-7, MDA-MB-231 and HCC1937 cells after 24 h (data 
reflect the mean and SD of results from three separate experiments, each performed in triplicates). 
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The IC50 values of cells treated with RAPTA-EA1 (40 µM) decrease rapidly in the 
HCC1937 and MDA-MB-231 cell lines. RAPTA-EA1 appears to be more active against the 
BRCA1-defective HCC1937 cells than the BRCA1-competent MCF-7 or MDA-MB-231 cells, 
consistent with the observation that RAPTA-EA1 more strongly affects variant BRCA1 
compared to the wild-type protein. Combined, these studies imply that an increased sensitivity 
in BRCA1-mutated breast cancer cells might be related to a dysfunctional BRCA1 unable to 
repair DNA damage induced by treatment with the complex, ultimately leading to cell death.227 
In addition, it has been reported that overexpression of BRCA1 in human BRCA1-competent 
breast cancer MCF-7 cells results in an increased resistance to cisplatin.229 In contrast, BRCA1-
defective HCC1937 cells are significantly more sensitive to cisplatin,230 consistent with this 
study. 
 
To determine the preferential binding sites of the RAPTA complexes on the BRCA1 ZF 
region, Electron Transfer Dissociation (ETD) fragmentation mass spectrometry was performed 
on a 50 amino acid synthetic peptide mimicking the ZF region of BRCA1 incubated with 
RAPTA-EA1 and RAPTA-C. ETD fragmentation is a well-established technique used to probe 
the localization of post-translational modifications231 (such as glycosylation and 
phosphorylation) and drug metalation sites on peptides232 and proteins.  ETD causes 
fragmentation of the N-Cα bonds of the peptide backbone generating C and Z type peptide 
fragments which can be used to identify modified amino acid residues on a peptide.  
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Figure 6.10 LTQ Orbitrap FTMS of RAPTA-C after incubation with the BRCA1 peptide. Top spectra: full scan 
900-1200 m/z mass spectra of the 1:5 peptide:complex ratio showing the formation single adduct peaks with 
different ligand states (shown in more detail in the inset). The ion at m/z 953.3306 (+6) corresponds to the native 
BRCA1 peptide.  Bottom specrtra: ETD spectra of the [BRCA1 +7H + RAPTA-C -2Cl]
9+ 
adduct after a 100 ms 
interaction period with the fluoroanthene radical anions showing metallation at the peptide fragment 
Lys25Phe26Cys27Met28Leu29
 
(corresponding sequence in black) and Lys
35 
(corresponding sequence in red). 
Residues labelled with * correspond to a metallated fragment. Residues in bold correspond to zinc binding residues 
on the peptide.   
 
       Initially full scans mass spectra of the 1:5 peptide:complex incubations were analyzed and 
showed adducts with a 1:1 stoichiometry for RAPTA-C, and up to 1:3 adducts with RAPTA-
EA1 (Figures 6.10  and 6.11). Adducts corresponding to RAPTA species that are consistent 
with previous MS studies were observed.182  Further ETD fragmentation was performed on 
suitable drug peptide adducts; for RAPTA-C the most intense adducts [Peptide + RAPTA-C -
2Cl] at +7 and +9 charge states and for RAPTA-EA [Peptide + RAPTA-EA -3Cl +2OH] at +8 
and +9 charge states were selected for ETD fragmentation. Analysis of C-type ETD fragments 
(fragments from the amino terminus) of RAPTA-C peptide adduct showed an absence of any 
metallated fragments before residue Cys24 (C24) and the first metallated fragment at residue 
Leu29 (C29) indicating that binding takes place along a short peptide stretch, 
Lys25Phe26Cys27Met28Leu29 (residues 45-49 on full length BRCA1). Analysis of Z fragments 
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(fragments from the carboxyl terminus) showed no metallated fragments until Lys34 (Z15), with 
a first metallated fragment at Lys35 (Z16), narrowing down to a binding site on Lys35 
corresponding to residue 55 on full length BRCA1 (Figure 6.10 and Appendix C Table C.1). 
For RAPTA-EA, similar analysis of C-type fragments showed the absence of metallated 
fragments until Phe23 (C23), and the first metallated fragment at Met28 (C28), narrowing down 
the binding site to a short peptide stretch Cys24Lys25Phe26Cys27Met28 (residues 44-48 on full 
length BRCA1). Z fragment analysis showed that similarly, RAPTA- EA binds at Lys35 (Figure 
6.11 and Appendix C Table C.2). The binding sites of the RAPTA complexes on the BRCA1 
RING domain are different to those reported for cisplatin, where binding was found at the His117 
residue.211 
 
 
Figure 6.11 LTQ Orbitrap FTMS of RAPTA-EA after incubation with the BRCA1 peptide. Top: full scan 900-
1200 m/z mass spectra of the 1:5 peptide:complex ratio showing the formation up to 3 adduct peaks with different 
ligand states. The ion at m/z 909.1456 (+7) corresponds to the native BRCA1 peptide.  Bottom: ETD spectra of 
the [BRCA1peptide + RAPTA-EA -3Cl +2OH] 9+ adduct after a 100 ms interaction period with the fluoroanthene 
radical anions showing metallation at the peptide fragment Cys
24
Lys
25
Phe
26
Cys
27
Met
28 
(corresponding sequence 
in black) and Lys
35
(corresponding sequence in red). Fragments labelled with * correspond to a metallated 
fragment. Residues in bold correspond to zinc binding residues on the peptide.   
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The similar binding sites observed for both RAPTA complexes suggest that the different 
arene ligands have little impact on the localization of binding, although it does significantly 
affect stoichiometry and kinetics. As mentioned above, RAPTA binding leads to zinc ion 
displacement, which is not surprising based on the close proximity of the binding regions to 
site I of the RING domain of BRCA1 (Cys24, Cys27 and Cys44, Cys47), which would also leads 
to conformational changes on this region and loss of protein function.  
 
Taken together the results from this study allow us to construct a functional model of 
RAPTA effects on the BRCA1 protein (Figure 6.12), where uptake and binding of RAPTA 
complexes to the ZF domain of the RING domain of BRCA1 results in zinc displacement, 
disrupting the secondary structure of the protein. As a consequence of this ruthenation process 
the RING heterodimer BRCA1/BARD1-mediated E3 ubiquitin ligase activity is inactivated 
resulting in a loss of protein function. 
 
 
Figure 6.12 Functional model of the effect of RAPTA complexes on BRCA1 protein.  
 
 
 
6.3 Conclusions 
In summary, RAPTA-EA1 binds to the ZF domain of the BRCA1 RING protein, especially in 
the variant protein, disrupting the secondary structure of the protein and resulting in ejection of 
the zinc ion from the binding site. This process results in a loss of protein function. These results 
indicate that the ZF motif of dysfunctional BRCA1 proteins could be a molecular target for 
ruthenium-based drugs in breast cancer chemotherapy and that RAPTA-EA1 in particular has 
potential in the treatment of breast cancers, especially if used in combination with DNA 
damaging agents.  
BRCA1-RAPTA 
Zn 
Cancer Cell 
protein 
misfolds 
uptake 
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6.4 Experimental 
For clarity and contextual understanding, the full body of results are presented here. MS top 
down experiments were performed in the EPFL. All other biochemistry experiments were 
conducted in the lab of Professor Adisorn Ratanaphan, Prince Songkla University, Songkhla, 
Thailand.  
 
6.4.1 Materials 
RAPTA-T, RAPTA-C116 and RAPTA-EA1120 were prepared as previously described. Cisplatin 
was purchased from Tokyo Chemical Industry Pte. Ltd, Tokyo, Japan. The synthetic peptide of 
the ZF region of BRCA1, from the N-terminus, amino acid sequence ILECPICLEL 
IKEPVSTKCD  HIFCKFCMLK LLNQKKGPSQ CPLCKNDITK, was purchased from 
CASLO ApS, Lynby, Denmark. 
 
6.4.2 Protein expression and purification 
The N-terminal BRCA1 RING domain proteins, both wild-type and variants (D67E and D67Y) 
containing 304 amino acid residues, were produced as previously described.[26] The purified 
protein was identified on 8% Coomassie blue-stained SDS-PAGE and subsequently confirmed 
by sequencing the tryptic digested peptides. 
 
6.4.3 Gel shift assay 
The interaction of complexes with the BRCA1 variants was investigated using a gel shift assay. 
The complexes were prepared as stock solutions in deionized water. The BRCA1 protein (10 
µM) was pre-incubated with 30 µM of ZnCl2 at 4 C for 8 h. The holo-BRCA1 protein was 
then incubated with the complexes at various molar ratios of protein: drug at 4 C for 24 h, and 
electrophoresed on 8% SDS/PAGE. The bands of protein were detected by silver staining.   
 
6.4.4 ICP-MS analysis 
The N-terminal BRCA1 (1-304) proteins, both wild-type and variant (D67E and D67Y), were 
prepared in deionized water. ZnCl2 was prepared as a 1 mM stock solution in deionized water. 
The holo-BRCA1 was pre-incubated with ZnCl2 at the molar ratio of 1:3 (BRCA1:ZnCl2) at 4 
C for 8 h, and any unbound ZnCl2 was removed by dialysis in deionized water. 10 µM of holo-
BRCA1 proteins were treated with the complexes (50 μM) for 24 h at 4 C. Unbound complex 
in the samples was removed by dialysis in deionized water. The amount of protein was then 
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determined by the Bradford assay, using BSA as a standard. Three microgram of metallated-
protein was used to determination complex binding. The extent of metalation was determined 
by inductively coupled plasma-mass spectrometry (ICP-MS) (Agilent Technologies, USA).  
 
6.4.5 Circular dichroism 
The N-terminal BRCA1 (1-304) proteins (10 μM), both wild-type and variant (D67E and 
D67Y), were pre-incubated with 3 mol. equiv. of ZnCl2 at 4 C for 8 h. The holo-BRCA1 
protein was treated with the complexes at various concentrations at 4 C for 24 h. Metal-
dependent folding of the protein was monitored by acquiring CD spectra over the range 200-
260 nm using a Jasco J720 spectropolarimeter (Japan Spectroscopic Co. Ltd., Japan). Binding 
measurements were carried out at 20 C using a 0.1 cm quartz cuvette. Five spectra were 
averaged with a step size of 0.1 nm, a 2 s response time and a 1 nm bandwidth. Data were 
baseline-corrected by the subtraction of each metal complex concentration. The secondary 
structures of proteins were predicted using the CONTIN program.233 The binding constant was 
determined as described previously.224 CD experiments, involving thermal denaturation, were 
performed in three separate scans in the range from 25 to 95 °C at 208 nm with a heating rate 
of 1 °C min–1. Thermal renaturation (20 °C after heating at 95 °C) was also observed after the 
same length of time as for denaturation. 
 
6.4.6 Zinc ejection assay 
The holo-BRCA1 protein was incubated with the complexes as described in the section on ICP-
MS analysis. Briefly, 10 µM of puriﬁed holo-BRCA1 protein was incubated with the complexes 
at various molar ratios of protein to drug in a zinc ejection assay buffer (10% glycerol, 50 mM 
Tris-HCl buffer, pH 7.6). The reaction mixtures were incubated in the dark for 8, 16, or 24 h at 
4 C. The ejection of zinc from the protein was monitored by the change in fluorescence of the 
zinc-selective fluorophore TSQ (6-Methoxy-8-p-Toluenesulfonamido-Quinoline) in the assay 
buffer. The zinc ejection assay was initiated by the addition of 20 µM (final concentration) TSQ 
in mixtures at room temperature. Immediately after reaction initiation the TSQ fluorescence 
was monitored at each concentration or time (excitation filter, 360 nm; emission filter, 490 nm) 
using a spectrofluorometer (FP 2600 Jasco Corporation). A zinc chloride standard curve was 
generated under the same conditions in the absence of BRCA1 protein (Figure 6.13). To control 
for fluorescence changes in the assay not due to the effect of the complexes binding to TSQ, 
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the results from above experiments were subtracted with fluorescence intensity of each 
compound in the presence of TSQ.  
 
 
Figure 6.13 A standard curve of ZnCl2 monitored by fluorescence spectrophotometry. Zinc chloride was 
dissolved in zinc ejection buffer (10% glycerol, 50 mM Tris-HCl buffer, pH 7.6) at various concentrations (µM; 
color lines). Fluorescence intensity was initiated by the addition of 20 µM (final concentration) TSQ in each 
concentration of zinc chloride at room temperature, and plotted against emission wavelength at 490 nm 
(excitation wavelength at 360 nm) using a spectrofluorometer (FP 2600 Jasco Corporation). 
 
6.4.7 In vitro ubiquitination assay and western blotting 
The in vitro ubiquitination assay was performed as previously described.[30] Briefly, the holo-
BRCA1 protein was pre-incubated with ZnCl2 at the molar ratio of 1:3 (BRCA1:  ZnCl2) at 4 
C for 8 h, and any unbound ZnCl2 was removed by dialysis against deionized water. The holo-
BRCA1 protein was then treated with thecomplexes at various concentrations for 24 h at 4 C. 
Unbound complexes in the samples were removed by dialysis against deionized water. The 
amount of protein was then determined by the Bradford assay using BSA as a standard .The 
ubiquitin ligase reactions (20 l) contained 20 M Ub, 300 nM E1, 5 M UbcH5c, 3 g BRCA1 
or a metallated-BRCA1 adduct, and 3 g BARD1 in a buffer [50 mM Tris (pH 7.5), 0.5 mM 
DTT, 5 mM ATP, 2.5 mM MgCl2 and 5 M ZnCl2]. Two separate reactions were incubated at 
37 C for 3 h, and then terminated by adding an equal volume of SDS-loading dye before 
electrophoresis on 8% SDS-PAGE. The separated protein was then transferred to the PVDF 
membrane and immunodetected with anti-His6 HRP (Horseradish Peroxidase) conjugated 
(chemiluminescent method, QIAGEN) at a dilution of 1:2000 and performed according to the 
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manufacturer’s protocol. The blot was detected by chemiluminescence (SuperSignal TM, 
Pierce) on X-ray film. The relative E3 ligase activity of the metallated-BRCA1 adduct was 
quantified by normalizing the density of an apparent band of the ubiquitinated-protein 
conjugates to that of the parental BRCA1 as the control, using a Bio-Rad GS-700 Imaging 
Densitometer. The experiment was performed in duplicate. 
 
6.4.8 Real-time monitoring of cell growth profiling 
Real time growth kinetics of MCF-7, MDA-MB-231 and HCC1937 cells towards complexes 
treatments were examined using the Real-Time Cellular Analyzer (RTCA) (xCELLigence 
System, Roche Applied Science, Mannheim, Germany). RTCA utilizes E-plate which contains 
interdigitated micro-electrodes integrated on the bottom of the E-plate. The cell number, 
viability, morphology and degree of adherence of cells in contact with the electrodes will affect 
the local ionic environment leading to an increase in the electrode impedance, represented as 
the Cell Index (CI). For each experiment, briefly, 100 µl of medium were added in 96-wells E-
plate and background readings were recorded. Cell suspension (100 µl) at cell density of 5x104 
cells/well was added to each well of the E-plate. The attachment, spreading and proliferation of 
the cells were monitored every 15 min over the following 7 hours for MCF-7 cells and 
HCC1937 cells and 18 hours for MDA-MB-231 cells (allowing cell attachment, spreading and 
cell entered logarithmic growth phase). When the cells entered logarithmic phase, the plate was 
removed from the RTCA machine. The cells were washed once with PBS to remove any cell 
debris and either fresh medium containing a various concentration of complexes or fresh 
medium (control) was added to each well. The plate was reinserted into the RTCA machine and 
proliferation of the cells was further assessed every 15 for the next 24 hours.  
6.4.9 Statistical analysis 
Values are shown as the standard error of the mean unless indicated otherwise. Data were 
analyzed and, where appropriate, the significance of the differences between the mean values 
was determined using one-way ANOVA. A probability of 0.01 was deemed statistically 
significant. The following notation was used throughout: * p < 0.01, relative to control. 
 
6.4.10 Mass spectrometry studies with model peptide 
The BRCA1 peptide (10 µM) was incubated with RAPTA-C or RAPTA-EA) at a 1:1 and 1:5 
protein:complex ratios at 4° C for 24 h. All incubations were performed in sterile MilliQ water. 
Incubated proteins were stored at -20 °C until analysis. Electron-Transfer Dissociation (ETD) 
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peptide fragmentation studies were performed on an ETD enabled hybrid linear ion trap (LTQ) 
Orbitrap Elite mass spectrometer (Thermo Scientific, Bremen, Germany) coupled to a Triversa 
Nanomate (Advion) chip-based electrospray system. The samples were  infused using a spray 
voltage of 1.6 kV. The automatic gain control (AGC) target was set to 1x106 for full scans in 
the Orbitrap mass analyzer. ETD experiments used fluoranthene as the reagent anion and the 
target for fluoranthene anions was set to 5x105. Precursor ions for MS/MS were detected in the 
Orbitrap mass analyzer at a resolving power of 120,000 (at 400 m/z) with an isolation width of 
3, and product ions were transferred to the FTMS operated with an AGC of 5x104 over a m/z 
range of 200-2000. The reaction time with the fluoranthene radical anions into the LTQ was set 
from 50 to 100 ms. A minimum of 100 scans were averaged for each ETD fragmentation 
spectra. The Orbitrap FTMS was calibrated for the normal mass range keeping a mass accuracy 
in the 1-3 ppm level. Data were analyzed using the tool available at 
http://www.cheminfo.org.180   
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7 Chapter 7 
Conclusions and perspectives 
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 The MS strategies developed and applied in this thesis represent a range of novel 
approaches to study the mechanism of action of metallodrugs. The methods used in this work 
were chosen and adapted to the unique chemical nature of metallodrugs, which oftentimes are 
prodrugs with labile ligands and have a variety of biological targets. We chose to focus on three 
aspects of metallodrug action, namely their intracellular distribution and ligand state, their 
biological protein targets, and finally the nature of their binding to proteins.  
 
 With respect to the imaging ruthenium and platinum metallodrugs, we developed a 
NanoSIMS imaging MS approach to visualize both the distribution and ligand state of these 
compounds with isotopic labelling. We showed that for cisplatin, ovarian cancer cells resistant 
to the drug exhibit markedly reduced cellular accumulation and in drug sensitive cells, we found 
accumulation in the mitochondria and authophagosome. For RAPTA-T, we observed partial 
loss of the arene and possibly the phosphine ligand which could be involved in drug activation. 
RAPTA-T’s distribution pattern was markedly different between ovarian and breast cancer 
cells, and we observed a larger extent of membrane association of the drug in invasive cancer 
cell lines, which could partly explain how RAPTA-T exerts its anti-metastatic activity.  
 
For determining protein targets of metallodrugs, we applied a protein expression 
profiling approach FITExP, which applies biological controls and statistical correlations to 
overcome limitations of simple protein expression studies in finding bone fide protein targets 
of drugs. Through FITExP analysis, the main targets obtained for cisplatin were DNA repair 
related, which were in line with the main mechanism of cisplatin on nuclear DNA. For RAPTA-
EA, the protein targets obtained were related to regulation of oxidative stress response and is 
thought to be conferred mainly by the ethacrynic acid moiety in the drug. This is in great 
contrast to the simple RAPTA-type complex RAPTA-T, which seemed to have a broad 
mechanism of action targeting proteins involved in both metastasis and tumorigenicity. We then 
cross validated the top two targets obtained from FITExP analysis of RAPTA-T namely 
MAT2A, which catalyzes the formation of S-adenosylmethionine a cellular methyl donor and 
PLD3 which catalyzes the hydrolysis of membrane phospholipids. We found RAPTA-T to be 
an uncompetitive inhibitor of MAT2A at an IC50 of ~75 µM, which suggests it could be useful 
for cancers where MAT2A is upregulated such as liver and colorectal cancers.  
 
For studying the binding nature of metallodrugs to proteins, we realized a large 
bottleneck to the application of MS for these studies is the lack of tools for automated matching 
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of complex MS spectra from modified proteins. Thus, a major focus was on the development 
and optimization of such a tool, which we named the MSAPM tool. This tool was then applied 
to study the interaction of metallodrugs with two biologically relevant proteins, ubiquitin and 
BRCA1. With the aid of the tool, we revealed the complexity of the interactions of cisplatin 
and RAPTA-T with ubiquitin, where the metallodrug was potentially bound to more than 10 
different sites. Through analysis of abundance of different metallated fragments obtained, we 
showed a preference of metal binding at more negatively charged regions on ubiquitin, and 
reason that this is due to the cationic nature of the metallodrug upon activation. For the zinc 
finger protein BRCA1, studying the interaction of RAPTA-C and RAPTA-EA on a 50 amino 
acid peptide mimicking the zinc finger region of the protein revealed that metallodrug binding 
occurred in close proximity to zinc binding sites which helped explain zinc displacement 
induced by these drugs. Overall, the tool greatly facilitated the use of MS in depth studies of 
metallodrug bound proteins.  
 
Looking ahead, the work presented in this dissertation opened up some new avenues 
which can be explored further. For visualization of metal drugs via NanoSIMS, the methods we 
developed can be further applied to study biologically relevant problems for a myriad of 
different metallodrugs. Fundamental improvements in NanoSIMS methods such as 
improvement of cell sample integrity for analysis, increasing sensitivity for transition metals, 
improving spatial resolution and increasing analytical throughput should be pursued.     
 
 For elucidating biological targets of metallodrugs, approaches that identify protein 
targets based on perturbation of protein stability (briefly discussed in Chapter 1) could be 
explored as these possess all the advantages of the FITExP for metallodrugs but do not rely on 
the assumption of exceptional regulation during late apoptosis making it more generalizable. 
Much work remains on the validation of the RAPTA-T target MAT2A, as binding assays should 
be carried out and cell/tissue level enzyme inhibition of RAPTA-T should be performed. For 
PLD3 validation, owing to the lack of activity of the expressed protein, alternate methods must 
be found to study the effects of RAPTA-T on PLD3, such as performing activity assays in 
whole cells. The use of structural methods such as NMR or protein crystallography as well as 
computational methods could also be explored to validate these targets.     
 
 For the MSAPM tool, a major challenge remains with the processing of MS spectra of 
very large proteins as the theoretical possibilities of protein modifications increase 
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exponentially with size which would need to be solved by improving the processing algorithm 
used. Implementation of additional functions such as identifying c-z and c-y internal fragments 
for ETD fragmentation, additional enzyme digest options and matching polynucleotide 
modifications should also be explored. In addition, integration of this tool to a protein/peptide 
database such as MASCOT could facilitate the use of this tool in identification of metallated 
proteins in large protein mixtures, which is currently a major challenge.  
 
 Studying the mechanism of action of metallodrugs is an imposing challenge mainly due 
to the lack of good methods to perform these studies. The MS methods developed in this 
dissertation can be used to solve part of the puzzle, but should be complemented with other 
analytical, biophysical and biochemical methods to obtain the full picture of metallodrug action. 
We sincerely hope that the developments described here can be applied and further improved 
upon to create robust and reliable methods in elucidating the mechanism of action of metal 
based anti-cancer drugs 
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Appendix A  
Tables of associated proteins obtained from FITExP 
analysis 
 
Protein Acronym P-value Regulation 
Interstitial collagenase  MMP1 1.33E-06 Up 
Pentraxin-related protein PTX3  PTX3 7.77E-06 Up 
Protein-methionine sulfoxide oxidase MICAL2  MICAL2 1.87E-04 Down 
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase  I3L1V2 2.41E-04 Down 
Transforming growth factor beta-1-induced transcript 1 protein  TGFB1I1 3.35E-04 Down 
Tubulin beta-2A chain  TUBB2A 4.81E-04 Up 
Stathmin  STMN1 7.28E-04 Down 
Tubulin beta-6 chain  TUBB6 9.47E-04 Up 
Cysteine-rich motor neuron 1 protein  CRIM1 1.70E-03 Down 
Transforming acidic coiled-coil-containing protein 1  G8JLK4 1.84E-03 Down 
Protein Niban NIBAN 4.30E-03 Down 
Ubiquitin-conjugating enzyme E2 C  UBE2C 4.93E-03 Down 
MAP7 domain-containing protein 1  MAP7D1 5.36E-03 Up 
Nucleolar complex protein 3 homolog  A6NJZ9 6.27E-03 Down 
Rac GTPase-activating protein 1  RACGAP1 6.83E-03 Down 
Calmodulin-regulated spectrin-associated protein 3  CAMSAP3 1.00E-02 Up 
Microtubule-associated protein RP/EB family member 2  G5E9I6 1.31E-02 Up 
Anterior gradient protein 2 homolog  B5MC07 1.31E-02 Up 
Insulin-like growth factor-binding protein 7  IGFBP7 1.43E-02 Up 
Protein kinase C and casein kinase substrate in neurons protein 3  PACSIN3 1.81E-02 Down 
Protein GREB1  GREB1 1.88E-02 Up 
Discoidin, CUB and LCCL domain-containing protein 2  DCBLD2 1.93E-02 Down 
Cyclin-dependent kinase 1  CDK1 1.96E-02 Down 
Monocarboxylate transporter 4  MCT4 2.09E-02 Down 
KN motif and ankyrin repeat domain-containing protein 2  KANK2 2.16E-02 Down 
Cysteine and glycine-rich protein 2  F8VW96 2.32E-02 Up 
Tubulin beta-3 chain  TUBB3 3.43E-02 Up 
Unconventional myosin-Vc  MYO5C 3.86E-02 Down 
Tubulin alpha-4A chain  A8MUB1 3.97E-02 Up 
Lysine-rich nucleolar protein 1 KNOP1 4.24E-02 Down 
EPH receptor B4, isoform CRA_b  Q96L35 4.89E-02 Up 
Table A.1 Associated protein list for Paclitaxel obtained from FITExP analysis. 
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Protein Acronym P-value Regulation 
Growth/differentiation factor 15  GDF15 4.01E-11 Up 
Heat shock 70 kDa protein 6   HSPA6 1.54E-09 Down 
Threonylcarbamoyladenosine tRNA methylthiotransferase  CDKAL1 3.22E-07 Down 
Interstitial collagenase  MMP1 1.13E-06 Up 
Methylated-DNA--protein-cysteine methyltransferase  MGMT 3.06E-05 Down 
Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1  BAIAP2L1 9.67E-05 Up 
Desmocollin-2  DSC2 1.14E-04 Up 
Protein GREB1  GREB1 1.39E-04 Down 
Ladinin-1  LAD1 1.58E-04 Up 
60S ribosomal protein L7-like 1  RPL7L1 2.30E-04 Down 
Protein S100-P  S100P 3.00E-04 Up 
Receptor tyrosine-protein kinase erbB-2  ERBB2 3.84E-04 Up 
Insulin-like growth factor-binding protein 7  IGFBP7 4.70E-04 Down 
Protein LLP homolog LLPH 7.96E-04 Down 
F-box/WD repeat-containing protein 7 B7Z2C8 1.03E-03 Down 
Integrin alpha-6 heavy chain (Fragment)  C9JK10 1.14E-03 Down 
Tubulin beta-2A chain  TUBB2A 1.29E-03 Up 
Ubiquitin-like protein ISG15  ISG15 1.58E-03 Up 
Probable dimethyladenosine transferase DIMT1 1.61E-03 Down 
DNA damage-binding protein 2  DDB2 1.77E-03 Up 
Syntaxin-8  STX8 2.06E-03 Down 
Alpha-2-HS-glycoprotein  FETUA 2.56E-03 Up 
Epidermal growth factor receptor kinase substrate 8-like protein 1 Eps8l1 2.97E-03 Up 
Pumilio domain-containing protein KIAA0020  KIAA0020 4.15E-03 Down 
Cyclin-dependent kinase inhibitor 1B  CDKN1B 4.33E-03 Up 
U3 small nucleolar RNA-associated protein 14 homolog A  E9PEL7 4.41E-03 Down 
HEAT repeat-containing protein 6  K7EIX2 5.01E-03 Down 
Beta-1-syntrophin  SNTB1 6.63E-03 Down 
60S ribosomal protein L7  RPL7 7.47E-03 Down 
DNA polymerase  A6NMQ1 7.58E-03 Down 
Anthrax toxin receptor 2  J3KPY9 8.06E-03 Down 
LIM and calponin homology domains-containing protein 1 (Fragment)  H0Y8P3 9.98E-03 Down 
Ferritin light chain  FTL 1.04E-02 Up 
C-terminal 80 kDa form (Fragment)  H0YDM2 1.11E-02 Down 
cAMP-dependent protein kinase inhibitor beta  Q5T0Z6 1.32E-02 Down 
Taperin  TPRN 1.33E-02 Up 
Epiplakin  EPIPL 1.42E-02 Up 
NADPH:adrenodoxin oxidoreductase, mitochondrial  E7EQC1 1.53E-02 Up 
Trans-acting T-cell-specific transcription factor GATA-3  GATA3 1.53E-02 Down 
HLA class II histocompatibility antigen gamma chain  E7ESL3 1.61E-02 Up 
MARCKS-related protein  MRP 1.86E-02 Up 
Retrotransposon-derived protein PEG10  PEG10 2.05E-02 Up 
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Kinesin-like protein KIF20A  B4DL79 2.08E-02 Up 
39S ribosomal protein L17, mitochondrial  MRPL17 2.34E-02 Up 
EPH receptor B4, isoform CRA_b  Q96L35 2.69E-02 Up 
Rho guanine nucleotide exchange factor 5  ARHGEF5 2.96E-02 Up 
Tubulin beta-3 chain  TUBB3 3.00E-02 Up 
Epiplakin E9PPU0 3.48E-02 Up 
Protein HEXIM1  HEXIM1 3.70E-02 Up 
RNA-binding protein with multiple-splicing  F5H357 3.85E-02 Down 
Claspin  CLSPN 3.91E-02 Up 
60S ribosomal protein L36  RPL36 4.17E-02 Down 
Nuclear factor NF-kappa-B p100 subunit  NFKB2 4.43E-02 Up 
Tetratricopeptide repeat protein 38  E7ES35 4.48E-02 Down 
Protein KTI12 homolog  KTI12 4.54E-02 Up 
Molybdopterin molybdenumtransferase  G3V582 4.69E-02 Down 
Table A.2 Associated protein list for Cisplatin obtained from FITExP analysis 
 
Protein Acronym P-value Regulation 
Heme oxygenase 1  HMOX1 1.64E-08 Up 
Heat shock 70 kDa protein 1A/1B  HSP71 5.85E-07 Up 
ATP-binding cassette sub-family B member 6, mitochondrial (Fragment)  H7BXK9 7.04E-07 Up 
All-trans-retinol 13,14-reductase (Fragment)  H7C3J0 2.31E-06 Down 
TRAF-type zinc finger domain-containing protein 1  TRAFD1 3.74E-06 Up 
Sequestosome-1  SQSTM1 4.18E-05 Up 
Probable ATP-dependent RNA helicase DDX58  F5H5W6 5.36E-05 Down 
Actin filament-associated protein 1-like 2  F5GZE1 6.72E-05 Down 
Protein POF1B  POF1B 8.45E-05 Down 
Torsin-4A TOR4A 1.03E-04 Down 
Sulfiredoxin-1 SRXN1 1.95E-04 Up 
Chloride intracellular channel protein 6  CLIC6 2.31E-04 Up 
DNA polymerase subunit gamma-1  POLG 2.57E-04 Down 
Gasdermin-D (Fragment)  E9PIB2 5.60E-04 Down 
DnaJ homolog subfamily B member 4  DNAJB4 7.26E-04 Up 
NAD(P)H dehydrogenase [quinone] 1  B4DLR8 1.29E-03 Up 
Transforming growth factor beta-1-induced transcript 1 protein  TGFB1I1 1.35E-03 Down 
Thioredoxin reductase 1, cytoplasmic  E7ESI6 1.89E-03 Up 
Plasminogen activator inhibitor 1  PAI1 2.05E-03 Up 
Glutamate--cysteine ligase regulatory subunit  GCLM 2.97E-03 Up 
Cytochrome c oxidase copper chaperone  C9J8T6 3.55E-03 Down 
Heat shock 70 kDa protein 4L  E7ES43 4.25E-03 Up 
Lamina-associated polypeptide 2, isoform alpha  TMPO 4.60E-03 Down 
General transcription factor 3C polypeptide 5  H7BY84 4.80E-03 Down 
Cysteine and histidine-rich domain-containing protein 1  E9PPQ5 5.29E-03 Up 
HAUS augmin-like complex subunit 8  C9JBZ4 5.90E-03 Down 
Heat shock protein 105 kDa  HSPH1 6.08E-03 Up 
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Tubulin beta-4A chain  TUBB4A 6.10E-03 Down 
Poly(A) RNA polymerase, mitochondrial PAPD1 6.91E-03 Down 
UDP-glucose 6-dehydrogenase  UGDH 7.60E-03 Up 
BRCA1-associated ATM activator 1  BRAT1 7.87E-03 Down 
Flavin reductase (NADPH) BLVRB 8.63E-03 Up 
DnaJ homolog subfamily B member 1  DNAJB1 9.58E-03 Up 
Sorting nexin-18  SNX18 9.73E-03 Down 
5'-nucleotidase domain-containing protein 2  E9PAL9 1.02E-02 Down 
Tripeptidyl-peptidase 1  TPP1 1.49E-02 Up 
Sterol O-acyltransferase 1 (Fragment)  B1APM4 1.55E-02 Up 
Interferon-induced protein with tetratricopeptide repeats 3  IFIT3 1.56E-02 Down 
SAGA-associated factor 29 homolog  SGF29 1.81E-02 Down 
Cadherin EGF LAG seven-pass G-type receptor 2  CELSR2 1.82E-02 Down 
Kinesin-like protein KIF20A  B4DL79 1.85E-02 Down 
TBC1 domain family member 15 (Fragment)  C9JA93 1.86E-02 Up 
Annexin A6  ANXA6 2.21E-02 Down 
Protein FAM83B  FAM83B 2.60E-02 Down 
Trans-acting T-cell-specific transcription factor GATA-3  GATA3 3.22E-02 Down 
NADP-dependent malic enzyme  ME1 3.25E-02 Up 
Mitochondrial genome maintenance exonuclease 1  MGME1 3.72E-02 Down 
Threonine--tRNA ligase, mitochondrial  TARS2 3.90E-02 Down 
Protein S100-A4  S100A4 4.13E-02 Down 
Coiled-coil-helix-coiled-coil-helix domain-containing protein 1  CHCHD1 4.31E-02 Down 
Glucose-6-phosphate 1-dehydrogenase  G6PD 4.39E-02 Up 
Insulin-like growth factor-binding protein 4 B4E351 4.49E-02 Down 
Ly6/PLAUR domain-containing protein 3  LYPD3 4.84E-02 Up 
Heat shock protein HSP 90-alpha  HSP90AA1 4.84E-02 Up 
Table A.3 Associated protein list for RAPTA-EA obtained from FITExP analysis 
 
Protein Acronym P-value Regulation 
EGF-like repeat and discoidin I-like domain-containing protein 3 EDIL3 3.22E-09 Up 
N-terminal Xaa-Pro-Lys N-methyltransferase 1  NTM1A 1.26E-07 Down 
Squalene monooxygenase  ERG1 2.66E-06 Down 
All-trans-retinol 13,14-reductase (Fragment)  H7C3J0 7.80E-06 Down 
Histone-lysine N-methyltransferase SETD7  SETD7 1.45E-05 Down 
S-adenosylmethionine synthase isoform type-2  MAT2A 1.46E-05 Up 
Protein GREB1  GREB1 3.09E-05 Down 
Ribosomal RNA small subunit methyltransferase NEP1  EMG1 3.23E-05 Down 
Metallothionein-2  MT2 1.02E-04 Up 
Chromosome transmission fidelity protein 8 homolog isoform 2  CHTF8 1.02E-04 Up 
Ubiquitin-conjugating enzyme E2 T  UBE2T 1.89E-04 Down 
Alpha-2-HS-glycoprotein  FETUA 2.58E-04 Up 
Programmed cell death protein 4  PDCD4 2.62E-04 Up 
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Chromatin target of PRMT1 protein  CHTOP 2.84E-04 Up 
BolA-like protein 1  BOLA1 4.21E-04 Up 
Torsin-4A  TOR4A 6.35E-04 Up 
Claspin  CLSPN 6.41E-04 Down 
Ribonucleoside-diphosphate reductase subunit M2 RRM2B 7.75E-04 Down 
Retrotransposon-derived protein PEG10  PEG10 1.08E-03 Down 
Laminin subunit beta-3  LAMB3 1.08E-03 Down 
Heat shock protein beta-8  HSPB8 1.39E-03 Down 
Sperm-associated antigen 5 SPAG5 1.71E-03 Down 
Importin subunit alpha-2 KPNA2 1.74E-03 Down 
Phospholipase D3  PLD3 1.88E-03 Up 
40S ribosomal protein S4, Y isoform 1 (Fragment)  C9JEH7 1.97E-03 Down 
G2 and S phase-expressed protein 1  GTSE1 3.08E-03 Down 
RNA-binding protein 47 RBM47 3.65E-03 Up 
Zinc finger HIT domain-containing protein 2  ZNHIT2 1.25E-02 Up 
Biogenesis of lysosome-related organelles complex 1 subunit 3  BLOC1S3 1.28E-02 Up 
DnaJ homolog subfamily A member 4 F5H170 1.71E-02 Down 
Proteasome subunit beta type-10 (Fragment)  J3QQN1 1.82E-02 Up 
[Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 1, 
mitochondrial  
PDP1 2.30E-02 Up 
BAG family molecular chaperone regulator 1  J3QTA2 2.39E-02 Up 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic  HMGCS1 2.53E-02 Down 
Myeloid leukemia factor 2  MLF2 2.67E-02 Down 
Neuropilin-1  Q5T7F1 2.78E-02 Up 
Desmocollin-2  DSC2 3.27E-02 Down 
DnaJ homolog subfamily A member 1  DNAJA1 3.30E-02 Down 
Nitric oxide synthase-interacting protein (Fragment) NOSIP 3.58E-02 Down 
Hepatocyte nuclear factor 3-alpha  B7ZAP5 3.67E-02 Up 
E3 ubiquitin-protein ligase AMFR  AMFR 4.70E-02 Down 
Phosphoserine aminotransferase  PSAT1 4.70E-02 Up 
Table A.4 Associated protein list for RAPTA-T obtained from FITExP analysis 
 
 
  
  
149 
 
Appendix B 
Tables of metallated fragment from MS/MS 
experiments of metallodrugs on ubiquitin 
 
Metallated adduct Similarity Abundance Type Theoretical mass Experimental mass PPM Error 
[3H + PtN2H8O + b74y36]5+ 87.2 2.76 R 4243.2670 4243.2642 -0.65 
[H + PtN2H6 + a57y36]3+ 83.9 2.17 R 2116.0869 2116.0853 -0.78 
[H + PtNH3 + a55y38]3+ 83.9 2.54 R 2142.0298 2142.0282 -0.77 
[PtN2H8O + b74y25]4+ 81.9 5.65 R 2956.5085 2956.5063 -0.74 
[PtN2H8O + b74y16]2+ 76.1 2.98 R 1935.0620 1935.0609 -0.57 
[3H + PtN2H6 + a71y56]7+ 70.9 2.40 R 5991.1186 5991.1147 -0.64 
[Pt + b18]3+ 97.3 17.73 L 2228.1005 2228.0988 -0.74 
[PtNH3 + b16]3+ 92.9 3.48 L 2017.0160 2017.0144 -0.82 
[PtN2H6 + a28y67]2+ 91.7 3.36 L 2227.0938 2227.0927 -0.49 
[PtNH3 + a22y71]2+ 90.4 5.21 L 1998.9716 1998.9705 -0.55 
[PtNH3 + a17]3+ 88.5 2.13 L 2088.0895 2088.0879 -0.79 
[Pt + b33y58]3+ 88.5 3.49 L 1862.8616 1862.8600 -0.88 
[PtN2H6 + a23y70]3+ 82.8 2.14 L 2000.9872 2000.9856 -0.82 
[Pt + a17]3+ 79.6 4.47 L 2071.0630 2071.0613 -0.79 
[H + Pt + a21y72]3+ 79.5 2.13 L 1980.9736 1980.9719 -0.83 
[2H + Pt + a30y74]4+ 75.2 2.70 L 3238.7307 3238.7285 -0.68 
[PtN2H6 + b28y66]2+ 75.1 3.93 L 2198.0673 2198.0662 -0.50 
[H + PtN2H8O + a29y65]3+ 72.6 1.56 L 2189.0907 2189.0891 -0.75 
[PtN2H8O + a29y65]2+ 72.5 3.33 L 2188.0829 2188.0818 -0.50 
[H + PtN2H6 + b29y65]3+ 70.6 9.61 L 2199.0751 2199.0734 -0.75 
[PtN2H6 + a30y63]2+ 70.1 2.57 L 2069.0247 2069.0236 -0.53 
[5H + PtN2H6 + y58]8+ 98.3 84.47 M 6762.5537 6762.5493 -0.65 
[6H + PtNH3 + y58]9+ 96.2 9.92 M 6746.5350 6746.5300 -0.73 
[4H + PtNH3 + b52]7+ 95.9 12.85 M 6051.1484 6051.1446 -0.63 
[7H + Pt + y74]10+ 95.6 5.81 M 8503.5450 8503.5396 -0.65 
[5H + PtNH3 + y58]8+ 95.2 39.73 M 6745.5272 6745.5228 -0.65 
[6H + PtN2H6 + y58]9+ 94.9 21.39 M 6763.5615 6763.5566 -0.73 
[7H + PtN2H6 + y74]10+ 94.8 6.50 M 8537.5981 8537.5927 -0.64 
[5H + Pt + y58]8+ 94.2 30.32 M 6728.5006 6728.4962 -0.65 
[5H + PtN2H8O + b64y71]8+ 94.1 9.65 M 6873.5732 6873.5688 -0.64 
[4H + Pt + b52]7+ 92.2 6.80 M 6034.1219 6034.1180 -0.64 
[6H + Pt + y58]9+ 91.6 7.22 M 6729.5084 6729.5035 -0.73 
[3H + Pt + a63y72]7+ 91.4 5.08 M 6761.5248 6761.5209 -0.57 
[6H + PtNH3 + b64y71]8+ 91.3 5.72 M 6839.5439 6839.5395 -0.64 
[6H + Pt + b71y64]8+ 90.7 5.56 M 6856.5381 6856.5337 -0.64 
[6H + PtN2H8O + b64y71]9+ 90.6 3.79 M 6874.5810 6874.5760 -0.72 
[4H + PtNH3 + y58]7+ 89.9 2.80 M 6744.5193 6744.5155 -0.57 
[6H + Pt + b61y73]8+ 89.7 2.16 M 6683.4580 6683.4536 -0.66 
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[4H + PtN2H6 + b52]7+ 88.2 4.49 M 6068.1750 6068.1711 -0.63 
[6H + PtNH3 + y74]10+ 85.7 6.40 M 8519.5638 8519.5583 -0.64 
[4H + Pt + a64y72]8+ 84.6 2.02 M 6891.5752 6891.5708 -0.64 
[6H + PtN2H8O + b63y73]8+ 83.6 2.33 M 6991.6752 6991.6708 -0.63 
[2H + PtN2H6 + a70y44]5+ 83.6 3.08 M 4522.3174 4522.3147 -0.61 
[4H + PtN2H6 + a72y61]8+ 83.5 2.61 M 6689.4659 6689.4615 -0.66 
[6H + PtN2H6 + b60y74]8+ 82.4 4.61 M 6717.5111 6717.5067 -0.65 
[6H + PtN2H6 + b73y60]8+ 82.1 4.51 M 6703.5179 6703.5135 -0.65 
[4H + Pt + y58]7+ 81.5 2.79 M 6727.4928 6727.4889 -0.57 
[6H + Pt + y75]10+ 81.3 2.67 M 8630.5958 8630.5903 -0.64 
[7H + PtNH3 + b63y71]9+ 79.6 1.15 M 6711.5091 6711.5042 -0.74 
[7H + PtN2H6 + b64y72]9+ 79.6 3.23 M 6956.6467 6956.6417 -0.71 
[H + PtN2H8O + a54y40]3+ 78.6 15.91 M 2270.1248 2270.1231 -0.72 
[6H + PtNH3 + y60]8+ 78.2 1.58 M 6974.6460 6974.6416 -0.63 
[3H + PtN2H6 + b52y62]5+ 78.0 2.83 M 4505.2770 4505.2742 -0.61 
[PtN2H8O + b56y44]4+ 77.3 1.20 M 2938.4867 2938.4845 -0.75 
[5H + Pt + y60]8+ 76.1 1.39 M 6956.6116 6956.6072 -0.63 
[3H + PtN2H6 + b50y75]6+ 76.0 1.62 M 5692.0571 5692.0538 -0.58 
[5H + Pt + y59]9+ 75.9 1.32 M 6857.5432 6857.5383 -0.72 
[7H + PtN2H8O + b64y72]9+ 74.7 1.58 M 6974.6572 6974.6523 -0.71 
[6H + PtN2H8O + a71y62]8+ 73.9 2.50 M 6666.4751 6666.4707 -0.66 
[5H + PtN2H8O + a68y67]9+ 73.1 1.81 M 6840.5265 6840.5216 -0.72 
[6H + PtN2H6 + a65y69]8+ 72.4 2.61 M 6686.4649 6686.4605 -0.66 
[6H + PtN2H8O + a61y73]9+ 71.3 1.56 M 6707.5268 6707.5218 -0.74 
[3H + Pt + a52]7+ 71.3 0.81 M 6005.1191 6005.1153 -0.64 
[5H + PtNH3 + a61y73]8+ 71.1 2.25 M 6671.4818 6671.4774 -0.66 
[7H + PtNH3 + b61y73]9+ 70.8 0.25 M 6701.4924 6701.4875 -0.74 
[5H + PtN2H8O + b61y66]7+ 70.2 5.72 M 5988.0812 5988.0773 -0.64 
[8H + PtN2H6 + b74]10+ 70.2 4.49 M 8665.6515 8665.6460 -0.63 
Table B.1 Most important metallated fragments obtained by CID fragmentation of the adduct [9H+ Ubiquitin + 
PtN2H8O]
11+ 
(m/z 801.4281) after incubation of ubiquitin with cisplatin (1:1, protein:drug ratio). Similarities are 
expressed as percentages, abundances are expressed as percentage of the most abundant peak in the spectra, and 
type is classified based on criteria in Figure 5.6. 
 
 
 
Metallated adduct Similarity Abundance Type Theoretical mass Experimental mass PPM Error 
[H + PtN2H6 + y24]4+ 96.3 5.04 R 2956.5323 2956.5301 -0.74 
[H + PtNH3 + y24]4+ 96.2 2.07 R 2939.5057 2939.5035 -0.75 
[Pt + b74y19]3+ 93.5 0.82 R 2275.1315 2275.1299 -0.72 
[H + PtNH3 + b74y25]4+ 93.1 1.44 R 2922.4792 2922.4770 -0.75 
[3H + PtN2H6 + y37]6+ 92.9 0.95 R 4485.3685 4485.3652 -0.73 
[H + Pt + a57y37]3+ 91.6 1.42 R 2210.0924 2210.0908 -0.74 
[Pt + b57y35]2+ 91.1 1.35 R 1980.9623 1980.9612 -0.55 
[PtN2H6 + y18]3+ 89.1 0.59 R 2326.2112 2326.2095 -0.71 
[H + PtN2H6 + a62y34]3+ 88.8 0.37 R 2465.2031 2465.2014 -0.67 
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[Pt + a57y37]2+ 88.6 0.90 R 2209.0846 2209.0835 -0.50 
[PtN2H6 + b62y24]2+ 88.3 0.34 R 1377.5879 1377.5868 -0.80 
[H + Pt + a73y21]3+ 87.3 0.79 R 2292.1594 2292.1578 -0.72 
[H + PtN2H6 + a59y36]3+ 85.8 0.39 R 2394.1772 2394.1755 -0.69 
[2H + PtN2H6 + y37]5+ 85.8 0.86 R 4484.3606 4484.3579 -0.61 
[H + PtNH3 + y26]3+ 74.3 0.39 R 3183.5753 3183.5736 -0.52 
 PtNH3 + b18]3+ 97.1 3.10 L 2245.1270 2245.1254 -0.73 
[PtN2H6 + a28y67]2+ 96.7 4.60 L 2227.0938 2227.0927 -0.49 
[Pt + b18]3+ 96.7 9.95 L 2228.1005 2228.0988 -0.74 
[PtNH3 + a17]3+ 95.5 1.45 L 2088.0895 2088.0879 -0.79 
[Pt + a17]3+ 94.4 2.56 L 2071.0630 2071.0613 -0.79 
[PtNH3 + b16]3+ 94.4 2.09 L 2017.0160 2017.0144 -0.82 
[PtNH3 + b17]3+ 93.0 1.35 L 2116.0844 2116.0828 -0.78 
[Pt + b36]3+ 91.9 0.49 L 4194.1376 4194.1359 -0.39 
[Pt + b16]3+ 91.2 1.26 L 1999.9895 1999.9878 -0.82 
[2H + PtNH3 + b33]5+ 90.7 0.62 L 3914.0317 3914.0289 -0.70 
[PtNH3 + b21]3+ 88.6 1.36 L 2544.2388 2544.2371 -0.65 
[Pt + b33y58]3+ 86.0 0.72 L 1862.8616 1862.8600 -0.88 
[PtN2H8O + b21y68]2+ 85.9 1.03 L 1618.7292 1618.7281 -0.68 
[Pt + b32]3+ 82.3 0.26 L 3766.8945 3766.8929 -0.44 
[Pt + a20]3+ 82.0 0.56 L 2384.1903 2384.1887 -0.69 
[Pt + b39]4+ 82.0 1.51 L 4503.2701 4503.2679 -0.49 
[PtNH3 + b36]3+ 81.7 0.36 L 4211.1641 4211.1625 -0.39 
[PtNH3 + a20]3+ 80.3 0.40 L 2401.2169 2401.2152 -0.69 
[H + Pt + b32]4+ 79.9 1.43 L 3767.9023 3767.9001 -0.58 
[Pt + a33y58]3+ 79.1 0.26 L 1834.8667 1834.8651 -0.90 
[PtN2H6 + b18]3+ 78.5 0.37 L 2262.1536 2262.1519 -0.73 
[PtNH3 + a24y72]2+ 77.6 0.30 L 2340.1666 2340.1655 -0.47 
[Pt + a18]3+ 77.5 1.78 L 2200.1056 2200.1039 -0.75 
[PtNH3 + a35y54]2+ 75.3 0.33 L 1637.7979 1637.7968 -0.67 
[Pt + a15]3+ 71.4 0.27 L 1842.9520 1842.9503 -0.89 
[Pt + b11]2+ 71.1 0.66 L 1442.6834 1442.6823 -0.76 
[5H + PtN2H8O + b63y71]7+ 98.4 32.43 M 6744.5306 6744.5267 -0.57 
[3H + PtNH3 + b52]6+ 98.1 4.84 M 6050.1406 6050.1373 -0.54 
[4H + Pt + y58]7+ 97.9 35.57 M 6727.4928 6727.4889 -0.57 
[3H + PtN2H6 + b52]6+ 97.9 7.03 M 6067.1672 6067.1639 -0.54 
[5H + PtN2H6 + y58]8+ 97.5 15.39 M 6762.5537 6762.5493 -0.65 
[5H + Pt + y58]8+ 97.2 10.98 M 6728.5006 6728.4962 -0.65 
[5H + PtNH3 + y58]8+ 96.9 10.27 M 6745.5272 6745.5228 -0.65 
[6H + PtN2H6 + b64y71]8+ 96.6 1.99 M 6856.5704 6856.5660 -0.64 
[4H + PtN2H6 + y58]7+ 96.1 49.31 M 6761.5459 6761.5420 -0.57 
[5H + PtN2H8O + b64y71]8+ 96.0 3.12 M 6873.5732 6873.5688 -0.64 
[4H + PtN2H8O + b63y71]6+ 96.0 1.40 M 6743.5227 6743.5194 -0.49 
[3H + Pt + b52]6+ 95.7 8.46 M 6033.1141 6033.1108 -0.55 
[6H + Pt + y74]9+ 95.4 5.92 M 8502.5372 8502.5323 -0.58 
[6H + PtNH3 + b64y7 ]8+ 95.4 2.35 M 6839.5439 6839.5395 -0.64 
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[4H + Pt + y60]7+ 95.1 3.38 M 6955.6038 6955.5999 -0.55 
[4H + Pt + y62]7+ 94.3 0.62 M 7197.7304 7197.7266 -0.53 
[3H + Pt + y58]6+ 94.1 1.23 M 6726.4850 6726.4817 -0.49 
[5H + PtNH3 + b64y71]7+ 93.6 3.35 M 6838.5360 6838.5322 -0.56 
[5H + Pt + b71y64]7+ 93.3 5.29 M 6855.5302 6855.5264 -0.56 
[3H + PtN2H8O + a61y67]6+ 92.8 2.19 M 6015.0921 6015.0888 -0.55 
[3H + PtN2H8O + b68y70]7+ 92.7 0.57 M 7181.6852 7181.6814 -0.53 
[2H + PtN2H8O + b69y42]4+ 92.6 1.68 M 4212.1169 4212.1147 -0.52 
[3H + PtNH3 + y61]7+ 92.5 1.65 M 7100.6651 7100.6613 -0.54 
[4H + PtNH3 + y60]7+ 92.3 2.74 M 6972.6303 6972.6265 -0.55 
[5H + PtNH3 + y62]7+ 91.9 0.45 M 7215.7648 7215.7610 -0.53 
[6H + PtN2H6 + y74]9+ 91.6 5.48 M 8536.5903 8536.5854 -0.58 
[H + PtN2H6 + a70y44]4+ 91.6 0.41 M 4521.3096 4521.3074 -0.49 
[5H + PtNH3 + b63y71]7+ 91.4 8.14 M 6709.4935 6709.4896 -0.57 
[4H + PtN2H6 + y60]7+ 91.3 6.07 M 6989.6569 6989.6530 -0.55 
[2H + Pt + b63y58]5+ 91.2 0.58 M 5275.6355 5275.6328 -0.52 
[6H + Pt + y73]9+ 91.1 2.27 M 8389.4532 8389.4482 -0.59 
[6H + PtNH3 + y74]9+ 91.1 5.92 M 8519.5638 8519.5588 -0.58 
[3H + PtN2H6 + b52y62]5+ 90.5 0.88 M 4505.2770 4505.2742 -0.61 
[3H + PtN2H6 + y58]6+ 90.2 1.84 M 6760.5381 6760.5348 -0.49 
[4H + Pt + y63]7+ 90.1 0.57 M 7298.7781 7298.7743 -0.53 
[4H + PtNH3 + b64y70]6+ 90.0 0.34 M 6709.4333 6709.4300 -0.49 
[H + PtN2H6 + b55y68]5+ 89.2 0.59 M 5418.7751 5418.7724 -0.51 
[2H + PtN2H8O + a57y58]4+ 89.2 1.86 M 4538.3335 4538.3313 -0.48 
[5H + Pt + a63]8+ 89.0 1.96 M 7282.7919 7282.7876 -0.60 
[3H + PtNH3 + y40]6+ 88.9 0.26 M 4777.4744 4777.4711 -0.69 
[2H + PtN2H8O + a48y61]4+ 88.8 10.78 M 3895.9886 3895.9864 -0.56 
[4H + PtN2H6 + y59]7+ 88.8 5.41 M 6890.5885 6890.5846 -0.56 
[5H + PtN2H6 + a60y72]7+ 88.3 0.66 M 6428.3559 6428.3521 -0.60 
[5H + Pt + b69y66]7+ 88.2 4.33 M 6872.5204 6872.5166 -0.56 
[4H + Pt + y44]7+ 88.1 0.31 M 5188.6987 5188.6949 -0.74 
[5H + PtNH3 + b58]7+ 87.8 2.95 M 6681.4695 6681.4657 -0.57 
[4H + Pt + y61]7+ 87.6 2.34 M 7084.6464 7084.6425 -0.54 
[6H + PtNH3 + a63y73]8+ 86.4 0.37 M 6928.6432 6928.6388 -0.63 
[3H + PtN2H6 + a63y66]7+ 86.2 0.35 M 6196.2136 6196.2097 -0.62 
[5H + PtN2H6 + y62]7+ 86.0 0.56 M 7232.7914 7232.7875 -0.53 
[5H + Pt + y62]8+ 85.9 0.52 M 7198.7383 7198.7339 -0.61 
[4H + PtNH3 + b63y73]6+ 84.8 0.17 M 6954.6225 6954.6192 -0.47 
[3H + PtNH3 + b62y74]7+ 84.7 1.21 M 6938.6037 6938.5999 -0.55 
[5H + Pt + y60]8+ 84.3 0.75 M 6956.6116 6956.6072 -0.63 
[4H + Pt + y65]8+ 84.3 0.75 M 7512.9099 7512.9055 -0.58 
[6H + Pt + b63y73]8+ 83.8 0.84 M 6939.6116 6939.6072 -0.63 
[2H + Pt + b46]5+ 83.7 0.55 M 5361.7776 5361.7749 -0.51 
[6H + PtN2H8O + a70y63]8+ 83.6 0.45 M 6654.4387 6654.4343 -0.66 
[PtN2H8O + a44y71]4+ 83.6 0.36 M 4547.4052 4547.4031 -0.48 
[2H + PtNH3 + b48]5+ 83.5 0.50 M 5563.9206 5563.9179 -0.49 
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[4H + PtNH3 + a59y75]8+ 83.0 1.02 M 6684.4896 6684.4853 -0.66 
[4H + Pt + b64y71]8+ 82.9 1.37 M 6820.5017 6820.4973 -0.64 
[5H + PtN2H8O + a69]8+ 82.9 0.66 M 8015.2049 8015.2006 -0.55 
[5H + PtNH3 + b58]8+ 82.3 0.71 M 6681.4695 6681.4652 -0.66 
[5H + PtNH3 + a69y67]7+ 82.2 0.51 M 6918.5735 6918.5697 -0.56 
[7H + Pt + b74y74]9+ 82.2 1.38 M 8371.4915 8371.4866 -0.59 
[3H + PtN2H8O + b42y72]6+ 82.1 0.39 M 4451.3239 4451.3206 -0.74 
[5H + PtN2H6 + b73y60]8+ 82.1 0.86 M 6702.5101 6702.5057 -0.65 
[5H + PtN2H6 + b58]7+ 81.7 2.39 M 6698.4961 6698.4923 -0.57 
[3H + PtN2H8O + a75y57]7+ 80.9 1.06 M 6578.4689 6578.4651 -0.58 
[5H + Pt + b74y58]8+ 80.7 0.37 M 6596.4471 6596.4427 -0.67 
[4H + PtNH3 + a61y73]8+ 79.7 0.86 M 6670.4740 6670.4696 -0.66 
[5H + PtN2H6 + b68y71]8+ 79.6 0.38 M 7293.7853 7293.7809 -0.60 
[3H + Pt + b62y7 ]7+ 79.4 0.98 M 7049.6358 7049.6319 -0.54 
[2H + PtN2H6 + b43y56]4+ 79.3 0.37 M 2848.4285 2848.4263 -0.77 
[2H + Pt + b44y67]4+ 79.2 0.98 M 4082.0778 4082.0756 -0.54 
[7H + PtN2H6 + b74]9+ 79.0 1.29 M 8664.6437 8664.6388 -0.57 
[4H + PtN2H6 + b73y60]7+ 78.9 2.39 M 6701.5023 6701.4984 -0.57 
[H + Pt + y44]5+ 78.3 0.45 M 5185.6753 5185.6725 -0.53 
[3H + Pt + b62y74]7+ 78.3 0.58 M 6921.5772 6921.5733 -0.55 
[4H + PtNH3 + a63]8+ 78.1 0.85 M 7298.8107 7298.8063 -0.60 
[6H + Pt + a70y68]8+ 77.9 1.39 M 7102.6709 7102.6665 -0.62 
[4H + PtN2H6 + b58y73]6+ 77.7 0.45 M 6325.3051 6325.3019 -0.52 
[3H + PtNH3 + b62y75]7+ 77.5 1.71 M 7066.6623 7066.6585 -0.54 
[8H + PtN2H8O + b74]10+ 77.4 0.23 M 8683.6621 8683.6566 -0.63 
[2H + PtN2H8O + a59y43]4+ 77.4 0.15 M 3149.5347 3149.5326 -0.70 
[6H + Pt + y75]10+ 77.4 0.98 M 8630.5958 8630.5903 -0.64 
[5H + PtN2H8O + b74y74]9+ 76.8 11.94 M 8421.5396 8421.5346 -0.59 
[5H + PtN2H6 + y59]8+ 76.7 0.70 M 6891.5963 6891.5919 -0.64 
[Pt + b52y58]3+ 76.3 0.21 M 3997.9627 3997.9611 -0.41 
[5H + Pt + a72y57]7+ 75.9 0.89 M 6202.2143 6202.2104 -0.62 
[6H + PtN2H6 + b58]8+ 75.8 0.86 M 6699.5039 6699.4995 -0.66 
[7H + Pt + y74]10+ 75.6 0.64 M 8503.5450 8503.5396 -0.65 
[6H + Pt + y72]9+ 75.3 0.43 M 8242.3847 8242.3798 -0.60 
[4H + PtN2H8O + a61y69]7+ 75.3 1.37 M 6230.2316 6230.2278 -0.62 
[5H + PtNH3 + a74y75]9+ 75.1 3.69 M 8486.5661 8486.5612 -0.58 
[4H + PtNH3 + y56]7+ 75.0 1.22 M 6560.4345 6560.4307 -0.59 
[4H + Pt + y61]8+ 74.8 0.38 M 7084.6464 7084.6420 -0.62 
[6H + PtN2H6 + a68y67]8+ 74.8 0.66 M 6823.5238 6823.5194 -0.64 
[5H + Pt + b74y64]7+ 74.8 0.46 M 7280.8165 7280.8127 -0.53 
[4H + Pt + y54]7+ 74.6 0.57 M 6327.3334 6327.3295 -0.61 
[4H + PtNH3 + a61y75]7+ 74.4 0.50 M 6911.6166 6911.6128 -0.56 
[4H + PtN2H8O + a68y66]7+ 74.3 0.68 M 6782.4973 6782.4934 -0.57 
[2H + PtN2H8O + a63y66]6+ 74.2 0.57 M 6213.2163 6213.2130 -0.53 
[2H + PtNH3 + a70y50]6+ 73.9 1.05 M 5188.6875 5188.6842 -0.63 
[2H + PtN2H6 + a63y48]4+ 73.5 0.33 M 4227.1642 4227.1620 -0.52 
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[4H + PtN2H8O + b71y62]7+ 73.5 2.51 M 6692.4543 6692.4505 -0.57 
[4H + Pt + a62y73]8+ 73.0 0.45 M 6781.5060 6781.5016 -0.65 
[6H + PtNH3 + a69y64]8+ 73.0 0.21 M 6633.4172 6633.4128 -0.66 
[4H + PtNH3 + b75y59]7+ 72.9 0.97 M 6798.5299 6798.5261 -0.56 
[5H + Pt + b64y73]8+ 72.4 0.36 M 7067.6463 7067.6419 -0.62 
[4H + PtN2H6 + b57y67]6+ 72.4 1.24 M 5520.8670 5520.8637 -0.60 
[3H + PtN2H8O + a62y72]7+ 72.2 2.95 M 6685.4935 6685.4896 -0.57 
[5H + Pt + b64y74]8+ 71.8 0.74 M 7180.7304 7180.7260 -0.61 
[3H + PtN2H8O + b74y58]7+ 71.2 12.17 M 6646.4951 6646.4913 -0.58 
[2H + PtNH3 + b52y75]6+ 71.0 0.39 M 5918.0923 5918.0890 -0.56 
[4H + PtN2H6 + a72y61]8+ 70.9 1.02 M 6689.4659 6689.4615 -0.66 
[5H + Pt + a63y71]8+ 70.5 0.69 M 6664.4720 6664.4676 -0.66 
[4H + Pt + b54]7+ 87.4 4.85 M 6247.2445 6247.2406 -0.61 
Table B.2 Most important metallated fragments obtained by CID fragmentation of the adduct [8H+ Ubiquitin + 
PtN2H8O]
10+ 
(m/z 881.4702) after incubation of ubiquitin with cisplatin (1:1, protein:drug ratio). Similarities are 
expressed as percentages, abundances are expressed as percentage of the most abundant peak in the spectra, and 
type is classified based on criteria in Figure 5.6. 
 
 
 
 
Metallated adduct Similarity Theoretical mass Experimental mass PPM Error 
[PtN2H6 + a30y75]3+ 85.2 3398.8267 3398.8251 -0.47 
[PtN2H8O + b27y72]2+ 84.7 2744.4050 2744.4038 -0.44 
[PtNH3 + b46y71]4+ 83.3 4758.4686 4758.4664 -0.46 
[PtN2H8O + y39]4+ 83.1 4712.4353 4712.4332 -0.45 
[PtN2H8O + a33y67]3+ 81.7 2857.4639 2857.4622 -0.59 
[4H + Pt + y58]7+ 80.8 6727.4928 6727.4886 -0.62 
[PtNH3 + a67y23]2+ 78.7 1833.8463 1833.8452 -0.60 
[Pt + a73y43]4+ 76.5 4740.4230 4740.4208 -0.46 
[PtN2H6 + a30y67]3+ 76.0 2468.2728 2468.2713 -0.61 
[PtN2H8O + a33y67]2+ 75.3 2857.4639 2857.4628 -0.38 
[PtNH3 + b45y52]3+ 74.8 2631.3375 2631.3357 -0.68 
[PtN2H6 + b44y53]2+ 74.5 2630.3382 2630.3372 -0.38 
[PtN2H6 + a46y72]4+ 71.9 4846.5686 4846.5664 -0.45 
[PtN2H8O + b50y67]4+ 70.2 4776.4904 4776.4880 -0.50 
[PtN2H8O + a47y52]2+ 70.2 2766.4383 2766.4372 -0.40 
[PtN2H6 + b31y57]2+ 70.0 1556.7400 1556.7390 -0.64 
[PtN2H6 + b27y74]2+ 69.0 2986.5469 2986.5458 -0.37 
[PtNH3 + a44y56]2+ 67.5 2914.4754 2914.4744 -0.34 
[PtN2H6 + b27y74]3+ 66.3 2986.5469 2986.5453 -0.54 
[4H + PtN2H8O + b55y66]6+ 64.8 5281.7400 5281.7370 -0.57 
Table B.3 Most important metallated fragments obtained by HCD fragmentation of the adduct [8H+ Ubiquitin + 
PtN2H8O]
10+ 
(m/z 881.4702) after incubation of ubiquitin with cisplatin (1:1, protein:drug ratio).  
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Metallated adduct Similarity Theoretical mass Experimental mass PPM Error 
[5H + Pt + z66]2+ 95.4 7624.9861 7624.9850 -0.14 
[7H + PtN2H8O + c37]2+ 94.7 4367.3353 4367.3342 -0.25 
[4H + PtNH3 + y67]2+ 93.6 7715.0528 7715.0518 -0.13 
[7H + PtN2H8O + z53]2+ 93.2 6252.3099 6252.3088 -0.18 
[5H + Pt + z62]2+ 92.7 7181.7117 7181.7106 -0.15 
[3H + PtN2H6 + y62]2+ 92.3 7230.7757 7230.7746 -0.15 
[H + Pt + c38]2+ 92.3 4406.2775 4406.2764 -0.25 
[4H + PtN2H6 + z65]2+ 92.2 7529.9364 7529.9354 -0.13 
[9H + PtN2H8O + c18]1+ 91.7 2306.2611 2306.2606 -0.22 
[4H + PtNH3 + y62]2+ 91.7 7214.7570 7214.7558 -0.17 
[2H + PtNH3 + c75]3+ 91.6 8716.6260 8716.6245 -0.17 
[H + PtNH3 + c59]2+ 91.3 6857.5281 6857.5270 -0.16 
[5H + PtNH3 + z65]2+ 91.1 7513.9177 7513.9166 -0.15 
[3H + PtN2H6 + z55]2+ 90.9 6444.3998 6444.3986 -0.19 
[6H + Pt + z59]2+ 90.9 6841.5245 6841.5234 -0.16 
[3H + PtNH3 + y45]2+ 90.7 5319.7444 5319.7434 -0.19 
[H + PtN2H6 + c38]2+ 90.4 4440.3306 4440.3294 -0.27 
[H + PtN2H6 + c59]2+ 90.2 6874.5547 6874.5536 -0.16 
[5H + PtNH3 + y74]3+ 89.7 8518.5559 8518.5543 -0.19 
[2H + Pt + c44]2+ 89.6 5160.6987 5160.6976 -0.21 
[7H + PtN2H8O + c65]2+ 89.4 7597.9673 7597.9662 -0.14 
[5H + PtN2H6 + z66]3+ 89.2 7659.0392 7659.0375 -0.22 
[7H + PtNH3 + z29]2+ 89.2 3541.8333 3541.8322 -0.31 
[5H + Pt + z66]3+ 89.0 7624.9861 7624.9845 -0.21 
[6H + Pt + z73]3+ 88.6 8372.4266 8372.4249 -0.20 
[PtN2H6 + c31]2+ 88.2 3702.9472 3702.9462 -0.27 
[PtNH3 + y17]1+ 88.2 2146.1213 2146.1207 -0.28 
[7H + PtN2H6 + c65]2+ 88.1 7579.9568 7579.9556 -0.16 
[9H + PtN2H8O + c74]4+ 88.1 8701.6965 8701.6944 -0.24 
[5H + PtN2H6 + z50]2+ 88.0 5890.1297 5890.1286 -0.19 
[PtN2H6 + c64]2+ 88.0 7485.8700 7485.8688 -0.16 
[2H + PtN2H8O + y36]2+ 88.0 4374.3126 4374.3116 -0.23 
[5H + PtNH3 + z73]3+ 87.9 8388.4453 8388.4437 -0.19 
[2H + Pt + c59]3+ 87.8 6841.5094 6841.5078 -0.23 
[6H + Pt + z70]3+ 87.6 7998.1948 7998.1932 -0.20 
[5H + Pt + y75]3+ 87.5 8629.5880 8629.5864 -0.19 
[7H + Pt + y31]2+ 87.3 3669.8919 3669.8908 -0.30 
[4H + PtNH3 + y75]3+ 87.2 8645.6067 8645.6049 -0.21 
[H + PtN2H6 + c75]3+ 87.2 8732.6448 8732.6430 -0.21 
[3H + Pt + c75]3+ 87.1 8700.6073 8700.6057 -0.18 
[4H + PtN2H8O + y50]2+ 87.0 5924.1590 5924.1580 -0.17 
[5H + PtNH3 + y65]3+ 86.7 7530.9442 7530.9426 -0.21 
[4H + PtN2H6 + y70]3+ 86.7 8047.2588 8047.2573 -0.19 
[H + PtNH3 + c44]2+ 86.6 5176.7174 5176.7162 -0.23 
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[PtN2H6 + c41]2+ 86.4 4810.4669 4810.4658 -0.23 
[4H + Pt + y66]2+ 86.2 7641.0048 7641.0038 -0.13 
[5H + PtN2H8O + y50]3+ 86.2 5925.1669 5925.1653 -0.27 
[4H + PtN2H6 + z70]3+ 86.1 8030.2323 8030.2305 -0.22 
[5H + PtN2H6 + z73]3+ 86.0 8405.4719 8405.4702 -0.20 
[H + Pt + c28]2+ 85.5 3300.6643 3300.6632 -0.33 
[8H + PtNH3 + z28]1+ 85.4 3414.7461 3414.7456 -0.15 
[2H + Pt + c62]2+ 85.3 7196.6950 7196.6938 -0.17 
[Pt + c24]2+ 85.1 2887.4131 2887.4120 -0.38 
[PtN2H6 + c30]2+ 85.0 3574.8886 3574.8876 -0.28 
[PtN2H6 + y25]2+ 84.6 3070.5514 3070.5504 -0.33 
[6H + PtN2H6 + z59]3+ 84.5 6875.5776 6875.5758 -0.26 
[2H + Pt + y52]2+ 84.5 6083.1911 6083.1900 -0.18 
[1H + PtNH3 + c38]2+ 84.5 4423.3040 4423.3030 -0.23 
[6H + Pt + y42]2+ 84.4 4933.5768 4933.5758 -0.20 
[5H + PtNH3 + y52]2+ 84.0 6103.2411 6103.2400 -0.18 
[4H + PtN2H8O + z50]2+ 83.9 5907.1325 5907.1314 -0.19 
[H + PtN2H6 + c42]2+ 83.9 4967.5758 4967.5746 -0.24 
[5H + PtN2H8O + y73]3+ 83.8 8440.5090 8440.5072 -0.21 
[4H + PtN2H8O + z27]2+ 83.4 3317.6934 3317.6922 -0.36 
[PtNH3 + c73]3+ 83.4 8501.4878 8501.4861 -0.20 
[4H + PtNH3 + y66]2+ 83.2 7658.0314 7658.0302 -0.16 
[H + PtN2H8O + y53]2+ 83.1 6263.2895 6263.2884 -0.18 
[PtN2H6 + c27]2+ 83.1 3262.6725 3262.6714 -0.34 
[9H + PtN2H8O + y36]2+ 83.1 4381.3674 4381.3664 -0.23 
[2H + Pt + c64]2+ 82.7 7453.8325 7453.8314 -0.15 
[Pt + y24]2+ 82.7 2921.4714 2921.4702 -0.41 
[3H + PtNH3 + y37]2+ 82.7 4468.3419 4468.3408 -0.25 
[4H + PtN2H8O + y23]1+ 82.5 2920.5449 2920.5443 -0.21 
[7H + Pt + z58]2+ 82.4 6713.4897 6713.4886 -0.16 
[6H + PtNH3 + c32]1+ 82.4 3806.9946 3806.9940 -0.16 
[5H + PtNH3 + z65]3+ 82.0 7513.9177 7513.9161 -0.21 
[2H + PtN2H6 + z45]3+ 81.9 5318.7366 5318.7348 -0.34 
[H + PtNH3 + y22]2+ 81.9 2726.3832 2726.3820 -0.44 
[PtN2H6 + c44]2+ 81.7 5192.7361 5192.7350 -0.21 
[PtN2H6 + z17]2+ 81.4 2146.1213 2146.1202 -0.51 
[5H + Pt + y70]3+ 81.4 8014.2135 8014.2120 -0.19 
[7H + PtN2H8O + z53]3+ 80.7 6252.3099 6252.3081 -0.29 
[9H + PtN2H6 + c65]3+ 80.6 7581.9724 7581.9708 -0.21 
[1H + PtN2H6 + c40]2+ 80.5 4683.4161 4683.4150 -0.23 
[5H + Pt + z75]3+ 80.4 8612.5614 8612.5599 -0.17 
[5H + PtNH3 + z29]1+ 80.4 3539.8176 3539.8171 -0.14 
[3H + PtN2H8O + y27]2+ 80.3 3333.7121 3333.7110 -0.33 
[H + PtN2H6 + z36]2+ 80.2 4338.2677 4338.2666 -0.25 
[H + PtN2H6 + c31]1+ 79.6 3703.9550 3703.9545 -0.13 
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[PtN2H6 + y30]2+ 79.5 3625.8531 3625.8520 -0.30 
[PtNH3 + c74]3+ 79.2 8657.5889 8657.5872 -0.20 
[5H + PtNH3 + y50]3+ 79.1 5890.1297 5890.1280 -0.29 
[7H + PtN2H8O + c65]3+ 79.1 7597.9673 7597.9656 -0.22 
[8H + PtN2H6 + y29]1+ 79.0 3576.8942 3576.8937 -0.14 
[6H + PtNH3 + z45]2+ 78.7 5305.7413 5305.7402 -0.21 
[9H + Pt + z28]1+ 78.6 3398.7274 3398.7269 -0.15 
[4H + PtNH3 + z62]3+ 78.6 7197.7304 7197.7287 -0.24 
[5H + PtN2H6 + y67]2+ 78.4 7733.0872 7733.0862 -0.13 
[1H + Pt + c39]2+ 78.3 4521.3044 4521.3034 -0.22 
[PtN2H6 + c74]3+ 78.2 8674.6155 8674.6137 -0.21 
[7H + PtN2H6 + z29]2+ 78.2 3558.8598 3558.8588 -0.28 
[3H + PtN2H6 + c54]2+ 78.1 6297.3163 6297.3152 -0.17 
[7H + Pt + z62]3+ 78.1 7183.7274 7183.7256 -0.25 
[9H + Pt + z70]3+ 77.9 8001.2183 8001.2166 -0.21 
[9H + PtN2H8O + c18]2+ 77.6 2306.2611 2306.2600 -0.48 
[4H + Pt + z65]2+ 77.6 7495.8833 7495.8822 -0.15 
[4H + PtN2H6 + y62]3+ 77.5 7231.7835 7231.7820 -0.21 
[PtN2H6 + c39]2+ 77.5 4554.3497 4554.3486 -0.24 
[H + PtN2H6 + z25]2+ 76.8 3054.5327 3054.5316 -0.36 
[H + Pt + c41]2+ 76.7 4777.4216 4777.4204 -0.25 
[6H + Pt + c75]3+ 76.5 8703.6308 8703.6291 -0.20 
[1H + PtNH3 + c59]3+ 76.5 6857.5281 6857.5266 -0.22 
[8H + PtN2H8O + y65]3+ 76.4 7569.0048 7569.0033 -0.20 
[PtN2H6 + c75]4+ 76.3 8731.6369 8731.6348 -0.24 
[2H + Pt + c51]2+ 75.9 5934.1058 5934.1048 -0.17 
[3H + PtN2H8O + y27]1+ 75.6 3333.7121 3333.7116 -0.15 
[2H + PtN2H6 + z66]3+ 75.4 7656.0157 7656.0141 -0.21 
[2H + PtN2H6 + y75]3+ 75.2 8660.6176 8660.6160 -0.18 
[2H + PtNH3 + c64]3+ 74.9 7470.8591 7470.8574 -0.23 
[3H + PtN2H6 + z59]3+ 74.9 6872.5541 6872.5524 -0.25 
[H + PtN2H6 + z75]3+ 74.8 8642.5832 8642.5815 -0.20 
[Pt + c29]2+ 74.6 3427.7515 3427.7504 -0.32 
[8H + PtN2H6 + z74]3+ 74.4 8521.5794 8521.5777 -0.20 
[7H + Pt + y31]1+ 73.6 3669.8919 3669.8913 -0.16 
[9H + Pt + z23]1+ 73.4 2856.4938 2856.4932 -0.21 
[9H + Pt + z36]2+ 73.3 4312.2772 4312.2760 -0.28 
[PtN2H8O + c75]3+ 73.0 8749.6475 8749.6458 -0.19 
[9H + PtN2H8O + y75]3+ 72.8 8685.6829 8685.6813 -0.18 
[4H + PtNH3 + y67]3+ 72.7 7715.0528 7715.0511 -0.22 
[7H + PtNH3 + z33]1+ 72.7 3930.0443 3930.0438 -0.13 
[2H + PtN2H6 + z74]3+ 72.6 8515.5325 8515.5309 -0.19 
[9H + Pt + z30]1+ 72.4 3583.8438 3583.8433 -0.14 
[5H + PtNH3 + y74]4+ 72.1 8518.5559 8518.5536 -0.27 
[5H + PtN2H8O + y24]1+ 72.1 2978.5741 2978.5736 -0.17 
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[1H + PtN2H6 + c33]2+ 72.0 3947.0769 3947.0758 -0.28 
[3H + Pt + c58]2+ 71.9 6679.4539 6679.4528 -0.16 
[3H + Pt + z38]2+ 71.9 4549.3158 4549.3146 -0.26 
[9H + PtN2H8O + z20]1+ 71.8 2538.3246 2538.3240 -0.24 
[4H + PtN2H6 + z69]2+ 71.7 7929.1846 7929.1834 -0.15 
[3H + Pt + z52]2+ 71.7 6067.1723 6067.1712 -0.18 
[9H + PtNH3 + z53]2+ 71.5 6219.2884 6219.2874 -0.16 
[4H + PtN2H6 + c75]3+ 71.4 8735.6682 8735.6667 -0.17 
[8H + Pt + c75]4+ 71.3 8705.6464 8705.6444 -0.23 
[7H + PtN2H8O + y50]2+ 70.9 5927.1825 5927.1814 -0.19 
[1H + Pt + y66]2+ 70.8 7637.9814 7637.9802 -0.16 
[8H + PtNH3 + z59]2+ 70.8 6860.5667 6860.5656 -0.16 
[8H + PtNH3 + y50]2+ 70.8 5893.1532 5893.1522 -0.17 
[8H + Pt + z62]2+ 70.6 7184.7352 7184.7340 -0.17 
[9H + PtN2H8O + y23]1+ 70.4 2925.5840 2925.5834 -0.21 
[H + PtN2H6 + c33]1+ 70.3 3947.0769 3947.0764 -0.13 
[8H + PtN2H8O + y73]3+ 70.2 8443.5325 8443.5309 -0.19 
[2H + PtN2H6 + z46]2+ 70.2 5446.7952 5446.7940 -0.22 
Table B.4 Most important metallated fragments obtained by ETD fragmentation of the adduct [8H+ Ubiquitin + 
PtN2H8O]
10+ 
(m/z 881.4702) after incubation of ubiquitin with cisplatin (1:1, protein:drug ratio). Similarities are 
expressed as percentages, abundances are expressed as percentage of the most abundant peak in the spectra, and 
type is classified based on criteria in Figure 5.6. 
 
 
 
Metallated adduct Similarity Abundance Type Theoretical mass Experimental mass PPM Error 
[PtNH3 + b74y19]3+ 95.9 1.88 R 2292.1581 2292.1564 -0.72 
[PtNH3 + a70y37]3+ 95.6 2.68 R 3766.8997 3766.8980 -0.44 
[PtN2H6 + y18]3+ 94.0 1.49 R 2326.2112 2326.2095 -0.71 
[PtN2H6 + b62y24]2+ 93.5 0.71 R 1377.5879 1377.5868 -0.80 
[H + PtN2H6 + y24]4+ 92.2 1.02 R 2956.5323 2956.5301 -0.74 
[Pt + b74y19]3+ 91.7 0.98 R 2275.1315 2275.1299 -0.72 
[Pt + a70y37]3+ 87.0 0.80 R 3749.8731 3749.8715 -0.44 
[2H + Pt + y37]5+ 86.8 4.40 R 4450.3075 4450.3048 -0.62 
[H + Pt + y24]4+ 86.6 0.58 R 2922.4792 2922.4770 -0.75 
[H + PtNH3 + a71y35]4+ 82.3 0.98 R 3624.8744 3624.8722 -0.61 
[PtN2H6 + a59y36]3+ 78.6 0.36 R 2393.1694 2393.1677 -0.69 
[2H + Pt + a70y37]4+ 76.8 0.82 R 3751.8888 3751.8866 -0.58 
[H + PtN2H6 + a62y34]3+ 76.5 0.64 R 2465.2031 2465.2014 -0.67 
[Pt + b63y36]2+ 74.8 0.76 R 2870.3917 2870.3906 -0.38 
[Pt + b73y33]4+ 73.7 2.96 R 3634.8350 3634.8328 -0.60 
[PtNH3 + a73y21]3+ 72.1 1.54 R 2308.1781 2308.1765 -0.71 
[2H + PtN2H6 + y37]5+ 95.0 3.58 R 4484.3606 4484.3579 -0.61 
[Pt + b36]3+ 96.0 2.94 L 4194.1376 4194.1359 -0.39 
[PtNH3 + b32y74]4+ 95.8 1.79 L 3524.8220 3524.8198 -0.62 
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[H + PtN2H6 + a28y67]3+ 94.0 1.23 L 2228.1016 2228.1000 -0.74 
[PtN2H6 + b31y70]4+ 93.7 0.72 L 2939.5057 2939.5035 -0.75 
[H + PtNH3 + a36y61]3+ 93.3 1.80 L 2509.2028 2509.2012 -0.66 
[H + PtNH3 + a36y53]2+ 92.9 2.21 L 1637.7979 1637.7968 -0.67 
[H + PtN2H6 + b39]4+ 92.1 5.76 L 4538.3310 4538.3288 -0.48 
[H + Pt + b32]4+ 90.9 3.35 L 3767.9023 3767.9001 -0.58 
[PtN2H6 + a28y67]2+ 90.3 10.01 L 2227.0938 2227.0927 -0.49 
[Pt + b16y73]2+ 90.2 1.37 L 1627.8063 1627.8052 -0.67 
[PtNH3 + b36]3+ 88.4 1.27 L 4211.1641 4211.1625 -0.39 
[PtNH3 + a32y73]4+ 88.3 0.67 L 3383.7430 3383.7408 -0.65 
[H + PtN2H6 + b36]4+ 84.9 2.96 L 4229.1985 4229.1963 -0.52 
[H + Pt + b30]3+ 83.2 2.04 L 3524.8168 3524.8152 -0.47 
[Pt + b33]3+ 83.1 0.78 L 3894.9895 3894.9878 -0.42 
[Pt + b22]2+ 76.8 1.13 L 2628.2599 2628.2588 -0.42 
[Pt + b21]2+ 76.2 1.39 L 2527.2122 2527.2111 -0.43 
[PtN2H6 + b38y58]3+ 76.1 0.60 L 2390.1684 2390.1667 -0.69 
[PtNH3 + b21]2+ 75.3 0.45 L 2544.2388 2544.2377 -0.43 
[PtNH3 + b16]3+ 75.2 0.47 L 2017.0160 2017.0144 -0.82 
[H + PtNH3 + b32y73]4+ 75.0 1.21 L 3412.7458 3412.7436 -0.64 
[Pt + b11]2+ 73.6 3.52 L 1442.6834 1442.6823 -0.76 
[3H + PtNH3 + y58]6+ 96.7 26.16 M 6743.5115 6743.5082 -0.49 
[3H + Pt + y60]6+ 96.4 7.06 M 6954.5960 6954.5927 -0.47 
[3H + Pt + b54]6+ 95.8 28.53 M 6246.2366 6246.2333 -0.53 
[4H + Pt + y58]7+ 95.7 26.37 M 6727.4928 6727.4889 -0.57 
[3H + Pt + y58]6+ 95.6 36.51 M 6726.4850 6726.4817 -0.49 
[4H + Pt + y62]7+ 95.5 7.44 M 7197.7304 7197.7266 -0.53 
[5H + Pt + y74]8+ 95.2 9.87 M 8501.5294 8501.5250 -0.52 
[4H + PtN2H6 + y63]7+ 94.9 10.05 M 7332.8312 7332.8274 -0.52 
[4H + Pt + b64y73]7+ 94.9 7.82 M 7066.6385 7066.6347 -0.54 
[2H + Pt + b52]5+ 94.8 4.64 M 6032.1062 6032.1035 -0.45 
[3H + Pt + y61]6+ 94.7 6.16 M 7083.6386 7083.6353 -0.46 
[4H + Pt + y60]7+ 94.6 9.44 M 6955.6038 6955.5999 -0.55 
[2H + PtNH3 + b51y70]6+ 94.3 2.41 M 5187.6909 5187.6876 -0.63 
[5H + PtNH3 + y73]8+ 94.1 4.99 M 8405.4719 8405.4675 -0.52 
[5H + PtN2H6 + y73]8+ 94.0 4.07 M 8422.4984 8422.4940 -0.52 
[4H + Pt + y61]7+ 93.8 11.56 M 7084.6464 7084.6425 -0.54 
[4H + PtN2H6 + a63y66]7+ 93.8 1.62 M 6197.2214 6197.2176 -0.62 
[3H + Pt + y62]6+ 93.7 1.98 M 7196.7226 7196.7193 -0.46 
[4H + PtNH3 + y65]7+ 93.4 3.31 M 7529.9364 7529.9326 -0.51 
[2H + PtN2H6 + b52]5+ 93.4 3.11 M 6066.1593 6066.1566 -0.45 
[3H + Pt + y59]6+ 92.7 8.51 M 6855.5275 6855.5243 -0.48 
[3H + PtNH3 + y60]6+ 92.5 5.97 M 6971.6225 6971.6192 -0.47 
[4H + PtN2H6 + y62]7+ 92.5 7.85 M 7231.7835 7231.7797 -0.53 
[5H + PtN2H6 + y74]8+ 92.1 8.53 M 8535.5825 8535.5781 -0.51 
[H + Pt + y40]4+ 92.1 2.32 M 4758.4322 4758.4300 -0.46 
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[4H + PtNH3 + y58]7+ 91.9 14.14 M 6744.5193 6744.5155 -0.57 
[4H + Pt + a63]7+ 91.5 8.35 M 7281.7841 7281.7803 -0.53 
[4H + PtNH3 + b71y64]6+ 91.5 3.68 M 6871.5490 6871.5457 -0.48 
[4H + PtNH3 + y61]7+ 91.3 8.58 M 7101.6729 7101.6691 -0.54 
[3H + PtN2H6 + b71y65]6+ 91.1 1.75 M 6988.6154 6988.6121 -0.47 
[4H + PtNH3 + y52]7+ 91.0 0.62 M 6102.2333 6102.2294 -0.63 
[5H + PtNH3 + y71]8+ 90.5 2.20 M 8159.3350 8159.3307 -0.54 
[H + PtNH3 + y40]4+ 90.5 2.89 M 4775.4587 4775.4565 -0.46 
[4H + PtNH3 + a70y68]6+ 90.4 1.58 M 7117.6818 7117.6785 -0.46 
[5H + PtNH3 + b63y71]7+ 90.2 9.04 M 6709.4935 6709.4896 -0.57 
[2H + PtN2H6 + a59y71]5+ 90.0 0.88 M 6212.2211 6212.2183 -0.44 
[4H + Pt + y59]7+ 90.0 4.96 M 6856.5354 6856.5315 -0.56 
[3H + Pt + y53]6+ 89.7 6.35 M 6213.2415 6213.2382 -0.53 
[2H + PtNH3 + b52]5+ 89.6 2.14 M 6049.1328 6049.1300 -0.45 
[4H + PtNH3 + b64y71]6+ 89.2 5.08 M 6837.5282 6837.5249 -0.48 
[4H + Pt + b63]7+ 89.1 4.53 M 7309.7790 7309.7752 -0.53 
[4H + PtNH3 + a71y62]6+ 89.0 2.56 M 6629.4223 6629.4190 -0.50 
[6H + Pt + y74]9+ 88.9 2.44 M 8502.5372 8502.5323 -0.58 
[4H + PtNH3 + a73y58]7+ 88.8 2.16 M 6428.3698 6428.3660 -0.60 
[2H + Pt + y58]5+ 88.7 1.55 M 6725.4771 6725.4744 -0.41 
[2H + PtNH3 + y61]6+ 88.7 3.26 M 7099.6573 7099.6540 -0.46 
[4H + PtNH3 + b63y71]6+ 88.5 9.45 M 6708.4856 6708.4823 -0.49 
[3H + Pt + a71y62]6+ 88.4 1.11 M 6611.3879 6611.3846 -0.50 
[3H + Pt + b62]7+ 88.2 3.06 M 7180.6762 7180.6724 -0.53 
[4H + Pt + y52]7+ 88.1 1.50 M 6085.2067 6085.2029 -0.63 
[4H + Pt + y63]7+ 87.8 8.24 M 7298.7781 7298.7743 -0.53 
[5H + PtNH3 + y60]7+ 87.6 5.94 M 6973.6382 6973.6343 -0.55 
[PtN2H6 + b51y38]2+ 87.6 1.40 M 1756.8462 1756.8451 -0.62 
[5H + Pt + a70y69]7+ 87.5 5.85 M 7214.7471 7214.7433 -0.53 
[3H + PtN2H6 + b58]6+ 87.5 6.77 M 6696.4804 6696.4772 -0.49 
[2H + Pt + b60]6+ 87.4 3.79 M 6938.5258 6938.5225 -0.47 
[4H + PtN2H6 + a59y71]7+ 87.4 1.83 M 6214.2367 6214.2329 -0.62 
[5H + PtNH3 + b64y71]7+ 86.5 2.82 M 6838.5360 6838.5322 -0.56 
[4H + PtNH3 + y70]7+ 86.0 0.48 M 8030.2323 8030.2284 -0.48 
[5H + PtN2H6 + y72]8+ 85.9 1.51 M 8275.4300 8275.4256 -0.53 
[4H + PtNH3 + y64]7+ 85.8 2.49 M 7428.8887 7428.8849 -0.52 
[H + PtN2H6 + a56y58]5+ 85.8 0.87 M 4432.2831 4432.2803 -0.62 
[4H + Pt + b74y56]7+ 85.5 0.89 M 6411.3545 6411.3507 -0.60 
[2H + PtNH3 + y53]6+ 85.5 7.24 M 6229.2602 6229.2569 -0.53 
[2H + PtN2H6 + b52y62]4+ 85.4 8.93 M 4504.2691 4504.2670 -0.49 
[5H + Pt + b72y69]7+ 85.1 4.16 M 7511.9272 7511.9234 -0.51 
[2H + Pt + a63y72]6+ 84.8 12.08 M 6760.5169 6760.5136 -0.49 
[H + PtN2H6 + a47y65]3+ 84.7 0.98 M 4177.1387 4177.1370 -0.39 
[4H + Pt + a70y70]6+ 84.7 1.38 M 7314.7870 7314.7837 -0.45 
[2H + PtNH3 + y40]5+ 84.6 4.91 M 4776.4666 4776.4638 -0.57 
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[5H + Pt + y72]8+ 84.1 2.69 M 8241.3769 8241.3725 -0.53 
[3H + PtN2H6 + b64y74]6+ 83.9 1.19 M 7212.7678 7212.7645 -0.46 
[5H + Pt + y64]7+ 83.9 5.25 M 7412.8700 7412.8662 -0.52 
[4H + PtNH3 + y63]7+ 83.7 9.75 M 7315.8047 7315.8008 -0.52 
[4H + Pt + b64y73]6+ 83.5 3.56 M 7066.6385 7066.6352 -0.47 
[6H + PtNH3 + y74]8+ 83.3 9.57 M 8519.5638 8519.5594 -0.52 
[6H + Pt + y70]8+ 83.1 2.19 M 8015.2214 8015.2170 -0.55 
[3H + PtN2H6 + y63]6+ 83.0 1.13 M 7331.8234 7331.8201 -0.45 
[H + PtN2H6 + b62y47]3+ 83.0 1.21 M 3997.9614 3997.9597 -0.41 
[2H + Pt + y50]5+ 82.8 1.06 M 5870.0797 5870.0770 -0.47 
[3H + Pt + a72y60]6+ 82.4 0.94 M 6525.3624 6525.3591 -0.50 
[3H + Pt + y42]5+ 82.2 0.76 M 4930.5534 4930.5506 -0.56 
[2H + PtNH3 + a69y54]6+ 82.1 1.04 M 5544.8571 5544.8538 -0.59 
[5H + PtNH3 + b58]7+ 82.0 2.04 M 6681.4695 6681.4657 -0.57 
[PtN2H6 + a47y52]2+ 81.8 1.71 M 2748.4277 2748.4266 -0.40 
[4H + Pt + b62y75]7+ 81.7 2.93 M 7050.6436 7050.6397 -0.54 
[2H + PtN2H6 + a65y71]6+ 81.7 0.64 M 6911.5762 6911.5729 -0.48 
[5H + Pt + b73y68]8+ 81.4 1.09 M 7511.9272 7511.9228 -0.58 
[4H + Pt + b63y71]7+ 81.3 2.71 M 6691.4591 6691.4552 -0.57 
[2H + Pt + y52]6+ 81.0 3.45 M 6083.1911 6083.1878 -0.54 
[5H + Pt + y73]8+ 80.6 6.93 M 8388.4453 8388.4409 -0.52 
[6H + PtNH3 + a68y73]8+ 80.4 2.12 M 7495.9085 7495.9041 -0.59 
[3H + PtN2H6 + b52]6+ 80.4 1.32 M 6067.1672 6067.1639 -0.54 
[6H + Pt + b75]9+ 80.3 2.21 M 8686.6042 8686.5993 -0.57 
[5H + PtN2H6 + b68y72]7+ 80.2 1.20 M 7392.8537 7392.8499 -0.52 
[2H + PtNH3 + b65y71]6+ 80.2 1.50 M 6922.5446 6922.5413 -0.48 
[H + Pt + b54y62]4+ 78.7 0.53 M 4682.3308 4682.3286 -0.47 
[Pt + b52y65]4+ 78.4 1.18 M 4783.3798 4783.3776 -0.46 
[4H + Pt + a72y60]7+ 78.2 1.14 M 6526.3702 6526.3664 -0.59 
[H + PtN2H6 + a66y50]5+ 77.7 1.14 M 4742.4108 4742.4080 -0.58 
[5H + PtNH3 + a63y66]7+ 77.6 0.47 M 6181.2027 6181.1988 -0.62 
[5H + PtNH3 + b58y73]7+ 77.6 0.74 M 6309.2864 6309.2826 -0.61 
[3H + Pt + a50]6+ 77.3 1.42 M 5761.0496 5761.0463 -0.57 
[4H + PtNH3 + a62y74]7+ 77.3 1.85 M 6911.6166 6911.6128 -0.56 
[3H + Pt + a64y73]7+ 77.0 1.23 M 7037.6358 7037.6319 -0.55 
[6H + PtNH3 + y75]8+ 76.8 1.95 M 8647.6223 8647.6180 -0.51 
[5H + PtN2H6 + y65]7+ 76.8 8.86 M 7547.9708 7547.9669 -0.51 
[3H + Pt + b60]7+ 76.6 2.68 M 6939.5336 6939.5298 -0.55 
[4H + PtN2H6 + b68y66]6+ 76.4 0.81 M 6792.4816 6792.4783 -0.48 
[3H + PtNH3 + a61y69]6+ 76.3 3.25 M 6194.1867 6194.1834 -0.53 
[4H + Pt + b63y71]6+ 75.9 3.95 M 6691.4591 6691.4558 -0.49 
[4H + Pt + a65y69]7+ 75.1 1.15 M 6650.3961 6650.3923 -0.58 
[3H + Pt + y70]7+ 75.1 0.80 M 8012.1979 8012.1940 -0.48 
[4H + Pt + b61]6+ 74.2 2.04 M 7053.6255 7053.6222 -0.47 
[2H + PtN2H6 + a68y67]6+ 74.0 2.96 M 6819.4925 6819.4892 -0.48 
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[4H + PtNH3 + a74y75]8+ 73.5 4.87 M 8485.5583 8485.5539 -0.52 
[3H + PtNH3 + b65y71]7+ 73.3 1.49 M 6923.5524 6923.5486 -0.55 
[4H + PtN2H6 + b69y68]6+ 73.0 2.97 M 7063.6348 7063.6315 -0.47 
[H + Pt + y43]4+ 72.9 0.63 M 5057.5803 5057.5781 -0.43 
[3H + PtNH3 + b63y71]5+ 71.9 0.45 M 6707.4778 6707.4751 -0.41 
[3H + Pt + b73y62]6+ 71.6 0.64 M 6908.5680 6908.5647 -0.48 
[3H + PtN2H6 + a63y70]6+ 71.6 0.48 M 6568.4145 6568.4112 -0.50 
[4H + PtNH3 + y56]6+ 71.5 1.17 M 6560.4345 6560.4312 -0.50 
[2H + Pt + b60]5+ 71.2 0.58 M 6938.5258 6938.5230 -0.40 
[H + PtNH3 + b56y55]3+ 70.8 0.40 M 4144.1397 4144.1380 -0.40 
[5H + Pt + a61y72]7+ 70.8 0.59 M 6507.3869 6507.3830 -0.59 
[3H + PtNH3 + b75y53]7+ 70.7 0.84 M 6155.2360 6155.2322 -0.62 
[4H + PtNH3 + b63y59]6+ 70.6 0.52 M 5423.7203 5423.7170 -0.61 
[2H + Pt + a61y69]6+ 70.4 1.65 M 6176.1523 6176.1490 -0.53 
[2H + PtNH3 + y58]5+ 92.1 0.76 M 6742.5037 6742.5009 -0.41 
[3H + Pt + b74y58]6+ 86.8 1.56 M 6594.4315 6594.4282 -0.50 
[H + Pt + b54y59]4+ 84.9 0.90 M 4341.1357 4341.1335 -0.51 
[3H + PtNH3 + a72y60]6+ 80.0 4.40 M 6542.3889 6542.3856 -0.50 
[4H + PtNH3 + b71y55]6+ 74.3 0.95 M 5888.0678 5888.0645 -0.56 
[H + PtNH3 + y42]4+ 73.6 0.62 M 4945.5643 4945.5621 -0.44 
[4H + PtNH3 + b65y73]7+ 72.5 0.94 M 7170.6971 7170.6932 -0.54 
[3H + PtN2H6 + b52]7+ 72.4 0.65 M 6067.1672 6067.1633 -0.63 
[H + Pt + y44]5+ 79.3 3.69 M 5185.6753 5185.6725 -0.53 
Table B.5 Most important metallated fragments obtained by CID fragmentation of the adduct [7H+ Ubiquitin + 
PtN2H6]
9+ 
(m/z 977.2928) after incubation of ubiquitin with cisplatin (1:1, protein:drug ratio). Similarities are 
expressed as percentages, abundances are expressed as percentage of the most abundant peak in the spectra, and 
type is classified based on criteria in Figure 5.6. 
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Metallated adduct Similarity Theoretical mass Experimental mass PPM Error 
[Pt + a49y63]4+ 95.4 4184.0996 4184.0972 -0.57 
[4H + Pt + y58]7+ 92.0 6727.4928 6727.4886 -0.62 
[4H + PtN2H6 + b64y70]6+ 91.3 6726.4598 6726.4566 -0.48 
[Pt + a54y40]3+ 90.8 2217.0533 2217.0516 -0.77 
[4H + PtNH3 + b63y71]6+ 90.7 6708.4856 6708.4824 -0.48 
[PtN2H6 + b62y24]2+ 90.3 1377.5879 1377.5868 -0.80 
[PtN2H6 + a62y24]2+ 90.1 1349.5930 1349.5918 -0.89 
[PtN2H6 + b71y44]4+ 89.9 4661.3808 4661.3784 -0.51 
[Pt + a73y43]4+ 88.5 4740.4230 4740.4208 -0.46 
[Pt + b57y35]2+ 87.8 1980.9623 1980.9612 -0.56 
[Pt + y42]4+ 87.8 4927.5299 4927.5276 -0.47 
[4H + PtNH3 + b64y71]6+ 87.3 6837.5282 6837.5250 -0.47 
[Pt + a54y58]3+ 87.2 4183.0904 4183.0887 -0.41 
[PtN2H6 + b62y29]2+ 86.5 1990.8950 1990.8940 -0.50 
[4H + PtNH3 + a61y69]6+ 86.1 6195.1945 6195.1914 -0.50 
[Pt + a50y56]3+ 85.5 3541.8135 3541.8117 -0.51 
[Pt + y43]4+ 85.0 5056.5725 5056.5704 -0.42 
[4H + Pt + y53]6+ 85.0 6214.2493 6214.2462 -0.50 
[4H + Pt + b63y71]6+ 84.7 6691.4591 6691.4556 -0.52 
[5H + PtNH3 + b63y71]7+ 84.5 6709.4935 6709.4895 -0.60 
[PtN2H6 + a24y75]3+ 84.5 2745.4042 2745.4026 -0.58 
[Pt + b54y31]2+ 84.2 1150.4609 1150.4598 -0.96 
[4H + PtNH3 + a71y62]6+ 84.2 6629.4223 6629.4192 -0.47 
[Pt + b74y19]3+ 83.5 2275.1315 2275.1298 -0.75 
[Pt + b32y58]2+ 83.5 1734.7667 1734.7656 -0.63 
[PtNH3 + a22y72]2+ 83.1 2098.0400 2098.0388 -0.57 
[PtN2H6 + a73y32]2+ 82.9 3527.8091 3527.8080 -0.31 
[Pt + y40]4+ 82.1 4757.4244 4757.4220 -0.50 
[Pt + a51y61]4+ 81.9 4212.0945 4212.0924 -0.50 
[PtNH3 + a44y56]2+ 81.7 2914.4754 2914.4744 -0.34 
[Pt + b51y70]4+ 81.7 5168.6487 5168.6464 -0.44 
[4H + Pt + b60y74]6+ 81.4 6681.4424 6681.4392 -0.48 
[4H + Pt + y59]6+ 81.2 6856.5354 6856.5318 -0.53 
[Pt + a74y40]4+ 81.2 4597.3760 4597.3736 -0.52 
[PtNH3 + a67y23]2+ 81.0 1833.8463 1833.8452 -0.60 
[PtNH3 + b50y48]2+ 80.7 2716.3903 2716.3892 -0.40 
[PtN2H6 + b46y71]4+ 80.6 4775.4951 4775.4928 -0.48 
[PtN2H6 + b62y30]2+ 80.5 2047.9165 2047.9154 -0.54 
[4H + PtNH3 + y58]6+ 78.8 6744.5193 6744.5160 -0.49 
[4H + PtNH3 + b63y73]6+ 78.8 6954.6225 6954.6192 -0.47 
[4H + Pt + a71y62]6+ 78.3 6612.3957 6612.3924 -0.50 
[PtNH3 + a48y52]3+ 78.0 2859.4961 2859.4944 -0.59 
[PtNH3 + a30y70]2+ 78.0 2766.4257 2766.4246 -0.40 
[PtN2H6 + a31y74]3+ 77.3 3398.8267 3398.8251 -0.47 
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[PtN2H6 + b43y54]2+ 77.2 2630.3382 2630.3372 -0.38 
[Pt + a75y42]3+ 77.1 4824.5029 4824.5013 -0.33 
[Pt + b75y30]3+ 77.1 3516.7679 3516.7662 -0.48 
[Pt + a74y41]3+ 76.8 4710.4600 4710.4584 -0.34 
[4H + Pt + a61y69]6+ 76.3 6178.1680 6178.1646 -0.55 
[Pt + b38y72]4+ 76.1 3868.9916 3868.9892 -0.62 
[Pt + b74y40]4+ 75.5 4625.3709 4625.3688 -0.45 
[PtN2H6 + a35y55]2+ 75.4 1755.8721 1755.8710 -0.63 
[4H + PtN2H6 + b58y73]6+ 75.3 6325.3051 6325.3020 -0.49 
[PtN2H6 + a36y75]3+ 75.3 4069.1553 4069.1535 -0.44 
[4H + Pt + a67y66]6+ 75.2 6593.3747 6593.3712 -0.53 
[Pt + b21]3+ 74.8 2527.2122 2527.2105 -0.67 
[PtN2H6 + a46y72]4+ 74.8 4846.5686 4846.5664 -0.45 
[Pt + a54y53]3+ 74.8 3669.8469 3669.8454 -0.41 
[PtNH3 + b59y52]4+ 74.7 4165.0798 4165.0776 -0.53 
[PtN2H6 + a70y35]3+ 74.7 3527.8091 3527.8074 -0.48 
[Pt + b31y58]2+ 74.5 1619.7397 1619.7386 -0.68 
[5H + Pt + b63y71]7+ 74.4 6692.4669 6692.4634 -0.52 
[PtN2H6 + a30y67]3+ 74.0 2468.2728 2468.2713 -0.61 
[PtN2H6 + b52y66]4+ 73.9 4945.5279 4945.5256 -0.47 
[PtN2H6 + a24y75]2+ 73.4 2745.4042 2745.4032 -0.36 
[PtNH3 + b31y70]3+ 73.4 2922.4792 2922.4776 -0.55 
[PtN2H6 + a33y70]3+ 73.3 3154.6327 3154.6311 -0.51 
[4H + PtN2H6 + b70y67]6+ 73.1 7061.6555 7061.6520 -0.50 
[PtNH3 + b50y52]2+ 73.0 3128.6337 3128.6326 -0.35 
[4H + PtN2H6 + b66y66]6+ 72.8 6542.3386 6542.3352 -0.52 
[PtNH3 + a66y51]4+ 72.7 4823.4448 4823.4428 -0.41 
[Pt + b54y58]3+ 72.3 4211.0853 4211.0838 -0.36 
[Pt + b50y70]4+ 72.2 5039.6061 5039.6040 -0.42 
[PtNH3 + a30y71]3+ 72.2 2894.5207 2894.5191 -0.55 
[PtNH3 + a32y65]3+ 72.1 2509.2154 2509.2138 -0.64 
[PtN2H6 + b70y46]4+ 72.1 4791.3822 4791.3800 -0.46 
[PtN2H6 + b27y74]2+ 71.6 2986.5469 2986.5458 -0.37 
[4H + PtNH3 + a60y72]6+ 71.4 6410.3215 6410.3184 -0.48 
[PtN2H6 + a38y74]3+ 71.2 4135.2022 4135.2006 -0.39 
[Pt + b72y40]3+ 70.9 4356.1857 4356.1839 -0.41 
[4H + Pt + a72y60]6+ 70.3 6526.3702 6526.3668 -0.52 
[Pt + a45y56]2+ 70.2 3044.5173 3044.5162 -0.36 
[4H + PtN2H6 + b64y71]7+ 70.0 6854.5548 6854.5512 -0.53 
[PtNH3 + b73y24]2+ 69.4 2650.3433 2650.3422 -0.42 
[Pt + b48y59]3+ 68.6 3641.7931 3641.7915 -0.44 
[5H + PtNH3 + b62y72]7+ 68.5 6680.4669 6680.4633 -0.54 
[4H + PtNH3 + b68y65]6+ 68.2 6647.3601 6647.3568 -0.50 
[5H + Pt + y71]8+ 68.1 8142.3085 8142.3040 -0.55 
[PtNH3 + a20y70]2+ 68.0 1654.8020 1654.8008 -0.73 
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[4H + PtNH3 + y58]7+ 67.8 6744.5193 6744.5154 -0.58 
[Pt + b31y70]3+ 67.7 2905.4526 2905.4511 -0.52 
[Pt + a73y21]3+ 67.6 2291.1516 2291.1498 -0.79 
[PtNH3 + b59y53]4+ 67.3 4294.1224 4294.1204 -0.47 
[PtNH3 + y43]4+ 67.2 5073.5990 5073.5968 -0.43 
[PtNH3 + a36y61]2+ 67.1 2508.1950 2508.1938 -0.48 
[Pt + a74y17]2+ 67.0 1969.0463 1969.0452 -0.56 
[Pt + b60y58]3+ 67.0 4904.3823 4904.3805 -0.37 
[PtNH3 + b44y70]3+ 66.3 4412.2681 4412.2665 -0.36 
[PtN2H6 + b43y54]3+ 66.1 2630.3382 2630.3367 -0.57 
[4H + PtNH3 + b74y60]7+ 66.1 6840.5768 6840.5729 -0.57 
[PtN2H6 + b63y31]3+ 65.7 2247.0486 2247.0468 -0.80 
[PtN2H6 + b58y33]2+ 65.6 1860.8572 1860.8562 -0.54 
[Pt + a50y69]4+ 65.3 4910.5635 4910.5612 -0.47 
[4H + Pt + b72y57]6+ 65.0 6229.2013 6229.1982 -0.50 
Table B.6 Most important metallated fragments obtained by HCD fragmentation of the adduct [7H+ Ubiquitin + 
PtN2H6]
9+ 
(m/z 977.2928) after incubation of ubiquitin with cisplatin (1:1, protein:drug ratio). 
 
 
 
 
 
 
 
 
 
 
Metallated adduct Similarity Theoretical mass Experimental mass PPM Error 
[4H + PtN2H6 + z70]3+ 95.9 8030.2323 8030.2305 -0.22 
[4H + PtN2H6 + z66]3+ 95.1 7658.0314 7658.0298 -0.21 
[4H + PtNH3 + y65]2+ 94.2 7529.9364 7529.9354 -0.13 
[9H + PtN2H6 + c69]3+ 94.1 8046.2471 8046.2454 -0.21 
[4H + PtN2H6 + z74]3+ 94.0 8517.5481 8517.5466 -0.18 
[4H + Pt + z66]2+ 93.5 7623.9783 7623.9772 -0.14 
[4H + PtN2H6 + z65]3+ 93.4 7529.9364 7529.9349 -0.20 
[Pt + c38]2+ 93.2 4406.2775 4406.2764 -0.25 
[4H + PtNH3 + z66]2+ 93.0 7641.0048 7641.0038 -0.13 
[H + PtN2H6 + c59]2+ 92.6 6874.5547 6874.5536 -0.16 
[6H + Pt + z58]2+ 92.3 6712.4819 6712.4808 -0.16 
[PtN2H6 + c42]2+ 92.2 4967.5758 4967.5746 -0.24 
[4H + PtN2H6 + z66]2+ 91.9 7658.0314 7658.0302 -0.16 
[2H + PtN2H6 + c75]4+ 91.8 8733.6526 8733.6504 -0.25 
[PtN2H6 + c64]2+ 91.5 7485.8700 7485.8688 -0.16 
[9H + Pt + z37]2+ 91.4 4440.3358 4440.3346 -0.27 
[2H + PtNH3 + c62]2+ 91.1 7213.7215 7213.7204 -0.15 
[5H + Pt + c74]3+ 91.1 8645.6015 8645.5998 -0.20 
[4H + Pt + y65]2+ 91.0 7512.9099 7512.9088 -0.15 
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[5H + Pt + z65]2+ 90.8 7496.8911 7496.8900 -0.15 
[4H + Pt + z66]3+ 90.0 7623.9783 7623.9765 -0.24 
[PtN2H6 + c75]3+ 89.9 8732.6448 8732.6430 -0.21 
[Pt + c59]2+ 89.8 6840.5016 6840.5004 -0.18 
[5H + PtNH3 + z75]3+ 89.3 8629.5880 8629.5864 -0.19 
[4H + PtNH3 + y67]2+ 89.2 7715.0528 7715.0518 -0.13 
[8H + Pt + z62]2+ 89.2 7184.7352 7184.7340 -0.17 
[6H + PtN2H6 + c65]2+ 89.0 7578.9490 7578.9478 -0.16 
[6H + PtN2H6 + z75]4+ 88.9 8647.6223 8647.6200 -0.27 
[5H + PtN2H6 + z73]3+ 88.8 8405.4719 8405.4702 -0.20 
[PtNH3 + c75]3+ 88.6 8715.6182 8715.6165 -0.20 
[7H + PtN2H6 + y53]2+ 88.2 6251.3259 6251.3248 -0.18 
[4H + PtN2H6 + z62]3+ 87.9 7214.7570 7214.7552 -0.25 
[2H + Pt + c59]3+ 87.8 6841.5094 6841.5078 -0.23 
[6H + PtN2H6 + y31]2+ 87.5 3702.9371 3702.9360 -0.30 
[2H + PtN2H6 + c54]2+ 87.0 6296.3085 6296.3074 -0.17 
[6H + Pt + z70]3+ 86.8 7998.1948 7998.1932 -0.20 
[5H + PtNH3 + c32]1+ 86.5 3805.9867 3805.9862 -0.13 
[6H + PtN2H6 + y29]2+ 86.1 3574.8786 3574.8774 -0.34 
[PtN2H6 + c62]2+ 85.7 7229.7402 7229.7392 -0.14 
[PtNH3 + c59]2+ 85.3 6856.5203 6856.5192 -0.16 
[5H + PtNH3 + z29]1+ 85.3 3539.8176 3539.8171 -0.14 
[8H + Pt + y24]2+ 85.2 2929.5340 2929.5328 -0.41 
[2H + Pt + c62]2+ 85.2 7196.6950 7196.6938 -0.17 
[5H + PtNH3 + z74]3+ 85.0 8501.5294 8501.5278 -0.19 
[3H + PtN2H6 + y62]3+ 84.8 7230.7757 7230.7740 -0.24 
[4H + Pt + y70]3+ 84.7 8013.2057 8013.2040 -0.21 
[7H + PtN2H6 + y24]1+ 83.7 2962.5792 2962.5787 -0.17 
[3H + Pt + c75]3+ 83.4 8700.6073 8700.6057 -0.18 
[5H + Pt + z75]3+ 83.1 8612.5614 8612.5599 -0.17 
[5H + PtN2H6 + z59]3+ 83.0 6874.5697 6874.5681 -0.23 
[7H + PtN2H6 + y33]1+ 83.0 3964.0974 3964.0969 -0.13 
[9H + Pt + z37]3+ 82.5 4440.3358 4440.3342 -0.36 
[PtN2H6 + c28]1+ 82.2 3333.7096 3333.7091 -0.15 
[PtN2H6 + y66]2+ 81.2 7671.0266 7671.0256 -0.13 
[2H + PtN2H6 + c58]3+ 81.0 6712.4992 6712.4976 -0.24 
[3H + PtNH3 + y52]2+ 80.8 6101.2254 6101.2244 -0.16 
[3H + PtN2H6 + z46]2+ 80.8 5447.8030 5447.8018 -0.22 
[PtN2H6 + c28]2+ 80.1 3333.7096 3333.7086 -0.30 
[7H + PtN2H6 + z36]2+ 79.9 4344.3146 4344.3136 -0.23 
[8H + Pt + z38]2+ 79.8 4554.3549 4554.3538 -0.24 
[Pt + y24]2+ 79.7 2921.4714 2921.4702 -0.41 
[7H + Pt + c61]2+ 79.6 7073.6755 7073.6744 -0.16 
[3H + Pt + c58]2+ 79.2 6679.4539 6679.4528 -0.16 
[4H + PtN2H6 + z68]2+ 79.2 7816.1005 7816.0994 -0.14 
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[4H + Pt + c61]2+ 79.1 7070.6520 7070.6510 -0.14 
[PtN2H6 + c31]1+ 78.9 3702.9472 3702.9467 -0.14 
[7H + PtNH3 + y33]1+ 78.8 3947.0709 3947.0703 -0.15 
[8H + Pt + y28]1+ 78.5 3414.7461 3414.7456 -0.15 
[PtN2H6 + c30]1+ 78.3 3574.8886 3574.8881 -0.14 
[4H + Pt + y65]3+ 78.2 7512.9099 7512.9081 -0.24 
[2H + PtNH3 + y73]3+ 77.6 8402.4484 8402.4468 -0.19 
[2H + Pt + c74]3+ 77.6 8642.5780 8642.5764 -0.19 
[6H + Pt + z32]1+ 77.6 3798.9259 3798.9253 -0.16 
[4H + Pt + c75]4+ 77.2 8701.6151 8701.6128 -0.26 
[6H + Pt + c75]3+ 77.1 8703.6308 8703.6291 -0.20 
[Pt + c42]2+ 76.9 4933.5227 4933.5216 -0.22 
[2H + PtNH3 + y55]2+ 76.4 6443.3919 6443.3908 -0.17 
[PtN2H6 + y75]3+ 76.2 8659.6098 8659.6080 -0.21 
[3H + PtNH3 + y45]2+ 76.2 5319.7444 5319.7434 -0.19 
[8H + PtNH3 + z33]1+ 75.7 3931.0522 3931.0516 -0.15 
[4H + PtN2H6 + y67]2+ 75.7 7732.0794 7732.0782 -0.16 
[PtN2H6 + c27]2+ 75.6 3262.6725 3262.6714 -0.34 
[PtN2H6 + c74]3+ 75.3 8674.6155 8674.6137 -0.21 
[PtNH3 + y17]1+ 75.2 2147.1291 2147.1286 -0.23 
[5H + Pt + z62]2+ 75.1 7181.7117 7181.7106 -0.15 
[5H + Pt + y66]3+ 74.7 7642.0127 7642.0110 -0.22 
[PtN2H6 + c35]2+ 74.6 4133.1410 4133.1398 -0.29 
[3H + PtN2H6 + c68]3+ 74.5 7927.1161 7927.1145 -0.20 
[PtNH3 + c64]2+ 74.4 7468.8434 7468.8424 -0.13 
[9H + Pt + z70]3+ 74.2 8001.2183 8001.2166 -0.21 
[4H + PtNH3 + c75]3+ 73.7 8718.6417 8718.6402 -0.17 
[PtNH3 + y36]2+ 73.2 4338.2677 4338.2666 -0.25 
[8H + Pt + z59]2+ 73.2 6843.5401 6843.5390 -0.16 
[2H + Pt + y75]3+ 72.7 8626.5645 8626.5627 -0.21 
[8H + PtN2H6 + c65]3+ 72.2 7580.9646 7580.9631 -0.20 
[5H + PtNH3 + z62]3+ 72.2 7198.7383 7198.7367 -0.22 
[5H + PtN2H6 + z50]2+ 71.8 5890.1297 5890.1286 -0.19 
[PtN2H6 + c64]3+ 71.3 7485.8700 7485.8682 -0.24 
[7H + PtNH3 + y74]3+ 71.3 8520.5716 8520.5700 -0.19 
[5H + PtN2H6 + c17]1+ 71.0 2155.1766 2155.1761 -0.23 
[PtN2H6 + c52]2+ 70.8 6081.1702 6081.1692 -0.16 
[8H + PtNH3 + z44]2+ 70.5 5192.7300 5192.7290 -0.19 
[4H + PtN2H6 + c75]3+ 70.5 8735.6682 8735.6667 -0.17 
[5H + PtNH3 + z69]2+ 70.4 7913.1659 7913.1648 -0.14 
Table B.7 Most important metallated fragments obtained by ETD fragmentation of the adduct [7H+ Ubiquitin + 
PtN2H6]
9+ 
(m/z 977.2928) after incubation of ubiquitin with cisplatin (1:1, protein:drug ratio).  
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Metallated adduct Similarity Abundance Type Theoretical mass Experimental mass PPM Error 
[Ru + b73y21]2+ 88.2 7.54 R 2226.0861 2226.0850 -0.49 
[C7H8Ru + b57y35]2+ 67.0 1.21 R 1979.9645 1979.9634 -0.56 
[C7H8Ru + a54y37]2+ 62.3 1.25 R 1906.9230 1906.9218 -0.63 
[C7H8Ru + a14]3+ 90.1 1.53 L 1728.8700 1728.8685 -0.87 
[C7H8Ru + b17]3+ 89.0 4.49 L 2098.0600 2098.0584 -0.76 
[C7H8Ru + b18]3+ 88.6 7.91 L 2227.1026 2227.1010 -0.72 
[C7H8Ru + b16]3+ 84.6 2.96 L 1998.9916 1998.9900 -0.80 
[C7H8Ru + a16]3+ 80.4 1.17 L 1970.9967 1970.9952 -0.76 
[C7H8Ru + a15]3+ 77.9 1.01 L 1841.9541 1841.9526 -0.81 
[C7H8Ru + a36y58]2+ 75.1 1.38 L 2133.0170 2133.0158 -0.56 
[C7H8Ru + a17]3+ 73.6 1.39 L 2070.0651 2070.0636 -0.72 
[C7H8Ru + b14]2+ 71.6 2.34 L 1756.8650 1756.8638 -0.68 
[C7H8Ru + b11]2+ 70.6 2.65 L 1441.6855 1441.6844 -0.76 
[C7H8Ru + a18]3+ 67.3 1.42 L 2199.1077 2199.1062 -0.68 
[C7H8Ru + a21y72]3+ 60.0 2.08 L 1978.9679 1978.9662 -0.86 
[4H + C7H8Ru + y58]8+ 89.9 6.03 M 6726.4949 6726.4904 -0.67 
[4H + C7H8Ru + b52]7+ 89.8 19.59 M 6033.1240 6033.1201 -0.65 
[5H + C7H8Ru + y58]9+ 88.5 1.96 M 6727.5028 6727.4982 -0.68 
[C7H8Ru + a44y49]2+ 87.3 3.41 M 2097.0435 2097.0424 -0.52 
[4H + C7H8Ru + a58y7]7+ 85.1 3.17 M 6016.1225 6016.1185 -0.66 
[6H + C7H8Ru + y74]10+ 79.8 1.65 M 8501.5394 8501.5340 -0.64 
[6H + C7H8Ru + a66y75]9+ 77.2 1.94 M 7468.8837 7468.8786 -0.68 
[6H + C7H8Ru + y60]9+ 75.4 1.76 M 6956.6216 6956.6166 -0.72 
[7H + C7H8Ru + b64y73]9+ 71.3 0.85 M 7068.6641 7068.6594 -0.66 
[C7H8Ru + a46y71]4+ 70.1 1.53 M 4712.4493 4712.4472 -0.45 
[C7H8Ru + b42y51]2+ 66.6 1.38 M 2126.0336 2126.0326 -0.47 
[5H + C7H8Ru + b60]8+ 64.3 1.14 M 6940.5514 6940.5472 -0.61 
[4H + C7H8Ru + b51y73]6+ 60.5 2.36 M 5545.9140 5545.9104 -0.65 
Table B.8 Most important metallated fragments obtained by CID fragmentation of the adduct [9H+ Ubiquitin + 
RuC7H8]]
11+ 
(m/z 796.6043) after incubation of ubiquitin with RAPTA-T (1:5, protein:drug ratio). Similarities 
are expressed as percentages, abundances are expressed as percentage of the most abundant peak in the spectra, 
and type is classified based on criteria in Figure 5.6. 
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Metallated adduct Similarity Theoretical mass Experimental mass PPM Error 
[Ru + a73y19]2+ 88.8 1997.9751 1997.9740 -0.55 
[Ru + a37y54]2+ 86.0 1737.8477 1737.8466 -0.63 
[C7H8Ru + a15]3+ 81.2 1841.9541 1841.9526 -0.81 
[C7H8Ru + a46y71]4+ 80.8 4712.4493 4712.4472 -0.45 
[C7H8Ru + a44y49]2+ 79.5 2097.0435 2097.0424 -0.52 
[C7H8Ru + b16]3+ 76.9 1998.9916 1998.9900 -0.80 
[C7H8Ru + a16]3+ 71.5 1970.9967 1970.9952 -0.76 
[C7H8Ru + b13]2+ 68.6 1655.8173 1655.8162 -0.66 
[C7H8Ru + b14]2+ 67.3 1756.8650 1756.8638 -0.68 
[Ru + a48y39]2+ 66.1 1328.6053 1328.6042 -0.83 
[C7H8Ru + a14]3+ 66.0 1728.8700 1728.8685 -0.87 
[C7H8Ru + a46y71]3+ 65.7 4712.4493 4712.4477 -0.34 
[C7H8Ru + b17]3+ 65.5 2098.0600 2098.0584 -0.76 
[C7H8Ru + b11]2+ 65.5 1441.6855 1441.6844 -0.76 
[Ru + a49y44]2+ 65.2 1980.9597 1980.9586 -0.56 
[C7H8Ru + a75y42]4+ 61.7 4823.5051 4823.5028 -0.48 
[Ru + b73y21]3+ 60.3 2226.0861 2226.0843 -0.81 
Table B.9 Most important metallated fragments obtained by HCD fragmentation of the adduct [9H+ Ubiquitin + 
RuC7H8]]
11+ 
(m/z 796.6043) after incubation of ubiquitin with RAPTA-T (1:5, protein:drug ratio). 
 
 
 
 
 
Metallated adduct Similarity Theoretical mass Experimental mass PPM Error 
[3H + C7H8Ru + c75]3+ 96.7 8699.6095 8699.6079 -0.18 
[3H + C7H8Ru + c59]2+ 96.2 6841.5194 6841.5182 -0.18 
[3H + C7H8Ru + c75]4+ 93.6 8699.6095 8699.6072 -0.26 
[C7H8Ru + c24]3+ 93.5 2886.4152 2886.4137 -0.52 
[C7H8Ru + c24]2+ 93.2 2886.4152 2886.4142 -0.35 
[7H + C7H8Ru + y31]2+ 92.3 3668.8940 3668.8930 -0.27 
[2H + C7H8Ru + c42]3+ 92.1 4933.5327 4933.5309 -0.36 
[C7H8Ru + c29]2+ 92.0 3426.7536 3426.7526 -0.29 
[7H + C7H8Ru + y29]3+ 92.0 3540.8354 3540.8337 -0.48 
[C7H8Ru + c28]2+ 91.6 3298.6587 3298.6576 -0.33 
[8H + C7H8Ru + y45]2+ 91.6 5306.7591 5306.7580 -0.21 
[3H + C7H8Ru + y75]3+ 91.5 8626.5745 8626.5729 -0.19 
[C7H8Ru + c74]3+ 91.0 8640.5724 8640.5706 -0.21 
[C7H8Ru + c28]3+ 90.9 3299.6665 3299.6649 -0.48 
[C7H8Ru + c40]2+ 90.5 4648.3652 4648.3640 -0.26 
[3H + C7H8Ru + c59]3+ 90.5 6841.5194 6841.5177 -0.25 
[C7H8Ru + c38]2+ 90.2 4405.2796 4405.2786 -0.23 
[6H + Ru + c75]3+ 90.0 8610.5704 8610.5688 -0.19 
[C7H8Ru + c39]2+ 89.8 4520.3066 4520.3054 -0.27 
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[2H + C7H8Ru + c38]3+ 89.6 4406.2875 4406.2857 -0.41 
[C7H8Ru + c27]2+ 89.5 3227.6215 3227.6204 -0.34 
[C7H8Ru + c30]2+ 89.5 3539.8377 3539.8366 -0.31 
[7H + C7H8Ru + y31]3+ 89.4 3668.8940 3668.8923 -0.46 
[C7H8Ru + c32]2+ 89.3 3782.9232 3782.9222 -0.26 
[C7H8Ru + c25]2+ 88.6 3000.4582 3000.4570 -0.40 
[3H + C7H8Ru + z17]2+ 88.5 2114.0938 2114.0928 -0.47 
[Ru + y41]2+ 88.4 4777.4480 4777.4468 -0.25 
[C7H8Ru + c23]2+ 88.1 2757.3727 2757.3716 -0.40 
[3H + C7H8Ru + z17]1+ 86.8 2114.0938 2114.0933 -0.24 
[2H + C7H8Ru + c44]2+ 86.4 5159.7008 5159.6998 -0.19 
[C7H8Ru + c27]3+ 85.7 3228.6294 3228.6276 -0.56 
[C7H8Ru + c24]1+ 85.4 2886.4152 2886.4147 -0.17 
[2H + C7H8Ru + c54]2+ 85.0 6261.2575 6261.2564 -0.18 
[C7H8Ru + c35]2+ 84.8 4098.0901 4098.0890 -0.27 
[4H + C7H8Ru + y27]2+ 84.8 3281.6584 3281.6574 -0.30 
[2H + Ru + z40]3+ 84.4 4649.3530 4649.3514 -0.34 
[8H + Ru + c65]3+ 84.4 7453.8511 7453.8495 -0.21 
[2H + C7H8Ru + c44]3+ 83.9 5159.7008 5159.6991 -0.33 
[C7H8Ru + c42]2+ 83.5 4932.5249 4932.5238 -0.22 
[C7H8Ru + c21]1+ 83.4 2543.2409 2543.2404 -0.20 
[C7H8Ru + c14]2+ 82.9 1773.8915 1773.8904 -0.62 
[C7H8Ru + c39]3+ 82.8 4520.3066 4520.3049 -0.38 
[8H + C7H8Ru + z33]2+ 82.5 3913.0278 3913.0266 -0.31 
[8H + C7H8Ru + y36]2+ 82.0 4327.2981 4327.2970 -0.25 
[C7H8Ru + c20]2+ 82.0 2428.2140 2428.2128 -0.49 
[C7H8Ru + c41]3+ 80.4 4776.4237 4776.4221 -0.33 
[8H + C7H8Ru + z29]2+ 80.1 3524.8167 3524.8156 -0.31 
[C7H8Ru + y75]3+ 80.0 8623.5510 8623.5495 -0.17 
[4H + C7H8Ru + c59]4+ 79.7 6842.5272 6842.5252 -0.29 
[3H + C7H8Ru + c51]3+ 79.2 5934.1158 5934.1143 -0.25 
[9H + C7H8Ru + y60]2+ 79.1 6959.6451 6959.6440 -0.16 
[9H + Ru + y37]2+ 78.9 4364.3019 4364.3008 -0.25 
[C7H8Ru + c16]1+ 78.8 2016.0182 2016.0176 -0.30 
[4H + C7H8Ru + c74]4+ 78.3 8643.5958 8643.5936 -0.25 
[4H + C7H8Ru + c74]3+ 78.0 8643.5958 8643.5943 -0.17 
[7H + C7H8Ru + z75]3+ 77.4 8613.5792 8613.5775 -0.20 
[C7H8Ru + c16]2+ 77.2 2016.0182 2016.0170 -0.60 
[C7H8Ru + c13]2+ 77.2 1672.8438 1672.8428 -0.60 
[C7H8Ru + c21]2+ 77.1 2543.2409 2543.2398 -0.43 
[C7H8Ru + c75]3+ 76.7 8696.5860 8696.5845 -0.17 
[2H + C7H8Ru + c53]3+ 76.4 6105.1564 6105.1548 -0.26 
[C7H8Ru + c28]1+ 75.6 3298.6587 3298.6581 -0.18 
[3H + Ru + c75]3+ 75.2 8607.5469 8607.5451 -0.21 
[C7H8Ru + c75]4+ 75.1 8696.5860 8696.5840 -0.23 
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[6H + C7H8Ru + y75]3+ 75.0 8629.5980 8629.5963 -0.20 
[C7H8Ru + c13]1+ 74.9 1672.8438 1672.8433 -0.30 
[C7H8Ru + c34]2+ 74.1 4040.0608 4040.0596 -0.30 
[9H + C7H8Ru + z44]2+ 73.9 5175.7135 5175.7124 -0.21 
[6H + C7H8Ru + c75]4+ 73.8 8702.6330 8702.6308 -0.25 
[9H + C7H8Ru + z36]2+ 73.7 4311.2793 4311.2782 -0.26 
[4H + C7H8Ru + y37]2+ 73.7 4451.3253 4451.3242 -0.25 
[2H + Ru + z23]1+ 73.7 2756.3786 2756.3780 -0.22 
[5H + Ru + c20]2+ 73.3 2341.1905 2341.1894 -0.47 
[C7H8Ru + c27]1+ 72.8 3227.6215 3227.6210 -0.15 
[C7H8Ru + c11]1+ 72.8 1458.7121 1458.7115 -0.41 
[3H + C7H8Ru + c51]2+ 72.6 5934.1158 5934.1148 -0.17 
[C7H8Ru + c17]3+ 72.5 2115.0866 2115.0849 -0.80 
[9H + C7H8Ru + y64]3+ 72.3 7415.9035 7415.9019 -0.22 
[C7H8Ru + c10]2+ 72.2 1330.6171 1330.6160 -0.83 
[C7H8Ru + c74]4+ 72.1 8640.5724 8640.5700 -0.28 
[C7H8Ru + c22]2+ 71.1 2644.2886 2644.2874 -0.45 
[7H + C7H8Ru + z33]3+ 70.6 3912.0199 3912.0183 -0.41 
[7H + C7H8Ru + y28]1+ 69.6 3412.7405 3412.7399 -0.18 
[C7H8Ru + c9]2+ 69.1 1273.5957 1273.5946 -0.86 
[9H + C7H8Ru + y60]3+ 69.1 6959.6451 6959.6433 -0.26 
[4H + Ru + y15]1+ 69.0 1812.9386 1812.9381 -0.28 
[6H + C7H8Ru + c75]3+ 68.6 8702.6330 8702.6313 -0.20 
[C7H8Ru + c23]3+ 68.4 2757.3727 2757.3711 -0.58 
[7H + C7H8Ru + c59]4+ 68.4 6845.5507 6845.5484 -0.34 
[C7H8Ru + c11]2+ 68.0 1458.7121 1458.7110 -0.75 
[5H + C7H8Ru + c43]2+ 67.6 5049.6402 5049.6392 -0.20 
[C7H8Ru + c14]1+ 67.0 1773.8915 1773.8910 -0.28 
[C7H8Ru + c8]2+ 66.7 1172.5480 1172.5468 -1.02 
[9H + C7H8Ru + c74]3+ 66.7 8648.6350 8648.6334 -0.19 
[3H + C7H8Ru + c28]2+ 66.7 3301.6821 3301.6810 -0.33 
[9H + C7H8Ru + y44]2+ 66.3 5192.7400 5192.7390 -0.19 
[Ru + c75]3+ 66.1 8604.5234 8604.5217 -0.20 
[3H + C7H8Ru + y50]2+ 65.9 5870.0897 5870.0886 -0.19 
[  C7H8Ru + c59]2+ 65.8 6838.4959 6838.4948 -0.16 
[3H + C7H8Ru + y40]2+ 65.4 4759.4500 4759.4488 -0.25 
[9H + Ru + z18]1+ 64.8 2191.1415 2191.1410 -0.23 
[6H + Ru + y37]2+ 64.2 4361.2784 4361.2772 -0.28 
[4H + C7H8Ru + c38]2+ 64.2 4408.3031 4408.3020 -0.25 
[3H + C7H8Ru + c58]2+ 64.1 6678.4561 6678.4550 -0.16 
[2H + Ru + y41]3+ 63.9 4779.4636 4779.4620 -0.33 
[6H + C7H8Ru + c59]2+ 63.7 6844.5429 6844.5418 -0.16 
[5H + C7H8Ru + y57]2+ 63.4 6630.4500 6630.4490 -0.15 
[9H + C7H8Ru + y75]3+ 63.1 8632.6214 8632.6197 -0.20 
[6H + C7H8Ru + c59]3+ 63.0 6844.5429 6844.5411 -0.26 
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[C7H8Ru + c26]3+ 63.0 3099.5266 3099.5250 -0.52 
[6H + C7H8Ru + c64]3+ 62.8 7456.8660 7456.8642 -0.24 
[5H + C7H8Ru + c54]2+ 62.7 6264.2810 6264.2798 -0.19 
[C7H8Ru + c45]3+ 62.6 5305.7614 5305.7598 -0.30 
[C7H8Ru + c7]2+ 61.9 1059.4639 1059.4628 -1.04 
[5H + Ru + z37]2+ 61.4 4343.2440 4343.2430 -0.23 
[9H + C7H8Ru + y29]2+ 61.2 3542.8511 3542.8500 -0.31 
[4H + Ru + y38]2+ 61.1 4474.2897 4474.2886 -0.25 
[3H + Ru + z64]4+ 61.1 7300.7674 7300.7652 -0.30 
[4H + C7H8Ru + z59]3+ 61.1 6838.5110 6838.5093 -0.25 
[9H + C7H8Ru + y42]2+ 61.1 4935.6025 4935.6014 -0.22 
[9H + C7H8Ru + z24]1+ 60.9 2912.5174 2912.5168 -0.21 
[9H + Ru + y18]1+ 60.8 2208.1681 2208.1675 -0.27 
[9H + C7H8Ru + z75]4+ 60.7 8615.5949 8615.5928 -0.24 
[6H + Ru + y10]1+ 60.7 1241.6784 1241.6779 -0.40 
[9H + Ru + c44]2+ 60.6 5074.6930 5074.6918 -0.24 
[9H + C7H8Ru + z60]3+ 60.5 6942.6185 6942.6168 -0.24 
[5H + C7H8Ru + c45]2+ 60.4 5309.7927 5309.7916 -0.21 
[2H + Ru + z53]3+ 60.3 6102.1467 6102.1449 -0.29 
[9H + C7H8Ru + y70]3+ 60.3 8017.2470 8017.2453 -0.21 
[5H + C7H8Ru + c44]2+ 60.2 5162.7243 5162.7232 -0.21 
Table B.10 Most important metallated fragments obtained by ETD fragmentation of the adduct [9H+ Ubiquitin 
+ RuC7H8]]
11+ 
(m/z 796.6043) after incubation of ubiquitin with RAPTA-T (1:5, protein:drug ratio). 
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Metallated adduct Similarity Abundance Type Theoretical mass Experimental mass PPM Error 
[Ru + b73y21]2+ 87.3 5.62 R 2226.0861 2226.0850 -0.49 
[C7H8Ru + a57y37]3+ 76.8 1.40 R 2208.0867 2208.0852 -0.68 
[C7H8Ru + b57y35]2+ 71.9 0.74 R 1979.9645 1979.9634 -0.56 
[C7H8Ru + a54y37]2+ 61.7 0.45 R 1906.9230 1906.9218 -0.63 
[C7H8Ru + b18]3+ 87.4 3.73 L 2227.1026 2227.1010 -0.72 
[C7H8Ru + b18y75]2+ 85.8 1.94 L 2096.0621 2096.0610 -0.52 
[C7H8Ru + b17]3+ 78.9 2.22 L 2098.0600 2098.0584 -0.76 
[C7H8Ru + a17]3+ 78.1 0.72 L 2070.0651 2070.0636 -0.72 
[C7H8Ru + a14]3+ 77.0 1.02 L 1728.8700 1728.8685 -0.87 
[C7H8Ru + a18]3+ 75.6 0.69 L 2199.1077 2199.1062 -0.68 
[C7H8Ru + b16]3+ 75.2 1.65 L 1998.9916 1998.9900 -0.80 
[C7H8Ru + b11]2+ 69.5 1.07 L 1441.6855 1441.6844 -0.76 
[C7H8Ru + a16]3+ 62.3 0.48 L 1970.9967 1970.9952 -0.76 
[4H + C7H8Ru + y58]8+ 89.4 2.18 M 6726.4949 6726.4904 -0.67 
[5H + C7H8Ru + b74y59]7+ 88.9 4.58 M 6724.4919 6724.4877 -0.62 
[7H + C7H8Ru + b74y75]9+ 87.1 2.12 M 8498.5523 8498.5470 -0.62 
[6H + Ru + b69y67]8+ 71.6 0.98 M 6837.4892 6837.4848 -0.64 
[C7H8Ru + a46y71]4+ 70.1 1.32 M 4712.4493 4712.4472 -0.45 
[5H + Ru + b69y67]7+ 67.1 0.58 M 6836.4814 6836.4779 -0.51 
[H + C7H8Ru + a50y62]4+ 66.8 1.94 M 4195.1381 4195.1360 -0.50 
[4H + C7H8Ru + b52]6+ 66.4 2.85 M 6033.1240 6033.1206 -0.56 
[5H + C7H8Ru + y58]7+ 66.3 4.58 M 6727.5028 6727.4991 -0.55 
Table B.11 Most important metallated fragments obtained by CID fragmentation of the adduct [8H+ Ubiquitin + 
RuC7H8]
10+ 
(m/z 876.1640) after incubation of ubiquitin with RAPTA-T (1:5, protein:drug ratio. Similarities are 
expressed as percentages, abundances are expressed as percentage of the most abundant peak in the spectra, and 
type is classified based on criteria in Figure 5.6. 
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Metallated adduct Similarity Theoretical mass Experimental mass PPM Error 
[C7H8Ru + b16]3+ 91.4 1998.9916 1998.9900 -0.80 
[Ru + a37y54]2+ 89.5 1737.8477 1737.8466 -0.63 
[C7H8Ru + a15]3+ 88.4 1841.9541 1841.9526 -0.81 
[Ru + b73y21]2+ 87.8 2226.0861 2226.0850 -0.49 
[C7H8Ru + b17]3+ 87.5 2098.0600 2098.0584 -0.76 
[C7H8Ru + a44y49]2+ 86.8 2097.0435 2097.0424 -0.52 
[C7H8Ru + b15]3+ 86.7 1869.9490 1869.9474 -0.86 
[C7H8Ru + a16]3+ 86.5 1970.9967 1970.9952 -0.76 
[Ru + a37y49]2+ 84.5 1154.5148 1154.5136 -1.04 
[C7H8Ru + b18]3+ 83.8 2227.1026 2227.1010 -0.72 
[C7H8Ru + b14]3+ 80.7 1756.8650 1756.8633 -0.97 
[Ru + a49y44]2+ 79.8 1980.9597 1980.9586 -0.56 
[C7H8Ru + a17]3+ 79.3 2070.0651 2070.0636 -0.72 
[C7H8Ru + b34y50]2+ 77.0 1135.5090 1135.5078 -1.06 
[Ru + b48y42]2+ 76.3 1623.7585 1623.7574 -0.68 
[C7H8Ru + a75y42]4+ 76.3 4823.5051 4823.5028 -0.48 
[C7H8Ru + b49y68]3+ 76.1 4711.3925 4711.3908 -0.36 
[Ru + b37y53]2+ 74.4 1652.7586 1652.7574 -0.73 
[C7H8Ru + b13]2+ 73.9 1655.8173 1655.8162 -0.66 
[Ru + b37y55]3+ 73.7 1866.8903 1866.8886 -0.91 
[Ru + a37y54]3+ 73.5 1737.8477 1737.8460 -0.98 
[C7H8Ru + a50y67]4+ 71.9 4695.4340 4695.4316 -0.51 
[Ru + a48y39]2+ 70.2 1328.6053 1328.6042 -0.83 
[C7H8Ru + a74y40]3+ 69.5 4596.3781 4596.3765 -0.35 
[Ru + b31y54]2+ 69.5 1126.5199 1126.5188 -0.98 
[C7H8Ru + b14]2+ 69.0 1756.8650 1756.8638 -0.68 
[C7H8Ru + b11]2+ 68.1 1441.6855 1441.6844 -0.76 
[C7H8Ru + b57y35]3+ 66.3 1979.9645 1979.9628 -0.86 
[C7H8Ru + a75y42]3+ 66.2 4823.5051 4823.5035 -0.33 
[Ru + a42y50]2+ 65.6 1906.9077 1906.9066 -0.58 
[C7H8Ru + b18y65]2+ 64.7 980.3919 980.3908 -1.12 
[Ru + a41y51]3+ 63.0 1849.8750 1849.8735 -0.81 
[Ru + b37y52]3+ 61.9 1523.7160 1523.7144 -1.05 
[C7H8Ru + a45y69]3+ 60.6 4412.2695 4412.2680 -0.34 
[C7H8Ru + a38y72]3+ 60.3 3839.9988 3839.9973 -0.39 
Table B.12 Most important metallated fragments obtained by HCD fragmentation of the adduct [8H+ Ubiquitin 
+ RuC7H8]
10+ 
(m/z 876.1640) after incubation of ubiquitin with RAPTA-T (1:5, protein:drug ratio.  
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Metallated adduct Similarity Theoretical mass Experimental mass PPM Error 
[2H + C7H8Ru + c75]4+ 91.0 8698.6017 8698.5996 -0.24 
[9H + Ru + y37]2+ 84.2 4364.3019 4364.3008 -0.25 
[C7H8Ru + c31]2+ 84.2 3667.8963 3667.8952 -0.30 
[2H + C7H8Ru + c74]4+ 83.6 8641.5802 8641.5780 -0.25 
[C7H8Ru + c30]2+ 83.3 3539.8377 3539.8366 -0.31 
[H + C7H8Ru + c38]2+ 82.7 4405.2796 4405.2786 -0.23 
[6H + C7H8Ru + z59]3+ 81.6 6840.5266 6840.5250 -0.23 
[C7H8Ru + c24]2+ 79.2 2886.4152 2886.4142 -0.35 
[C7H8Ru + c28]2+ 79.1 3298.6587 3298.6576 -0.33 
[H + C7H8Ru + c38]3+ 78.1 4405.2796 4405.2780 -0.36 
[2H + C7H8Ru + z17]2+ 77.0 2113.0860 2113.0850 -0.47 
[C7H8Ru + c42]3+ 75.4 4931.5170 4931.5155 -0.30 
[7H + C7H8Ru + y29]3+ 72.6 3540.8354 3540.8337 -0.48 
[C7H8Ru + c14]2+ 71.4 1773.8915 1773.8904 -0.62 
[C7H8Ru + c31]3+ 70.8 3667.8963 3667.8945 -0.49 
[C7H8Ru + c9]2+ 69.6 1273.5957 1273.5946 -0.86 
[C7H8Ru + c10]2+ 66.1 1330.6171 1330.6160 -0.83 
[H + C7H8Ru + c28]3+ 66.0 3299.6665 3299.6649 -0.48 
[C7H8Ru + c75]5+ 65.3 8696.5860 8696.5835 -0.29 
[5H + C7H8Ru + c75]4+ 65.2 8701.6251 8701.6228 -0.26 
[C7H8Ru + c24]3+ 61.0 2886.4152 2886.4137 -0.52 
[5H + C7H8Ru + c74]4+ 60.6 8644.6037 8644.6016 -0.24 
Table B.13 Most important metallated fragments obtained by ETD fragmentation of the adduct [8H+ Ubiquitin + 
RuC7H8]
10+ 
(m/z 876.1640) after incubation of ubiquitin with RAPTA-T (1:5, protein:drug ratio.  
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Appendix C 
Tables of metallated fragment from MS/MS 
experiments of metallodrugs on BRCA1 peptide 
 
 
 
 
 
 
 
 
 
 
 
Ion Type (Fragment from ETD) Theoretical m/z Experimental m/z Mass Error (ppm) 
C12 +  1385.78949 1385.79004 -0.40 
[C15  + H] 2+  855.98027 855.98082 -0.64 
[C24  + H] 2+  1373.69987 1373.700415 -0.40 
[C29  + RAPTA-C -2Cl ] 3+  1253.59048 1253.591027 -0.44 
[C30  + RAPTA-C -2Cl ] 3+  1296.2888 1296.289347 -0.42 
[C32  + RAPTA-C -2Cl ] 3+  1371.67817 1371.678723 -0.40 
[C33  + H + RAPTA-C -2Cl ] 4+  1057.52118 1057.52173 -0.52 
[C34  + RAPTA-C -2Cl ] 3+  1452.37868 1452.379223 -0.37 
[C36  + RAPTA-C -2Cl ] 3+  1537.77532 1537.775867 -0.36 
[C39  + H + RAPTA-C -2Cl ] 3+  1618.48001 1618.48056 -0.34 
[C45  + H + RAPTA-C -2Cl ] 3+  1842.58292 1842.583473 -0.30 
[C48  + H + RAPTA-C -2Cl ] 4+  1467.22358 1467.224133 -0.38 
[Z6  + H]+  702.39066 702.3912 -0.77 
[Z14  + H] 2+  744.35898 744.35953 -0.74 
[Z15  + H] 2+  808.40646 808.40701 -0.68 
[Z16  + RAPTA-C -2Cl ] 2+  1067.99151 1067.99206 -0.51 
[Z17  + RAPTA-C -2Cl ] 2+  1132.0208 1132.02135 -0.49 
[Z18  + RAPTA-C -2Cl ] 3+  792.69466 792.69521 -0.69 
[Z20  + RAPTA-C -2Cl ] 2+  1302.12633 1302.126875 -0.42 
[Z26  + H + RAPTA-C -2Cl ] 3+  1118.55067 1118.551217 -0.49 
[Z30  + H + RAPTA-C -2Cl ] 3+  1285.29086 1285.29141 -0.43 
[Z38  + 2H + RAPTA-C -2Cl ] 4+  1179.06361 1179.064155 -0.46 
[Z45  + H + RAPTA-C -2Cl ] 4+  1381.9324 1381.932948 -0.40 
[Z49  + RAPTA-C -2Cl ] 4+  1492.22759 1492.228143 -0.37 
[Z50  + 2H + RAPTA-C -2Cl ] 5+  1217.00347 1217.004022 -0.45 
Table C.1 Most important C and Z fragments obtained by ETD fragmentation of the adduct [BRCA1 +5H + 
RAPTA-C -2Cl]
7+ 
(m/z 871.8649) after incubation of BRCA1 peptide with RAPTA-C (1:5, protein:drug ratio)  
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Ion Type (Fragment from ETD) Theoretical m/z Experimental m/z Mass Error (ppm) 
C12 +  1385.78949 1385.79004 -0.40 
[C15 + H] 2+  855.98027 855.98082 -0.64 
[C18 + H] 2+  1014.0676 1014.068155 -0.55 
[C20 + H] 2+  1123.08567 1123.086215 -0.49 
[C29  + 3H + RAPTA-EA +2OH -3Cl ] 3+  1339.93206 1339.93261 -0.41 
[C31  + 2H + RAPTA-EA +2OH -3Cl ] 3+  1419.98913 1419.989677 -0.39 
[C32  + H + RAPTA-EA +2OH -3Cl ] 3+  1457.34787 1457.348423 -0.38 
[C34  + 2H + RAPTA-EA +2OH -3Cl ] 4+  1153.7881 1153.78865 -0.48 
[C36  + H + RAPTA-EA +2OH -3Cl ] 4+  1217.58363 1217.584175 -0.45 
[C39  + H + RAPTA-EA +2OH -3Cl ] 3+  1703.81377 1703.81432 -0.32 
[C46  + 2H + RAPTA-EA +2OH -3Cl ] 4+  1474.70006 1474.700613 -0.37 
[C47  + H + RAPTA-EA +2OH -3Cl ] 4+  1503.20484 1503.20539 -0.37 
[C50  + 5H + RAPTA-EA +2OH -3Cl ] 5+  1271.81537 1271.815914 -0.43 
Z14 2+  743.35116 743.351705 -0.73 
Z15 2+  807.39864 807.399185 -0.68 
[Z16  + H + RAPTA-EA +2OH -3Cl ] 2+  1196.49606 1196.49661 -0.46 
[Z16  + 2H + RAPTA-EA +2OH -3Cl ] 3+  797.9998 798.00035 -0.69 
[Z18  + RAPTA-EA +2OH -3Cl ] 2+  1317.0429 1317.04345 -0.42 
[Z20  + 2H + RAPTA-EA +2OH -3Cl ] 3+  954.08968 954.0902267 -0.57 
[Z38  + 3H + RAPTA-EA +2OH -3Cl ] 3+  1657.75469 1657.75524 -0.33 
[Z38  + 3H + RAPTA-EA +2OH -3Cl ] 4+  1243.31588 1243.31643 -0.44 
[Z41  + 4H + RAPTA-EA +2OH -3Cl ] 4+  1332.13361 1332.13416 -0.41 
[Z45  + 2H + RAPTA-EA +2OH -3Cl ] 3+  1928.24642 1928.246963 -0.28 
[Z5  + H] +  574.29569 574.29624 -0.96 
[Z50  + 3H + RAPTA-EA +2OH -3Cl ] 4+  1585.50675 1585.507303 -0.35 
Table C.2 Most important C and Z fragments obtained by ETD fragmentation of the adduct [BRCA1 +7H + 
RAPTA-EA +2OH  -3Cl]
8+ 
(m/z 795.1339) after incubation of BRCA1 peptide with RAPTA-EA (1:5, 
protein:drug ratio). 
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